<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD002095.pub4" GROUP_ID="UPPERGI" ID="407999092322103969" MERGED_FROM="" MODIFIED="2013-04-30 15:34:28 +0100" MODIFIED_BY="Karin Dearness" NOTES="&lt;p&gt;Converted to RM5 by CB&lt;/p&gt;&lt;p&gt;Exported from Review Manager 4.2.8&lt;br&gt;Exported from Review Manager 4.2.6&lt;br&gt;Exported from Review Manager 4.2.3&lt;/p&gt;&lt;p&gt;&lt;/p&gt;" NOTES_MODIFIED="2013-04-30 10:28:20 -0400" NOTES_MODIFIED_BY="Karin Dearness" REVIEW_NO="37" REVMAN_SUB_VERSION="5.2.3 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="12.0">
<COVER_SHEET MODIFIED="2013-04-30 15:34:28 +0100" MODIFIED_BY="Karin Dearness">
<TITLE MODIFIED="2008-11-19 06:14:03 -0500" MODIFIED_BY="Cathy Bennett">Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease</TITLE>
<CONTACT MODIFIED="2013-04-30 15:34:28 +0100" MODIFIED_BY="Karin Dearness"><PERSON ID="16697" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Mattijs</FIRST_NAME><MIDDLE_INITIALS>E</MIDDLE_INITIALS><LAST_NAME>Numans</LAST_NAME><POSITION>Professor</POSITION><EMAIL_1>m.numans@vumc.nl</EMAIL_1><EMAIL_2>m.numans@vumc.nl</EMAIL_2><URL>www.vumc.nl</URL><MOBILE_PHONE>++31 653 720990</MOBILE_PHONE><ADDRESS><DEPARTMENT>Department of General Practice and Elderly Care Medicine, EMGO Institute for Health and Care Research, and Alzheimer Center</DEPARTMENT><ORGANISATION>VU University Medical Center</ORGANISATION><ADDRESS_1>Van der Boechorststraat 7</ADDRESS_1><ADDRESS_2>12</ADDRESS_2><CITY>Amsterdam</CITY><COUNTRY CODE="NL">Netherlands</COUNTRY></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2013-04-30 15:34:28 +0100" MODIFIED_BY="Karin Dearness"><PERSON ID="362938CC82E26AA2017F61BBEF43B956" ROLE="AUTHOR"><PREFIX>Mrs</PREFIX><FIRST_NAME>Kirsten</FIRST_NAME><MIDDLE_INITIALS>E</MIDDLE_INITIALS><LAST_NAME>Sigterman</LAST_NAME><EMAIL_1>kirstensigterman@yahoo.com</EMAIL_1><ADDRESS><DEPARTMENT>Institut für Allgemeinmedizin / Institute of General Practice</DEPARTMENT><ORGANISATION>Technische Universität München Klinikum rechts der Isar</ORGANISATION><ADDRESS_1>Orleansstrasse 47</ADDRESS_1><CITY>Munich</CITY><ZIP>81667</ZIP><COUNTRY CODE="DE">Germany</COUNTRY><PHONE_1>+4989614658917</PHONE_1><FAX_1>+4989614658915</FAX_1></ADDRESS></PERSON><PERSON ID="19854" ROLE="AUTHOR"><PREFIX>Mr</PREFIX><FIRST_NAME>Bart</FIRST_NAME><LAST_NAME>van Pinxteren</LAST_NAME><SUFFIX>MD</SUFFIX><POSITION>General Practitioner</POSITION><EMAIL_1>bvanpinxteren@hetnet.nl</EMAIL_1><URL>www.bartvanpinxteren.nl</URL><ADDRESS><ORGANISATION>Huisartsen Oog in Al</ORGANISATION><ADDRESS_1>Handelstraat 55a</ADDRESS_1><CITY>Utrecht</CITY><ZIP>3533GH</ZIP><REGION>Utrecht</REGION><COUNTRY CODE="NL">Netherlands</COUNTRY><PHONE_1>+31 30 2988555</PHONE_1><FAX_1>+31 30 2988559</FAX_1></ADDRESS></PERSON><PERSON ID="19938" ROLE="AUTHOR"><FIRST_NAME>Peter</FIRST_NAME><MIDDLE_INITIALS>A</MIDDLE_INITIALS><LAST_NAME>Bonis</LAST_NAME><SUFFIX>MD</SUFFIX><EMAIL_1>pbonis@uptodate.com</EMAIL_1><ADDRESS><DEPARTMENT>Tufts Medical Centre</DEPARTMENT><ORGANISATION>Tufts Medical Centre/Division of Gastroenterology</ORGANISATION><ADDRESS_1>800 Washington Street</ADDRESS_1><ADDRESS_2>Box 63</ADDRESS_2><CITY>Boston</CITY><ZIP>02111</ZIP><REGION>MA</REGION><COUNTRY CODE="US">USA</COUNTRY><PHONE_1>+1 617 636 5883</PHONE_1><FAX_1>+1 617 636 8628</FAX_1></ADDRESS></PERSON><PERSON ID="6755" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Joseph</FIRST_NAME><LAST_NAME>Lau</LAST_NAME><POSITION>Co-Director</POSITION><EMAIL_1>jlau1@tuftsmedicalcenter.org</EMAIL_1><EMAIL_2>jlau1@tuftsmedicalcenter.org</EMAIL_2><ADDRESS><DEPARTMENT>Center for Evidence-based Medicine</DEPARTMENT><ORGANISATION>Brown University Public Health Program</ORGANISATION><ADDRESS_1>121 S. Main Street</ADDRESS_1><CITY>Providence</CITY><ZIP>02912</ZIP><REGION>RI</REGION><COUNTRY CODE="US">USA</COUNTRY><PHONE_1>401-863-6795</PHONE_1></ADDRESS></PERSON><PERSON ID="16697" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Mattijs</FIRST_NAME><MIDDLE_INITIALS>E</MIDDLE_INITIALS><LAST_NAME>Numans</LAST_NAME><POSITION>Professor</POSITION><EMAIL_1>m.numans@vumc.nl</EMAIL_1><EMAIL_2>m.numans@vumc.nl</EMAIL_2><URL>www.vumc.nl</URL><MOBILE_PHONE>++31 653 720990</MOBILE_PHONE><ADDRESS><DEPARTMENT>Department of General Practice and Elderly Care Medicine, EMGO Institute for Health and Care Research, and Alzheimer Center</DEPARTMENT><ORGANISATION>VU University Medical Center</ORGANISATION><ADDRESS_1>Van der Boechorststraat 7</ADDRESS_1><ADDRESS_2>12</ADDRESS_2><CITY>Amsterdam</CITY><COUNTRY CODE="NL">Netherlands</COUNTRY></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2013-02-04 11:18:48 -0500" MODIFIED_BY="Karin L Dearness">
<UP_TO_DATE>
<DATE DAY="1" MONTH="6" YEAR="2012"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="16" MONTH="12" YEAR="2011"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="1" MONTH="6" YEAR="2014"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="4" YEAR="1999"/>
<REVIEW_PUBLISHED ISSUE="2" YEAR="2000"/>
<LAST_CITATION_ISSUE ISSUE="11" YEAR="2010"/>
</DATES>
<WHATS_NEW MODIFIED="2012-11-08 09:20:41 -0500" MODIFIED_BY="Karin L Dearness">
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2012-11-08 09:20:37 -0500" MODIFIED_BY="[Empty name]">
<DATE DAY="1" MONTH="6" YEAR="2012"/>
<DESCRIPTION>
<P>Searches rerun and two new studies identified and included.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2012-11-08 09:20:41 -0500" MODIFIED_BY="Karin Dearness">
<DATE DAY="1" MONTH="6" YEAR="2012"/>
<DESCRIPTION>
<P>Two new studies identified and included. Conclusions not changed.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2010-11-15 09:51:18 -0500" MODIFIED_BY="Karin L Dearness">
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2010-11-15 09:51:18 -0500" MODIFIED_BY="Karin L Dearness">
<DATE DAY="17" MONTH="9" YEAR="2010"/>
<DESCRIPTION>
<P>Review is being republished to reflect change in authorship with 2009 update.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2010-09-17 14:14:44 -0400" MODIFIED_BY="Karin L Dearness">
<DATE DAY="5" MONTH="10" YEAR="2009"/>
<DESCRIPTION>
<P>Updated, 1 study added (<LINK REF="STD-Uemura-2008" TYPE="STUDY">Uemura 2008</LINK>)</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2008-11-19 09:38:15 -0500" MODIFIED_BY="Cathy Bennett">
<DATE DAY="30" MONTH="10" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2008-11-18 11:27:58 -0500" MODIFIED_BY="Cathy Bennett">
<DATE DAY="18" MONTH="5" YEAR="2006"/>
<DESCRIPTION>
<P>Minor update</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS" MODIFIED="2008-11-18 11:28:02 -0500" MODIFIED_BY="Cathy Bennett">
<DATE DAY="12" MONTH="3" YEAR="2006"/>
<DESCRIPTION>
<P>Conclusions changed</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS">
<DATE DAY="11" MONTH="3" YEAR="2006"/>
<DESCRIPTION>
<P>Substantive amendment</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2008-11-18 11:28:05 -0500" MODIFIED_BY="Cathy Bennett">
<DATE DAY="1" MONTH="1" YEAR="2006"/>
<DESCRIPTION>
<P>New studies found and included or excluded</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES>
<SOURCE>
<NAME>Department of General Practice, University Medical Center Utrecht</NAME>
<COUNTRY CODE="NL">Netherlands</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES>
<SOURCE>
<NAME>Division of Clinical Care Research; New England Medical Center; Boston</NAME>
<COUNTRY CODE="US">USA</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2013-04-30 10:28:20 -0400" MODIFIED_BY="Karin L Dearness">
<SUMMARY MODIFIED="2013-03-24 04:52:17 -0400" MODIFIED_BY="Kirsten E. Sigterman">
<TITLE MODIFIED="2013-02-04 11:17:40 -0500" MODIFIED_BY="Cathy Bennett">Short-term treatment with medications for heartburn symptoms</TITLE>
<SUMMARY_BODY MODIFIED="2013-03-24 04:52:17 -0400" MODIFIED_BY="Cathy Bennett">
<P>Patients with only mild or intermittent heartburn may have adequate relief with lifestyle modifications and with antacids, although other options are available. The two most commonly used drugs for treatment of heartburn are H2-receptor antagonists (H2RAs) and proton pump inhibitors (PPIs). These drugs act by suppressing the release of acid from the stomach. This review found that in the short term PPIs relieve heartburn better than H2RAs in patients who are treated without specific diagnostic testing. Although the difference is smaller, this is also true for patients with gastro-oesophageal reflux disease (GORD), who have a normal upper endoscopy . In summary, proton pump inhibitor drugs appear to be more effective than H2-receptor antagonists for relieving heartburn.<BR/>
</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2013-03-24 08:52:44 -0400" MODIFIED_BY="Cathy Bennett">
<ABS_BACKGROUND MODIFIED="2013-03-24 07:58:13 -0400" MODIFIED_BY="Cathy Bennett">
<P>Approximately 25% of adults regularly experience heartburn, a symptom of gastro-oesophageal reflux disease (GORD). Most patients are treated empirically (without specific diagnostic evaluation e.g. endoscopy. Among patients who have an upper endoscopy, findings range from a normal appearance, mild erythema to severe oesophagitis with stricture formation. Patients without visible damage to the oesophagus have endoscopy negative reflux disease (ENRD). The pathogenesis of ENRD, and its response to treatment may differ from GORD with oesophagitis.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2009-11-03 05:12:44 -0500" MODIFIED_BY="Cathy Bennett">
<P>Summarise, quantify and compare the efficacy of short-term use of proton pump inhibitors (PPI), H2-receptor antagonists (H2RA) and prokinetics in adults with GORD, treated empirically and in those with endoscopy negative reflux disease (ENRD).</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2012-11-08 09:21:35 -0500" MODIFIED_BY="Cathy Bennett">
<P>We searched MEDLINE (January 1966 to November 2011), EMBASE (January 1988 to November 2011), and EBMR in November 2011.<BR/>
</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2009-11-03 05:23:45 -0500" MODIFIED_BY="Cathy Bennett">
<P>Randomised controlled trials reporting symptomatic outcome after short-term treatment for GORD using proton pump inhibitors, H2-receptor antagonists or prokinetic agents. Participants had to be either from an empirical treatment group (no endoscopy used in treatment allocation) or from an endoscopy negative reflux disease group (no signs of erosive oesophagitis).</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2009-11-03 05:08:55 -0500" MODIFIED_BY="Cathy Bennett">
<P>Two authors independently assessed trial quality and extracted data.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2013-03-24 08:52:44 -0400" MODIFIED_BY="Kirsten E. Sigterman">
<P>Thirty-four trials (1314 participants) were included: fifteen in the empirical treatment group, fifteen in the ENRD group and four in both. In empirical treatment of GORD the risk ratio (RR) for heartburn remission (the primary efficacy variable) in placebo-controlled trials for PPI was 0.37 (two trials, 95% confidence interval (CI) 0.32 to 0.44), for H2RAs 0.77 (two trials, 95% CI 0.60 to 0.99) and for prokinetics 0.86 (one trial, 95% CI 0.73 to 1.01). In a direct comparison PPIs were more effective than H2RAs (seven trials, RR 0.66, 95% CI 0.60 to 0.73) and prokinetics (two trials, RR 0.53, 95% CI 0.32 to 0.87).</P>
<P>In treatment of ENRD, the RR for heartburn remission for PPI versus placebo was 0.71 (ten trials, 95% CI 0.65 to 0.78) and for H2RA versus placebo was 0.84 (two trials, 95% CI 0.74 to 0.95). The RR for PPI versus H2RA was 0.78 (three trials, 95% CI 0.62 to 0.97) and for PPI versus prokinetic 0.72 (one trial, 95% CI 0.56 to 0.92).</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS>
<P>PPIs are more effective than H2RAs in relieving heartburn in patients with GORD who are treated empirically and in those with ENRD, although the magnitude of benefit is greater for those treated empirically.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2013-04-30 10:28:20 -0400" MODIFIED_BY="Karin L Dearness">
<BACKGROUND MODIFIED="2013-03-24 07:23:30 -0400" MODIFIED_BY="Karin L Dearness">
<CONDITION MODIFIED="2013-03-24 07:23:30 -0400" MODIFIED_BY="Cathy Bennett">
<P>Approximately one in four adults in Western society experience heartburn at least monthly, while 5% suffer from it daily (<LINK REF="REF-Corder-1996" TYPE="REFERENCE">Corder 1996</LINK>; <LINK REF="REF-Isolauri-1995" TYPE="REFERENCE">Isolauri 1995</LINK>; <LINK REF="REF-Locke-1997" TYPE="REFERENCE">Locke 1997</LINK>; <LINK REF="REF-Nebel-1976" TYPE="REFERENCE">Nebel 1976</LINK>; <LINK REF="REF-Thompson-1982" TYPE="REFERENCE">Thompson 1982</LINK>). Heartburn is associated with reduced quality of life (<LINK REF="REF-Dimenas-1996" TYPE="REFERENCE">Dimenas 1996</LINK>), with billions of dollars spent annually on healthcare costs associated with its evaluation and treatment. Heartburn, especially if accompanied by acid regurgitation, is the typical clinical manifestation of gastro-oesophageal reflux disease (GORD), a term referring to both symptoms and oesophageal mucosal damage resulting from reflux of gastric acid into the oesophagus. A consensus of experts defined GORD as a condition that develops when the reflux of stomach contents causes troublesome symptoms and/or complications. Novel aspects of the new definition include a patient-centred approach that is independent of endoscopic findings (<LINK REF="REF-Vakil-2006" TYPE="REFERENCE">Vakil 2006</LINK>). The disease was sub-classified into oesophageal and extra-oesophageal syndromes. The accuracy of symptoms in diagnosis of GORD depends on the nature and severity of symptoms and the reference standard used. One study (<LINK REF="REF-Klauser-1990" TYPE="REFERENCE">Klauser 1990</LINK>) found that clearly dominant heartburn had a positive predictive value of 81% in diagnosing GORD (when defined by oesophageal pH (acidity) monitoring). Accuracy was reduced when the presence of heartburn alone was considered. Monitoring of oesophageal pH has been proposed as a reference standard for GORD, but is inconvenient and the result is negative in more than one third of patients with chronic heartburn. Furthermore, many patients with a normal pH do respond to antacids and have symptoms reproducible by acid infusion, while some even have oesophageal mucosa damage (<LINK REF="REF-Rodriguez-1999" TYPE="REFERENCE">Rodriguez 1999</LINK>; <LINK REF="REF-Shi-1995" TYPE="REFERENCE">Shi 1995</LINK>). The main importance of the use of endoscopy lies in diagnosing oesophagitis with possible complications such as bleeding, stricture formation, Barrett's metaplasia and adeno-carcinoma. However, between half and two-thirds of patients presenting with typical GORD symptoms have no endoscopic abnormalities (<LINK REF="REF-Joelsson-1989" TYPE="REFERENCE">Joelsson 1989</LINK>; <LINK REF="REF-Johansson-1986b" TYPE="REFERENCE">Johansson 1986b</LINK>; <LINK REF="REF-Johnsson-1987" TYPE="REFERENCE">Johnsson 1987</LINK>; <LINK REF="REF-Robinson--1998" TYPE="REFERENCE">Robinson 1998</LINK>; <LINK REF="REF-Tefera-1997" TYPE="REFERENCE">Tefera 1997</LINK>). Their condition is referred to as endoscopy negative reflux disease (ENRD). The severity and chronicity of symptoms in patients with ENRD is similar to that of patients with oesophagitis (<LINK REF="REF-Dent-1998" TYPE="REFERENCE">Dent 1998</LINK>; <LINK REF="REF-Johansson-1986b" TYPE="REFERENCE">Johansson 1986b</LINK>).</P>
</CONDITION>
<INTERVENTION MODIFIED="2013-03-24 04:59:29 -0400" MODIFIED_BY="Cathy Bennett">
<P>Several drugs are available for treatment of GORD. The most commonly used are H2-receptor antagonists (H2RAs) and proton pump inhibitors (PPIs). Prokinetic agents are used much less commonly.</P>
</INTERVENTION>
<THEORY MODIFIED="2013-03-24 04:59:56 -0400" MODIFIED_BY="Karin L Dearness">
<P>H2-receptor antagonists and proton pump inhibitors improve symptoms by reducing gastric acid secretion and hence oesophageal acid exposure. By contrast, prokinetic agents work principally by increasing lower oesophageal sphincter tone, thereby reducing reflux.</P>
</THEORY>
<IMPORTANCE MODIFIED="2013-03-24 05:00:30 -0400" MODIFIED_BY="Kirsten E. Sigterman">
<P>There is considerable variability in the choice of initial therapy and the use of endoscopy across healthcare settings. The variability is in part related to an incomplete understanding of response to treatment in clinically relevant subgroups of patients. This concern is particularly relevant for patients with ENRD, since most studies of GORD therapy have focused on patients with oesophagitis (<LINK REF="REF-Chiba-1997" TYPE="REFERENCE">Chiba 1997</LINK>). Similarly, the degree to which one option or another is better in patients who do not undergo investigation (i.e. are treated empirically) is incompletely understood.</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2013-03-24 05:01:16 -0400" MODIFIED_BY="Kate Cahill">
<P>Summarise, quantify and compare the efficacy of the short-term use of proton pump inhibitors, H2-receptor antagonists and prokinetics in adults with suspected gastro-oesophageal reflux disease who are treated empirically and in those with endoscopy negative reflux disease.</P>
</OBJECTIVES>
<METHODS MODIFIED="2013-04-30 10:28:20 -0400" MODIFIED_BY="Karin L Dearness">
<SELECTION_CRITERIA MODIFIED="2013-02-04 11:18:23 -0500" MODIFIED_BY="Cathy Bennett">
<CRIT_STUDIES>
<P>Randomised controlled trials with a single- or double-blinded design, in which one of the intervention types was contrasted with placebo or another intervention type.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2013-02-04 11:18:23 -0500" MODIFIED_BY="Cathy Bennett">
<UL>
<LI>Adults</LI>
<LI>Either gender</LI>
<LI>Predominant heartburn (a retrosternal burning sensation), diagnosed as GORD or reflux-like dyspepsia</LI>
<LI>Classifiable in one of the following two groups:</LI>
<UL>
<LI>empirical treatment group: no endoscopy performed or endoscopy results not used in allocating treatment;</LI>
<LI>endoscopy negative reflux disease group: on endoscopy either a normal oesophageal mucosa or diffuse erythema (i.e. no erosive oesophagitis).</LI>
</UL>
</UL>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2012-10-08 05:39:54 -0400" MODIFIED_BY="Cathy Bennett">
<P>Short-term treatment (one to twelve weeks) with proton pump inhibitors (esomeprazole, lansoprazole, omeprazole, pantoprazole, rabeprazole and dexlansoprazole), H2-receptor antagonists (cimetidine, famotidine, nizatidine and ranitidine) or prokinetics (cisapride, domperidone and metoclopramide).</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2013-01-14 07:51:03 -0500" MODIFIED_BY="Cathy Bennett">
<P>We studied the following comparisons for both the empirical treatment group and the ENRD group:<BR/>
</P>
<UL>
<LI>PPI versus placebo;</LI>
<LI>H2RA versus placebo;</LI>
<LI>prokinetic versus placebo;</LI>
<LI>PPI versus H2RA;</LI>
<LI>PPI versus prokinetic;</LI>
<LI>H2RA versus prokinetic.</LI>
</UL>
<CRIT_OUTCOMES_PRIMARY MODIFIED="2009-11-03 05:26:02 -0500" MODIFIED_BY="Cathy Bennett">
<P>Heartburn remission (defined as no more than one day per week with mild heartburn).</P>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2009-11-03 05:26:05 -0500" MODIFIED_BY="Cathy Bennett">
<P>(Partial) symptom relief; quality of life.</P>
<P>Studies using other types of symptomatic outcome measures were not included in our formal analysis.</P>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2013-03-24 05:07:59 -0400" MODIFIED_BY="Cathy Bennett">
<ELECTRONIC_SEARCHES MODIFIED="2013-03-24 05:07:59 -0400" MODIFIED_BY="Cathy Bennett">
<P>We constructed the original search strategy in <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK> by using a combination of MeSH subject headings and text words relating to the symptoms of gastro oesophageal reflux disease (GORD) and the associated pharmacological interventions. We applied the standard Cochrane search strategy filter for identifying randomised controlled trials to this search strategy.</P>
<P>For the updated review, the Cochrane Highly Sensitive Search Strategy for identifying randomised trials in MEDLINE, sensitivity maximising version; Ovid format (<LINK REF="REF-Cochrane-Handbook" TYPE="REFERENCE">Cochrane Handbook</LINK>), was combined with the search terms in the Appendices to identify randomised controlled trials in MEDLINE. The MEDLINE search strategy was adapted for use in the other databases searched.</P>
<P>We identified new reports of trials for the updated review by searching MEDLINE January 1966 to November 2011 (<LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>), EMBASE January 1988 to November 2011 (<LINK REF="APP-03" TYPE="APPENDIX">Appendix 3</LINK>), and evidence-based medicine reviews (including Cochrane DSR, ACP Journal Club, DARE, CCTR, CMR, HTA, and NHSEED to November 2011; <LINK REF="APP-04" TYPE="APPENDIX">Appendix 4</LINK>). We did not confine our search to English language publications. Searches in all databases were first conducted in December 2005, updated in November 2008 and in November 2011.<BR/>
</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2013-03-24 05:06:03 -0400" MODIFIED_BY="Cathy Bennett">
<P>We handsearched reference lists from trials selected by electronic searching to identify further relevant trials.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2013-04-30 10:28:20 -0400" MODIFIED_BY="Karin L Dearness">
<STUDY_SELECTION MODIFIED="2013-03-24 05:06:24 -0400" MODIFIED_BY="Cathy Bennett">
<P>We screened the titles and abstracts of trials identified using the search strategy first. Two review authors independently assessed the full articles of selected trials to confirm eligibility, assess quality and extract data using a data extraction form.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2013-03-24 05:07:01 -0400" MODIFIED_BY="Cathy Bennett">
<P>We recorded the following features:<BR/>
</P>
<UL>
<LI>Setting;</LI>
<LI>Country of origin;</LI>
<LI>Method of randomisation;</LI>
<LI>Adequacy of allocation concealment;</LI>
<LI>Details of blinding of participants and outcome assessors;</LI>
<LI>Inclusion and exclusion criteria used;</LI>
<LI>Baseline comparability between treatment groups;</LI>
<LI>Treatments compared and number of participants in each arm;</LI>
<LI>Outcome data in two-by-two tables or change in group means and standard deviations, when appropriate;</LI>
<LI>Drop-outs reported and their reasons.</LI>
</UL>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2013-03-24 05:11:54 -0400" MODIFIED_BY="Karin L Dearness">
<P>Two review authors independently assessed the full articles of selected trials to assess the risk of bias using the method described in the <LINK REF="REF-Cochrane-Handbook" TYPE="REFERENCE">Cochrane Handbook</LINK>.</P>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2013-03-24 09:52:27 -0400" MODIFIED_BY="Kirsten E. Sigterman">
<P>We expressed the impact of interventions as risk ratios together with 95% confidence intervals. We attempted meta-analysis only if there were sufficient trials of similar comparisons reporting the same outcomes. risk ratio were combined for binary outcomes.</P>
</EFFECT_MEASURES>
<UNIT_OF_ANALYSIS MODIFIED="2013-03-24 05:12:53 -0400" MODIFIED_BY="Karin L Dearness">
<P>We did not encounter any unit of analysis issues.</P>
</UNIT_OF_ANALYSIS>
<MISSING_DATA MODIFIED="2013-03-24 05:16:52 -0400" MODIFIED_BY="Karin L Dearness">
<P>So far we made no attempt to retrieve missing data; where applicable it is mentioned in the relevant sections.</P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2013-04-30 10:28:20 -0400" MODIFIED_BY="Karin L Dearness">
<P>We originally evaluated statistical heterogeneity between studies by using the Chi² test comparing numbers of participants symptom-free and considering significant for P values less than 0.10. For this update, we have classified studies secondarily with the I² statistic. The I² statistic describes the percentage of total variation across studies that is due to heterogeneity rather than chance (<LINK REF="REF-Higgins-2003" TYPE="REFERENCE">Higgins 2003</LINK>). This method does not inherently depend on the number of studies in the meta-analysis. A value of 0% indicates no observed heterogeneity, and larger values show increasing heterogeneity.</P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2013-04-22 10:32:46 -0400" MODIFIED_BY="Karin L Dearness">
<P>If a study protocol described an unpublished or unavailable trial, we assessed whether the prespecified primary and secondary outcomes of interest to this review were predicted in the results in the outcomes section. We did not search for unpublished studies. In one of our comparisons (PPI versus placebo in ENRD) this 2013 update counted 10 studies for the first time. Following Cochrane guidelines this would implicate testing for &#8220;small study effects&#8221; However, this is a comparison tested to potentially host only substantial heterogeneity until now. All studies are still comparable in size.  We considered testing on "small study effects" not adding substantial information. <BR/>
</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2013-03-24 09:53:06 -0400" MODIFIED_BY="Cathy Bennett">
<P>We compared the efficacy of PPI, H2RA and prokinetics with placebo and with each other. For each study, we calculated risk ratios and their 95% confidence intervals from the extracted data, and considered the finding statistically significant when the confidence interval did not include one. We calculated the number needed to treat for an additional beneficial outcome by taking the inverse of the absolute risk difference. We conducted all analyses on an intention-to-treat (ITT) basis, i.e. including all participants randomised. For the purposes of our formal meta-analysis, we calculated a pooled estimate of the risk ratios for heartburn relief if appropriate, using a random-effects model, which provides a more conservative estimate of the overall treatment response by incorporating between-study heterogeneity.</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2013-03-24 05:45:34 -0400" MODIFIED_BY="[Empty name]">
<P>Where we detected significant heterogeneity, we investigated possible explanations and summarised the data using a random-effects model. We stratified data on an ITT basis, and where possible we performed subgroup analysis of double- versus single-blind conditions, dose, drug class and duration of therapy. We compared change in quality of life in individual studies using group means.</P>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2013-03-24 05:46:54 -0400" MODIFIED_BY="Karin L Dearness">
<P>We performed additional pooling using a fixed-effect model to test whether point estimates were similar. If we found no difference, we have reported only the random-effects values, as these are more conservative.</P>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2013-04-30 10:27:25 -0400" MODIFIED_BY="Karin L Dearness">
<STUDY_DESCRIPTION MODIFIED="2013-04-22 10:40:12 -0400" MODIFIED_BY="Cathy Bennett">
<SEARCH_RESULTS MODIFIED="2013-03-24 05:55:49 -0400" MODIFIED_BY="Cathy Bennett">
<P>The search strategy defined above generated over 3000 references (<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>). After screening titles, abstracts and, if necessary, the full paper, we included 34 trials in our analysis. From 19 trials we extracted data on outcome of empirical treatment for gastro-oesophageal reflux disease (GORD), and from 19 trials data on outcome of treatment for endoscopy negative reflux disease (ENRD); four trials presented data on both groups (<LINK REF="STD-Armstrong-2001" TYPE="STUDY">Armstrong 2001</LINK>; <LINK REF="STD-Bate-1997" TYPE="STUDY">Bate 1997</LINK>; <LINK REF="STD-Galmiche-1997" TYPE="STUDY">Galmiche 1997</LINK>; <LINK REF="STD-Venables-1997" TYPE="STUDY">Venables 1997</LINK>). Thirty-one other studies did not present dichotomous outcome measures, or did not match our inclusion criteria, and were subsequently excluded. They are listed in the table <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>.</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2013-04-22 10:40:12 -0400" MODIFIED_BY="Cathy Bennett">
<SUBSECTION>
<HEADING LEVEL="4">Design</HEADING>
<P>All included studies used a double-blinded and parallel group design. In three of them (<LINK REF="STD-Behar-1978" TYPE="STUDY">Behar 1978</LINK>; <LINK REF="STD-Bright_x002d_Asare-1980" TYPE="STUDY">Bright-Asare 1980</LINK>; <LINK REF="STD-McCallum-1977" TYPE="STUDY">McCallum 1977</LINK>) the term 'randomisation' was not stated explicitly, although some form of allocation concealment was suggested. The other studies were all described as randomised. In three studies a cross-over design was used. From two of them (<LINK REF="REF-Johansson-1986b" TYPE="REFERENCE">Johansson 1986b</LINK>; <LINK REF="STD-McCallum-1977" TYPE="STUDY">McCallum 1977</LINK>) we extracted only data from the first treatment period, while the third study (<LINK REF="STD-Watson-1997" TYPE="STUDY">Watson 1997</LINK>) did not provide these data, so we used data from the full cross-over study (a carry-over effect was not anticipated).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Setting</HEADING>
<P>The 34 trials were conducted in North America, Europe, Australia, South Africa, China and Japan. All but five (<LINK REF="STD-Bright_x002d_Asare-1980" TYPE="STUDY">Bright-Asare 1980</LINK>; <LINK REF="REF-Johansson-1986b" TYPE="REFERENCE">Johansson 1986b</LINK>; <LINK REF="STD-McCallum-1977" TYPE="STUDY">McCallum 1977</LINK>; <LINK REF="STD-Tan-2011" TYPE="STUDY">Tan 2011</LINK>; <LINK REF="STD-Watson-1997" TYPE="STUDY">Watson 1997</LINK>) were multicentre trials. In six (<LINK REF="STD-Armstrong-2005" TYPE="STUDY">Armstrong 2005</LINK>; <LINK REF="STD-Carlsson-1998" TYPE="STUDY">Carlsson 1998</LINK>; <LINK REF="STD-Hatlebakk-1999" TYPE="STUDY">Hatlebakk 1999</LINK>; <LINK REF="STD-Rush-1995" TYPE="STUDY">Rush 1995</LINK>; <LINK REF="STD-Talley-2002" TYPE="STUDY">Talley 2002</LINK>; <LINK REF="STD-Venables-1997" TYPE="STUDY">Venables 1997</LINK>), participants were exclusively recruited by primary care physicians. Recruitment in another (<LINK REF="STD-Bardhan-1999" TYPE="STUDY">Bardhan 1999</LINK>) was from both primary and secondary care centres. One trial studied patients referred to a regional ambulatory pH monitoring service (<LINK REF="STD-Watson-1997" TYPE="STUDY">Watson 1997</LINK>), and one included only patients referred for possible anti-reflux surgery (<LINK REF="REF-Johansson-1986b" TYPE="REFERENCE">Johansson 1986b</LINK>). The other studies provided no details on participant recruitment.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Participants</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Empirical Treatment Group</HEADING>
<P>We extracted data from a total of 6734 participants in nineteen trials. The mean number randomised per trial in this group was 354 (range 34 to 994). The mean age of all participants was 51 years (range 18 to 87), with 54% male. One trial included participants with symptoms of heartburn and regurgitation (<LINK REF="STD-McCallum-1977" TYPE="STUDY">McCallum 1977</LINK>), one with two of the following: heartburn, epigastric pain and regurgitation (<LINK REF="STD-Hallerback-1998" TYPE="STUDY">Hallerback 1998</LINK>), one with long-standing symptoms of GORD (<LINK REF="REF-Johansson-1986b" TYPE="REFERENCE">Johansson 1986b</LINK>) and another with symptoms of heartburn, acid eructation or pain on swallowing/dysphagia (<LINK REF="STD-Van-Zyl-2004" TYPE="STUDY">Van Zyl 2004</LINK>).</P>
<P>In all other trials, the primary inclusion criterion was heartburn meeting various criteria concerning severity, frequency and duration. Positive Bernstein testing was additionally required for all participants in two studies (<LINK REF="STD-Behar-1978" TYPE="STUDY">Behar 1978</LINK>; <LINK REF="STD-Bright_x002d_Asare-1980" TYPE="STUDY">Bright-Asare 1980</LINK>), and only for participants with no signs of oesophagitis in two other studies (<LINK REF="STD-Sabesin-1991" TYPE="STUDY">Sabesin 1991</LINK>; <LINK REF="STD-Sontag-1987" TYPE="STUDY">Sontag 1987</LINK>). In one trial reflux had to be demonstrable on x-ray or oesophagoscopy (<LINK REF="STD-McCallum-1977" TYPE="STUDY">McCallum 1977</LINK>). In seven trials endoscopy was either not performed (<LINK REF="STD-Armstrong-2005" TYPE="STUDY">Armstrong 2005</LINK>; <LINK REF="STD-Castell-1998" TYPE="STUDY">Castell 1998</LINK>; <LINK REF="STD-Rush-1995" TYPE="STUDY">Rush 1995</LINK>; <LINK REF="STD-Talley-2002" TYPE="STUDY">Talley 2002</LINK>; <LINK REF="STD-Van-Zyl-2004" TYPE="STUDY">Van Zyl 2004</LINK>) or its findings were not described (<LINK REF="STD-Bright_x002d_Asare-1980" TYPE="STUDY">Bright-Asare 1980</LINK>; <LINK REF="STD-McCallum-1977" TYPE="STUDY">McCallum 1977</LINK>). Participants with circumferential oesophagitis or oesophageal ulcer were excluded from seven trials (<LINK REF="STD-Armstrong-2001" TYPE="STUDY">Armstrong 2001</LINK>; <LINK REF="STD-Bardhan-1999" TYPE="STUDY">Bardhan 1999</LINK>; <LINK REF="STD-Bate-1997" TYPE="STUDY">Bate 1997</LINK>; <LINK REF="STD-Galmiche-1997" TYPE="STUDY">Galmiche 1997</LINK>; <LINK REF="STD-Hallerback-1998" TYPE="STUDY">Hallerback 1998</LINK>; <LINK REF="STD-Johnsson-2003" TYPE="STUDY">Johnsson 2003</LINK>; <LINK REF="STD-Venables-1997" TYPE="STUDY">Venables 1997</LINK>). One trial excluded participants with continuous (but non-circumferential) mucosal breaks (<LINK REF="STD-Hatlebakk-1999" TYPE="STUDY">Hatlebakk 1999</LINK>). Other common reasons for exclusion were: Barrett's oesophagus, oesophageal stricture, peptic ulcer disease and the recent use of antisecretory drugs.<BR/>
</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Endoscopy Negative Group</HEADING>
<P>We extracted data from 6406 participants in nineteen trials. The mean number of participants randomised per trial was 337 (range 19 to 947). The mean age of the participants was 48 years (range 18 to 80), with 41% male. One trial included participants with both heartburn and regurgitation (<LINK REF="STD-Riemann-1991" TYPE="STUDY">Riemann 1991</LINK>), three with either heartburn or regurgitation (<LINK REF="STD-Fujiwara-2005" TYPE="STUDY">Fujiwara 2005</LINK>; <LINK REF="STD-Tan-2011" TYPE="STUDY">Tan 2011</LINK>; <LINK REF="STD-Watson-1997" TYPE="STUDY">Watson 1997</LINK>) and one with heartburn, regurgitation or dysphagia (<LINK REF="STD-Schenk-1997" TYPE="STUDY">Schenk 1997</LINK>). In all other trials, heartburn was the primary inclusion criterion. Additional positive Bernstein testing was required in one study (<LINK REF="STD-Robinson-1991" TYPE="STUDY">Robinson 1991</LINK>), a normal 24-hour pH study in another (<LINK REF="STD-Watson-1997" TYPE="STUDY">Watson 1997</LINK>). Participants with any degree of erosive oesophagitis were excluded from all studies in this group. Other common exclusion criteria were: Barrett's oesophagus, oesophageal stricture, peptic ulcer disease and the recent use of antisecretory drugs.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Intervention</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Empirical Treatment Group</HEADING>
<P>Ten trials studied a proton pump inhibitor (PPI). This included fourteen treatment arms studying esomeprazole (20 mg twice and 40 mg once daily), omeprazole (10, 20 and 40 mg once daily) and pantoprazole (20 and 40 mg once daily) versus placebo (two studies; two and eight weeks), versus H2-receptor antagonists (H2RAs) (seven studies; two and four weeks), or versus prokinetics (one study; four weeks).</P>
<P>Fourteen trials studied an H2RA, including fifteen treatment arms: cimetidine (300 and 400 mg four times daily), famotidine (20 mg twice and 40 mg once daily), nizatidine (150 mg twice daily) and ranitidine (150 mg twice and 300 mg once daily) versus placebo (six studies; two, six, eight and twelve weeks), versus PPIs (seven studies; two and four weeks), or versus prokinetics (one study; eight weeks).<BR/>
<BR/>Five trials studied a prokinetic agent (five treatment arms): metoclopramide (10 mg four times daily) and cisapride (10 mg four times and 20 mg twice daily) versus placebo (four studies; four and eight weeks), versus PPI (two studies; four and eight weeks), or versus H2RA (one study; eight weeks).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Endoscopy Negative Group</HEADING>
<P>Seventeen trials studied PPIs (28 treatment arms): esomeprazole (20 and 40 mg once daily), omeprazole (10, 20 and 40 mg once daily), lansoprazole (15 and 30 mg once daily), pantoprazole (40 mg once daily), rabeprazole (20 mg once daily) and dexlansoprazole (30 and 60mg once daily) versus placebo (ten trials; two, four and eight weeks), versus H2RAs (five studies; four and eight weeks), or versus prokinetics (one study; four weeks).</P>
<P>Seven trials studied H2RAs (eight treatment arms): cimetidine (200 or 400 mg four times daily), famotidine (20 mg twice or 40 mg once daily), nizatidine (150 mg twice daily) and ranitidine (150 mg twice daily) versus placebo (two studies; two and six weeks), or versus PPIs (five studies; four and eight weeks).</P>
<P>Prokinetics were studied in one trial (one treatment arm), where cisapride (10 mg four times daily) was compared with a PPI (four weeks).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Outcome</HEADING>
<P>Symptomatic outcome measures were used in all trials, since this was one of the inclusion criteria for this review. Data on heartburn outcome were provided in most detail, often expressed in terms of severity and frequency, using measures such as visual analogue scales (VAS), four-grade Likert or own-symptom scores. In some studies a distinction was made between outcome for daytime and night time heartburn. Many studies provided limited data on regurgitation, dysphagia and other symptoms. The primary efficacy variable of this review was remission of heartburn, defined as no more than one day with mild heartburn per week. Eleven trials used a quality of life instrument in assessing therapeutic response. The Gastro-intestinal Symptom Rating Scale (GSRS) was used in seven (<LINK REF="STD-Armstrong-2001" TYPE="STUDY">Armstrong 2001</LINK>; <LINK REF="STD-Armstrong-2005" TYPE="STUDY">Armstrong 2005</LINK>; <LINK REF="STD-Carlsson-1998" TYPE="STUDY">Carlsson 1998</LINK>; <LINK REF="STD-Fujiwara-2005" TYPE="STUDY">Fujiwara 2005</LINK>; <LINK REF="STD-Galmiche-1997" TYPE="STUDY">Galmiche 1997</LINK>; <LINK REF="STD-Lind-1997" TYPE="STUDY">Lind 1997</LINK>; <LINK REF="STD-Talley-2002" TYPE="STUDY">Talley 2002</LINK>), the Psychological General Well-Being index (PGWB index) in two (<LINK REF="STD-Galmiche-1997" TYPE="STUDY">Galmiche 1997</LINK>; <LINK REF="STD-Lind-1997" TYPE="STUDY">Lind 1997</LINK>), the Short-Form Health Survey (SF-36) in four (<LINK REF="STD-Armstrong-2001" TYPE="STUDY">Armstrong 2001</LINK>; <LINK REF="STD-Fujiwara-2005" TYPE="STUDY">Fujiwara 2005</LINK>; <LINK REF="STD-Rush-1995" TYPE="STUDY">Rush 1995</LINK>; <LINK REF="STD-Tan-2011" TYPE="STUDY">Tan 2011</LINK>) and the heartburn-specific questionnaire in one (<LINK REF="STD-Rush-1995" TYPE="STUDY">Rush 1995</LINK>).</P>
</SUBSECTION>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2013-03-24 06:29:18 -0400" MODIFIED_BY="Cathy Bennett">
<P>We excluded 31 potentially eligible trials. See the <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK> table for details.</P>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2013-04-22 10:40:18 -0400" MODIFIED_BY="Karin L Dearness">
<P>The risk of bias assessments are shown in <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>.</P>
<ALLOCATION MODIFIED="2013-03-24 06:34:38 -0400" MODIFIED_BY="Karin L Dearness">
<P>Six of the more recent trials (<LINK REF="STD-Armstrong-2005" TYPE="STUDY">Armstrong 2005</LINK>; <LINK REF="STD-Fass-2009" TYPE="STUDY">Fass 2009</LINK>; <LINK REF="STD-Katz-2003" TYPE="STUDY">Katz 2003</LINK>; <LINK REF="STD-Lind-1997" TYPE="STUDY">Lind 1997</LINK>; <LINK REF="STD-Talley-2002" TYPE="STUDY">Talley 2002</LINK>; <LINK REF="STD-Tan-2011" TYPE="STUDY">Tan 2011</LINK>) were classified as having a low risk of selection bias, indicating adequate allocation concealment. In all the other trials, little or no information was provided on allocation concealment. In those cases we classified the risk of bias as unclear.</P>
</ALLOCATION>
<BLINDING MODIFIED="2013-03-24 06:36:29 -0400" MODIFIED_BY="Karin L Dearness">
<P>Performance bias and detection bias were evaluated for the 2013 update. In 17 studies (<LINK REF="STD-Armstrong-2001" TYPE="STUDY">Armstrong 2001</LINK>; <LINK REF="STD-Armstrong-2005" TYPE="STUDY">Armstrong 2005</LINK>; <LINK REF="STD-Bardhan-1999" TYPE="STUDY">Bardhan 1999</LINK>; <LINK REF="STD-Bate-1996" TYPE="STUDY">Bate 1996</LINK>; <LINK REF="STD-Castell-1998" TYPE="STUDY">Castell 1998</LINK>; <LINK REF="STD-Fass-2009" TYPE="STUDY">Fass 2009</LINK>; <LINK REF="STD-Galmiche-1997" TYPE="STUDY">Galmiche 1997</LINK>; <LINK REF="STD-Hatlebakk-1999" TYPE="STUDY">Hatlebakk 1999</LINK>; <LINK REF="STD-Johnsson-2003" TYPE="STUDY">Johnsson 2003</LINK>: <LINK REF="STD-Kahrilas-2005" TYPE="STUDY">Kahrilas 2005</LINK>; <LINK REF="STD-Katz-2003" TYPE="STUDY">Katz 2003</LINK>; <LINK REF="STD-Richter-2000b" TYPE="STUDY">Richter 2000b</LINK>; <LINK REF="STD-Rush-1995" TYPE="STUDY">Rush 1995</LINK>; <LINK REF="STD-Talley-2002" TYPE="STUDY">Talley 2002</LINK>; <LINK REF="STD-Tan-2011" TYPE="STUDY">Tan 2011</LINK>; <LINK REF="STD-Van-Zyl-2004" TYPE="STUDY">Van Zyl 2004</LINK>; <LINK REF="STD-Venables-1997" TYPE="STUDY">Venables 1997</LINK>) blinding was assessed as being adequate. In one trial (<LINK REF="STD-Fujiwara-2005" TYPE="STUDY">Fujiwara 2005</LINK>) no blinding was described, so we classified it as having a high risk of bias. None of the other trials provided enough information to classify the risk of bias.</P>
</BLINDING>
<EXCLUSIONS MODIFIED="2013-03-24 06:37:21 -0400" MODIFIED_BY="Karin L Dearness">
<P>The quality of data reporting by most trials was poor; ITT analysis was reported in only a few studies, although in most cases data could be re-analysed on an ITT basis from the data presented. Data could be analysed only per protocol from four studies (<LINK REF="STD-Bardhan-1999" TYPE="STUDY">Bardhan 1999</LINK>; <LINK REF="STD-McCallum-1977" TYPE="STUDY">McCallum 1977</LINK>; <LINK REF="STD-Riemann-1991" TYPE="STUDY">Riemann 1991</LINK>; <LINK REF="STD-Schenk-1997" TYPE="STUDY">Schenk 1997</LINK>).</P>
</EXCLUSIONS>
<SELECTIVE_REPORTING MODIFIED="2013-03-24 06:39:20 -0400" MODIFIED_BY="Karin L Dearness">
<P>There was insufficient information to permit judgement of low or high risk of reporting bias in any trials. All are assessed as being at unclear risk. <LINK REF="STD-Fass-2009" TYPE="STUDY">Fass 2009</LINK> measured quality of life as a secondary outcome, but did not report the results.</P>
</SELECTIVE_REPORTING>
<OTHER_BIAS_SOURCES MODIFIED="2013-04-22 10:40:18 -0400" MODIFIED_BY="Karin L Dearness">
<P>
<LINK REF="STD-Galmiche-1997" TYPE="STUDY">Galmiche 1997</LINK>, testing PPI versus prokinetics, used an inadequate dose of omeprazole (10mg) in one treatment arm, which could have decreased the relative efficacy of the PPI. <LINK REF="STD-Castell-1998" TYPE="STUDY">Castell 1998</LINK> selected participants by means of a placebo run-in period, which could have increased the relative efficacy of the cisapride. <LINK REF="STD-Johansson-1986a" TYPE="STUDY">Johansson 1986a</LINK> used a cross-over design.</P>
<P>We found no obvious potential source of bias in the remaining trials, apart from the fact that the use of antacids as rescue medication was allowed in most of the included trials. Since a higher use of rescue medication can be expected, and was observed, in the study group randomised to receive the less effective drug or placebo, the clinical outcome in this group may improve, thereby decreasing the relative efficacy of the more effective drug. This effect may also account for the high healing rate observed in placebo groups from oesophagitis trials (<LINK REF="REF-Chiba-1997" TYPE="REFERENCE">Chiba 1997</LINK>).</P>
</OTHER_BIAS_SOURCES>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2013-04-30 10:27:25 -0400" MODIFIED_BY="Cathy Bennett">
<SUBSECTION>
<HEADING LEVEL="3">Empirical treatment for gastro-oesophageal reflux disease (GORD)</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Heartburn remission</HEADING>
<P>The risk ratio (RR) in the two placebo-controlled proton pump inhibitor (PPI) trials was in favour of the PPI: 0.37 (95% CI 0.32 to 0.44; <LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>, <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>). For H2RA versus placebo (two trials) RR was 0.77 (95% CI 0.60 to 0.99; <LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>, <LINK REF="FIG-04" TYPE="FIGURE">Figure 4</LINK>) and for prokinetic versus placebo (one trial) 0.86 (95% CI 0.73 to 1.01; <LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK>). Seven trials compared a PPI with an H2RA. PPIs were significantly (P &lt; 0.05) more effective (RR 0.66, 95% CI 0.60 to 0.73; <LINK REF="CMP-004.01" TYPE="ANALYSIS">Analysis 4.1</LINK>, <LINK REF="FIG-05" TYPE="FIGURE">Figure 5</LINK>). The RR for PPI versus prokinetic (two trials) was 0.53 (95% CI 0.32 to 0.87; <LINK REF="CMP-005.01" TYPE="ANALYSIS">Analysis 5.1</LINK>). None of the trials comparing H2RAs with prokinetics reported outcome in terms of complete heartburn relief.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Overall symptom improvement</HEADING>
<P>For H2RA (four trials) and prokinetic (two trials) the RR in placebo-controlled trials was 0.72 (95% CI 0.63 to 0.81; <LINK REF="CMP-002.04" TYPE="ANALYSIS">Analysis 2.4</LINK>) respectively 0.71 (95% CI 0.56 to 0.91; <LINK REF="CMP-003.04" TYPE="ANALYSIS">Analysis 3.4</LINK>). The RR in the one trial directly comparing a PPI with an H2RA in this category was 0.29 (95% CI 0.17 to 0.51; <LINK REF="CMP-004.02" TYPE="ANALYSIS">Analysis 4.2</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Daytime heartburn relief</HEADING>
<P>The RR for H2RA versus placebo (four trials) was 0.80 (95% CI 0.71 to 0.89; <LINK REF="CMP-002.02" TYPE="ANALYSIS">Analysis 2.2</LINK>) and for prokinetic versus placebo (two trials) 0.63 (95% CI 0.51 to 0.77; <LINK REF="CMP-003.02" TYPE="ANALYSIS">Analysis 3.2</LINK>). When H2RA and prokinetic were directly compared (<LINK REF="STD-Bright_x002d_Asare-1980" TYPE="STUDY">Bright-Asare 1980</LINK>), no significant difference in efficacy was demonstrated (RR 0.83, 95% CI 0,30 to 2,29; <LINK REF="CMP-006.01" TYPE="ANALYSIS">Analysis 6.1</LINK>). No PPI trials were included.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Night time heartburn relief</HEADING>
<P>The RR for H2RA versus placebo (three trials) was 0.77 (95% CI 0.63 to 0.94; <LINK REF="CMP-002.03" TYPE="ANALYSIS">Analysis 2.3</LINK>) and for prokinetic versus placebo (one trial) 0.51 (95% CI 0.41 to 0.64; <LINK REF="CMP-003.03" TYPE="ANALYSIS">Analysis 3.3</LINK>). No PPI trials were included.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Treatment for endoscopy negative reflux disease (ENRD)</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Heartburn remission</HEADING>
<P>Ten placebo-controlled PPI trials in this group used this outcome measure. The RR for PPI was 0.71 (95% CI 0.65 to 0.78; <LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>, <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>). For H2RA versus placebo (two trials) the RR was 0.84 (95% CI 0.74 to 0.95; <LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>, <LINK REF="FIG-04" TYPE="FIGURE">Figure 4</LINK>). In four trials PPIs were directly compared with H2RAs; the RR was 0.78 (95% CI 0.62 to 0.97; <LINK REF="CMP-004.01" TYPE="ANALYSIS">Analysis 4.1</LINK>, <LINK REF="FIG-05" TYPE="FIGURE">Figure 5</LINK>). In the only trial comparing a PPI with prokinetic treatment the outcome was in favour of the former (RR 0.72, 95% CI 0.56 to 0.92; <LINK REF="CMP-005.01" TYPE="ANALYSIS">Analysis 5.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Overall symptom improvement</HEADING>
<P>When PPIs were compared with placebo (six trials) the RR was 0.62 (95% CI 0.55 to 0.69; <LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>). For H2RA versus placebo (two trials) the RR was 0.41 (95% CI 0.13 to 1.33; <LINK REF="CMP-002.04" TYPE="ANALYSIS">Analysis 2.4</LINK>). In the two trials directly comparing the two groups, PPIs were superior to H2RAs (RR 0.82, 95% CI 0.73 to 0.93; <LINK REF="CMP-004.02" TYPE="ANALYSIS">Analysis 4.2</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Daytime heartburn relief</HEADING>
<P>The only trial included here compared H2RA with placebo (RR 0.75, 95% CI 0.61 to 0.93; <LINK REF="CMP-002.02" TYPE="ANALYSIS">Analysis 2.2</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Night time heartburn relief</HEADING>
<P>The RR for H2RA versus placebo (one trial) was 0.80 (95% CI 0.59 to 1.08; <LINK REF="CMP-002.03" TYPE="ANALYSIS">Analysis 2.3</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Quality of life</HEADING>
<P>For empirical treatment of GORD no significant difference between omeprazole 20 mg once, omeprazole 10 mg once and cisapride 10 mg four times daily was found with respect to the change in global psychological general well being (PGWB) and gastrointestinal symptom rating scale (GSRS). However, improvement in the reflux dimension of the GSRS was significantly greater (P &lt; 0.05) with a PPI than with an H2RA (three trials) and greater with omeprazole 20 mg once daily than with cisapride 10 mg four times daily. In one trial (<LINK REF="STD-Armstrong-2005" TYPE="STUDY">Armstrong 2005</LINK>) total GSRS in four weeks improved significantly more (P &lt; 0.001) with omeprazole 20 mg once than with ranitidine 150 mg twice daily. Significant differences (P &lt; 0.05) were found between the effect of ranitidine 150 mg twice daily and placebo on all scales of the heartburn-specific quality of life questionnaire, but only on three (physical functioning, bodily pain and vitality) of the acute form of the SF-36.</P>
<P>In ENRD, therapy with PPIs compared with placebo significantly improved the PGWB index and the GSRS reflux dimension (P &lt; 0.05) , but not the global GSRS score and the SF-36. No difference in improvement in the reflux dimension of the GSRS (two trials) or in SF-36 (one trial) could be demonstrated in this category between PPIs and H2RAs.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Other findings</HEADING>
<P>Whether use of antacids as rescue medication was permitted was unclear in six trials, while it was permitted explicitly in all others. In general antacid use was significantly higher in the placebo group or in the group randomised to receive the least effective drug.</P>
<P>Two studies presented data on outcome in subgroups with normal pH study (<LINK REF="STD-Schenk-1997" TYPE="STUDY">Schenk 1997</LINK>; <LINK REF="STD-Watson-1997" TYPE="STUDY">Watson 1997</LINK>). In both trials omeprazole (40 mg once or 20 mg twice daily) was significantly superior to placebo in providing heartburn control. <LINK REF="STD-Lind-1997" TYPE="STUDY">Lind 1997</LINK> stratified participants according to percentage of time with pH below four. They found that sufficient heartburn control with omeprazole was achieved in all participants, with efficacy increasing with increasing baseline levels of acid reflux.</P>
<P>
<LINK REF="STD-Bate-1997" TYPE="STUDY">Bate 1997</LINK> stratified participants according to heartburn severity at entry. They found that the treatment effect of omeprazole was higher in participants with baseline mild heartburn compared with those with moderate or severe heartburn. In two studies (<LINK REF="STD-Bate-1997" TYPE="STUDY">Bate 1997</LINK>; <LINK REF="STD-Galmiche-1997" TYPE="STUDY">Galmiche 1997</LINK>) a direct comparison was made between subgroups of participants with and without oesophagitis. Omeprazole was superior to both cimetidine and cisapride regardless of the presence or absence of oesophagitis. However, the relative efficacy of omeprazole was higher in the presence of oesophagitis. <LINK REF="STD-Johnsson-2003" TYPE="STUDY">Johnsson 2003</LINK> found that esomeprazole was more effective in achieving heartburn relief in participants with erosive oesophagitis than in participants without, and more effective in participants with a positive pH-study than in participants without.</P>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2013-04-30 10:27:40 -0400" MODIFIED_BY="Karin L Dearness">
<SUMMARY_OF_RESULTS MODIFIED="2013-03-24 09:53:21 -0400" MODIFIED_BY="Cathy Bennett">
<P>We found evidence in the international literature that when patients are selected primarily based on symptoms (i.e. heartburn meeting certain criteria) and the diagnostic probability of gastro-oesophageal reflux disease (GORD) is high, proton pump inhibitors (PPIs) are superior to both H2-receptor antagonists (H2RAs) (seven trials) and prokinetics in achieving heartburn remission. H2RAs are also effective in promoting symptom relief, while the evidence for efficacy of prokinetics is less clear. We identified only two placebo-controlled PPI trials on short-term empirical treatment for GORD.</P>
<P>Furthermore we found evidence that in patients with endoscopy negative reflux disease (ENRD), a short course of antisecretory drugs is effective in controlling symptoms. In this group PPIs were also superior to H2RAs (four trials), although the difference was smaller compared to studies of patients treated empirically. In the only trial comparing an antisecretory (omeprazole) with a prokinetic agent (cisapride) outcome was in favour of the PPI. We did not find any placebo-controlled trials on the efficacy of prokinetics for ENRD.</P>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2013-03-24 07:26:47 -0400" MODIFIED_BY="Karin L Dearness">
<P>Data on the efficacy of PPIs and H2RAs in empirical treatment of GORD and in treatment of ENRD seem to be sufficient, and can be applied to daily practice. Very few data exist on the efficacy of prokinetics.</P>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2013-03-24 07:27:51 -0400" MODIFIED_BY="Karin L Dearness">
<P>In total, we included 34 randomised controlled trials. In general, they provided little or no information on allocation concealment. The quality of the data reporting of most trials was poor.</P>
</QUALITY_OF_EVIDENCE>
<POTENTIAL_BIASES MODIFIED="2013-04-30 10:27:40 -0400" MODIFIED_BY="Cathy Bennett">
<P>Heterogeneity was tested for the primary outcome variable only. We detected statistical heterogeneity in the PPI versus H2RA trials. Both in the empirical treatment group (I² = 56%, moderate heterogeneity) and in the ENRD group (I² = 47%, moderate heterogeneity), this was caused by the results of one trial (<LINK REF="STD-Bate-1997" TYPE="STUDY">Bate 1997</LINK>), for which we could find no clear explanation. Heterogeneity in the PPI versus prokinetic trials (empirical treatment group, I² = 87%, considerable heterogeneity) was caused by the inclusion of results from the treatment arm using a low dose omeprazole (10 mg), which decreased the relative efficacy of the PPI arm. In trials studying PPI versus placebo for ENRD (I² = 78%, substantial heterogeneity), heterogeneity was caused by two trials (<LINK REF="STD-Bate-1996" TYPE="STUDY">Bate 1996</LINK>; <LINK REF="STD-Carlsson-1998" TYPE="STUDY">Carlsson 1998</LINK>) and could not be explained. Finally, the placebo-controlled H2RA trials for empirical treatment of GORD (I² = 77%, substantial heterogeneity) were heterogeneous because of differences in treatment duration. Heterogeneity overall had little impact on outcome, with sensitivity analyses revealing no large changes in pooled risk ratios. Furthermore, we detected no differences in the direction of results.</P>
<P>The chronic relapsing nature of GORD often requires long-term or maintenance treatment. When GORD is treated, clinical response typically is achieved within a couple of weeks (<LINK REF="REF-Chiba-1997" TYPE="REFERENCE">Chiba 1997</LINK>). Since our main interest was drug efficacy and not long-term disease management, we focused on short-term trials. Theoretically differences in treatment duration between drug groups can mask differences in efficacy. However, for the primary outcome measure we found no important differences in duration between placebo-controlled PPI or H2RA trials.</P>
<P>It can be argued that our 'empirical group' is not truly empirical, since in most of the trials an endoscopy was performed and patients were excluded because of either severe or complicated oesophagitis or peptic ulcer disease (PUD). Most studies did not provide details on the number of participants excluded for this reason. We believe these numbers were not high enough to have had a significant impact on the clinical outcomes, since the incidence of PUD and severe or complicated oesophagitis amongst participants presenting with predominant heartburn is low. In one study (<LINK REF="STD-Hallerback-1998" TYPE="STUDY">Hallerback 1998</LINK>) only 14 participants out of 441 (3%) were excluded on the basis of these endoscopic findings. The empirical group evaluated in the review in our opinion represents a good reflection of the adult population presenting with uncomplicated GORD.</P>
<P>We excluded trials presenting only symptom scores as the outcome variable, because their results are difficult to pool and do not translate easily to daily practice. Symptom relief was defined in different ways in the studies we included. To present a robust conclusion, we focused attention on complete or near complete symptom relief in our formal meta-analysis.</P>
</POTENTIAL_BIASES>
<AGREEMENT MODIFIED="2013-03-24 07:37:29 -0400" MODIFIED_BY="Kirsten E. Sigterman">
<P>The efficacy of antisecretory and prokinetic agents in controlling symptoms and promoting endoscopic healing in patients with oesophagitis has previously been established (<LINK REF="REF-Chiba-1997" TYPE="REFERENCE">Chiba 1997</LINK>; <LINK REF="REF-Galmiche-1990" TYPE="REFERENCE">Galmiche 1990</LINK>; <LINK REF="REF-Janisch-1988" TYPE="REFERENCE">Janisch 1988</LINK>; <LINK REF="REF-Maleev-1990" TYPE="REFERENCE">Maleev 1990</LINK>). PPIs have been proven to be superior to H2RAs, and the efficacy of prokinetics is similar to that of H2RAs. Prokinetics are no longer used widely since the availability of cisapride has been severely restricted.</P>
<P>Guidelines for medical treatment of GORD have been developed in different countries (<LINK REF="REF-Devault-2005" TYPE="REFERENCE">Devault 2005</LINK>; <LINK REF="REF-Kroes-1999" TYPE="REFERENCE">Kroes 1999</LINK>). Most patients with suspected GORD are treated empirically. However, broad consensus has not been achieved on the optimal initial approach based upon patient characteristics. As a result there is substantial variability in the choice of initial therapy across varied healthcare settings. Much of the literature supporting the use of specific drug therapy has been based upon treatment trials that focused on patients with oesophagitis. There is far less detailed information on patients with ENRD, even though such patients represent a substantial subgroup of GORD.</P>
<P>GORD is a long-term disease. Whether the short-term results reported in this review are applicable to long-term management strategies is unclear. In particular, the effectiveness of H2RA deteriorates with time, and thus PPIs may have a benefit in ENRD with long-term use (<LINK REF="REF-Lewin-2001" TYPE="REFERENCE">Lewin 2001</LINK>). On the other hand the pharmacokinetics of H2RAs are superior to PPIs for rapid relief of symptoms. Thus the smaller difference between PPIs and H2RAs in the short-term studies in patients with ENRD is clinically relevant; such patients may achieve adequate symptom relief with long-term use of an H2RA as needed. By contrast, patients who require regular therapy may achieve more effective long-term symptom relief with a PPI (<LINK REF="REF-Ip-2005" TYPE="REFERENCE">Ip 2005</LINK>).</P>
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2013-03-24 09:53:25 -0400" MODIFIED_BY="Cathy Bennett">
<IMPLICATIONS_PRACTICE MODIFIED="2013-03-24 09:53:25 -0400" MODIFIED_BY="Cathy Bennett">
<P>Proton pump inhibitors (PPIs) are more effective than H2-receptor antagonists (H2RAs) for treatment of heartburn in patients treated empirically and in patients with endoscopy negative reflux disease (ENRD), although H2RAs are also effective. PPIs are more effective than H2RAs in studies with longer follow-up, but which focused mainly on participants with oesophagitis (<LINK REF="REF-Ip-2005" TYPE="REFERENCE">Ip 2005</LINK>).</P>
<P>Both a PPI and an H2RA are therefore reasonable options for achieving short-term symptom relief in patients with ENRD. However, this review did not address the relative efficacy of these drugs in the long-term management of ENRD.</P>
<P>While prokinetics are considered to be as effective as H2RAs, evidence is weak for their use in empirical treatment of gastro-oesophageal reflux disease (GORD), and even weaker for ENRD. Furthermore, the availability of the only prokinetic studied in this review, cisapride, has been severely restricted since 2001 because of a risk of cardiac arrhythmias. Thus the clinical importance of our findings regarding cisapride is mainly relevant as a background for future prokinetic drugs.<BR/>
</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2013-03-24 07:46:18 -0400" MODIFIED_BY="Cathy Bennett">
<P>Further studies are needed to clarify whether subgroups of people can be identified who would benefit most from initial therapy with a PPI or in whom (in contrast) an H2RA would be sufficient, especially form a long-term management perspective.</P>
<P>The efficacy of H2RAs decreases with regular dosing over time, potentially making them less effective than PPIs for long-term use. However, the pharmacokinetics of H2RAs are superior to PPIs for achieving rapid relief of symptoms, an important objective in patients with troubling intermittent symptoms. People with ENRD who have only intermittent symptoms may therefore be better off with a strategy involving intermittent use of an H2RA as needed. Our review did not evaluate a number of alternative strategies used in clinical practice, including combination drugs (H2RA plus an antacid), lifestyle modifications combined with drugs, and short-term (two weeks) use of a PPI as needed. Further studies are needed to evaluate these various strategies directly.</P>
<P>Future trials using heartburn as an end point should define treatment success as complete heartburn relief and use a validated quality of life measure, ideally with the same measure used across studies to facilitate comparisons. Such studies should also consider explicitly the use of rescue medications, such as antacids, since they may be important confounders of the main end points. Standardised criteria for defining GORD based upon symptoms alone should also be developed for use in clinical trials.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2013-03-24 07:46:31 -0400" MODIFIED_BY="Kate Cahill">
<P>This research originated from the GORD guidelines project that was initiated by the European Society for Primary Care Gastroenterology (ESPCG).</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>None known.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2013-03-24 07:47:12 -0400" MODIFIED_BY="Cathy Bennett">
<P>Van Pinxteren: data collection, data analysis, writing.<BR/>Numans: data collection, data analysis, writing.<BR/>Sigterman: data collection, data analysis, critical appraisal of the manuscript.<BR/>Bonis: data analysis, writing.<BR/>Lau: data analysis, writing.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES MODIFIED="2013-02-04 07:21:45 -0500" MODIFIED_BY="Cathy Bennett">
<P>
<BR/>
</P>
</PUBLIC_NOTES>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2013-03-25 14:28:24 -0400" MODIFIED_BY="Karin L Dearness">
<STUDIES MODIFIED="2013-03-24 09:26:36 -0400" MODIFIED_BY="Jan Lilleyman">
<INCLUDED_STUDIES MODIFIED="2013-03-24 09:13:40 -0400" MODIFIED_BY="Jan Lilleyman">
<STUDY DATA_SOURCE="PUB" ID="STD-Armstrong-2001" MODIFIED="2013-03-24 08:56:11 -0400" MODIFIED_BY="Jan Lilleyman" NAME="Armstrong 2001" YEAR="2001">
<REFERENCE MODIFIED="2013-03-24 08:56:11 -0400" MODIFIED_BY="Jan Lilleyman" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Armstrong D, Paré P, Pericak D, Pyzyk M; Canadian Pantoprazole GERD Study Group</AU>
<TI>A randomized, controlled comparison of pantoprazole and nizatidine in a mixed patient population with erosive esophagitis or endoscopy-negative reflux disease</TI>
<SO>American Journal of Gastroenterology</SO>
<YR>2001</YR>
<VL>96</VL>
<PG>2849-57</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2009-11-10 10:31:48 -0500" MODIFIED_BY="Jan Lilleyman" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Paré P, Armstrong D, Pericak D, Pyzyk M</AU>
<TI>Pantoprazole rapidly improves health-related quality of life in patients with heartburn</TI>
<SO>Journal of Clinical Gastroenterology</SO>
<YR>2003</YR>
<VL>37</VL>
<PG>132-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Armstrong-2005" MODIFIED="2013-03-24 08:56:52 -0400" MODIFIED_BY="Jan Lilleyman" NAME="Armstrong 2005" YEAR="2005">
<REFERENCE MODIFIED="2013-03-24 08:56:52 -0400" MODIFIED_BY="Jan Lilleyman" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Armstrong D, Veldhuyzen van Zanten SJO, Barkun AN, Chiba N, Thomson ABR, Smyth S, et al; The CADET-HR Study Group</AU>
<TI>Heartburn-dominant, uninvestigated dyspepsia: a comparison of 'PPI-start' and H2-RA-start' management strategies in primary care - the CADET-HR Study</TI>
<SO>Alimentary Pharmacology and Therapeutics</SO>
<YR>2005</YR>
<VL>21</VL>
<PG>1189-202</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bardhan-1999" MODIFIED="2013-02-04 11:21:44 -0500" MODIFIED_BY="Jan Lilleyman" NAME="Bardhan 1999" YEAR="1999">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Bardhan KD, Muller-Lissner S, Bigard MA, Bianchi Porro G, Ponce J, Hosie J, et al</AU>
<TI>Symptomatic gastro-oesophageal reflux disease: double blind controlled study of intermittent treatment with omeprazole or ranitidine</TI>
<SO>BMJ</SO>
<YR>1999</YR>
<VL>318</VL>
<PG>502-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1999147883"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-02-04 11:21:44 -0500" MODIFIED_BY="Karin Dearness" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bardhan KD, Muller-Lissner S, Bigard MA, Bianchi Porro G, Ponce J, Hosie J, et al</AU>
<TI>Symptomatic gastroesophageal reflux disease (GERD): intermittent treatment (IT) with omeprazole (OM) and ranitidine (RAN) as a strategy for management</TI>
<SO>Gastroenterology</SO>
<YR>1997</YR>
<VL>112</VL>
<NO>Suppl</NO>
<PG>A65</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2009-11-10 10:33:25 -0500" MODIFIED_BY="Jan Lilleyman" NOTES="&lt;p&gt;Wiklund I, Bardhan KD, Muller-Lissner S, Bigard MA, Bianchi Porro G, Ponce J, Hosie J, Scott M, Weir D, Fulton C, Gillon K, Peacock R. Quality of life during acute and intermittent treatment of gastro-oesophageal reflux disease with omeprazole compared with ranitidine. Results from a multicentre clinical trial. Ital J Gastroenterol Hepatol 1998; 30: 19-27.&lt;/p&gt;" NOTES_MODIFIED="2009-11-10 10:33:25 -0500" NOTES_MODIFIED_BY="Jan Lilleyman" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wiklund I, Bardhan KD, Muller-Lissner S, Bigard MA, Bianchi Porro G, Ponce J, et al</AU>
<TI>Quality of life during acute and intermittent treatment of gastro-oesophageal reflux disease with omeprazole compared with ranitidine. Results from a multicentre clinical trial</TI>
<SO>Italian Journal of Gastroenterology and Hepatology</SO>
<YR>1998</YR>
<VL>30</VL>
<PG>19-27</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1998277486"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bate-1996" MODIFIED="2009-11-10 10:34:12 -0500" MODIFIED_BY="Jan Lilleyman" NAME="Bate 1996" YEAR="19961">
<REFERENCE MODIFIED="2009-11-10 10:34:12 -0500" MODIFIED_BY="Jan Lilleyman" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Bate CM, Griffin SM, Keeling PWN, Axon ATR, Dronfield MW, Chapman RWG, et al</AU>
<TI>Reflux symptom relief with omeprazole in patients without unequivocal oesophagitis</TI>
<SO>Alimentary Pharmacology and Therapeutics</SO>
<YR>1996</YR>
<VL>10</VL>
<PG>547-55</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1997006465"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bate CM, Griffin SM, Keeling PWN, Axon ATR, Dronfield MW, Chapman RWG, et al</AU>
<TI>Symptom relief with omeprazole in patients without unequivocal oesophagitis</TI>
<SO>Gut</SO>
<YR>1995</YR>
<VL>37</VL>
<PG>A45</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bate-1997" MODIFIED="2013-03-24 08:58:57 -0400" MODIFIED_BY="Jan Lilleyman" NAME="Bate 1997" YEAR="1997">
<REFERENCE MODIFIED="2013-03-24 08:58:57 -0400" MODIFIED_BY="Jan Lilleyman" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bate CM, Green JRB, Axon ATR, Murray FE, Tildesley G, Emmas CE, et al</AU>
<TI>Omeprazole is more effective than cimetidine for the relief of all grades of gastro-oesophageal reflux disease-associated heartburn, irrespective of the presence or absence of endoscopic oesophagitis</TI>
<SO>Alimentary Pharmacology and Therapeutics</SO>
<YR>1997</YR>
<VL>11</VL>
<PG>755-63</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1997450498"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Behar-1978" MODIFIED="2013-03-24 08:59:30 -0400" MODIFIED_BY="Kate Cahill" NAME="Behar 1978" YEAR="1978">
<REFERENCE MODIFIED="2013-03-24 08:59:30 -0400" MODIFIED_BY="Kate Cahill" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Behar J, Brand DL, Brown FC, Castell DO, Cohen S, Crossley RJ, et al</AU>
<TI>Cimetidine in the treatment of symptomatic gastroesophageal reflux. A double blind controlled trial</TI>
<SO>Gastroenterology</SO>
<YR>1978</YR>
<VL>74</VL>
<PG>441-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1978085485"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bright_x002d_Asare-1980" MODIFIED="2013-03-24 09:00:38 -0400" MODIFIED_BY="Jan Lilleyman" NAME="Bright-Asare 1980" YEAR="1980">
<REFERENCE MODIFIED="2013-03-24 08:59:53 -0400" MODIFIED_BY="Jan Lilleyman" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bright-Asare P, El-Bassoussi M</AU>
<TI>Cimetidine, metoclopramide, or placebo in the treatment of symptomatic gastroesophageal reflux</TI>
<SO>Journal of Clinical Gastroenterology</SO>
<YR>1980</YR>
<VL>2</VL>
<PG>149-56</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1981070602"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Carlsson-1998" MODIFIED="2013-03-24 09:01:20 -0400" MODIFIED_BY="Jan Lilleyman" NAME="Carlsson 1998" YEAR="1998">
<REFERENCE MODIFIED="2009-11-10 11:14:32 -0500" MODIFIED_BY="Jan Lilleyman" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Carlsson R, Dent J, Watts R, Riley S, Sheikh R, Hatlebakk J, et al</AU>
<TI>Gastro-oesophageal reflux disease in primary care: an international study of different treatment strategies with omeprazole</TI>
<SO>European Journal of Gastroenterology and Hepatology</SO>
<YR>1998</YR>
<VL>10</VL>
<PG>119-24</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1998241142"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-03-24 09:01:20 -0400" MODIFIED_BY="Karin Dearness" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dent J, Watts R, Riley S, Sheikh R, De Groot G, Van Oudvorst A, et al</AU>
<TI>Gastroesophageal reflux disease (GERD) in primary care - an international placebo controlled study of different treatment strategies with omeprazole</TI>
<SO>Gastroenterology</SO>
<YR>1996</YR>
<VL>110</VL>
<PG>A93</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Castell-1998" MODIFIED="2013-03-24 09:01:43 -0400" MODIFIED_BY="Jan Lilleyman" NAME="Castell 1998" YEAR="1998">
<REFERENCE MODIFIED="2013-03-24 09:01:43 -0400" MODIFIED_BY="Jan Lilleyman" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Castell DO, Sigmund C, Patterson D, Lambert R, Hasner D, Clyde C, et al</AU>
<TI>Cisapride 20 mg b.i.d. provides symptomatic relief of heartburn and related symptoms of chronic mild to moderate gastroesophageal reflux disease</TI>
<SO>American Journal of Gastroenterology</SO>
<YR>1998</YR>
<VL>93</VL>
<PG>547-52</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1998235980"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fass-2009" MODIFIED="2012-11-08 10:10:03 -0500" MODIFIED_BY="[Empty name]" NAME="Fass 2009" YEAR="2009">
<REFERENCE MODIFIED="2012-11-08 10:10:03 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fass R, Chey WD, Zakko SF, Andhivarothai N, Palmer RN, Perez MC, et al</AU>
<TI>Clinical trial: the effects of the proton pump inhibitor dexlansoprazole MR on daytime and nighttime heartburn in patients with non-erosive reflux disease</TI>
<SO>Alimentary Pharmacology and Therapeutics</SO>
<YR>2009</YR>
<VL>29</VL>
<PG>1261-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fujiwara-2005" MODIFIED="2013-03-24 09:02:26 -0400" MODIFIED_BY="Jan Lilleyman" NAME="Fujiwara 2005" YEAR="2005">
<REFERENCE MODIFIED="2013-03-24 09:02:26 -0400" MODIFIED_BY="Jan Lilleyman" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fujiwara Y, Higuchi K, Nebiki H, Chono S, Uno H, Kitada K, et al</AU>
<TI>Famotidine vs. omeprazole: a prospective randomized multicentre trial to determine efficacy in non-erosive gastro-oesophageal reflux disease</TI>
<SO>Alimentary Pharmacology and Therapeutics</SO>
<YR>2005</YR>
<VL>21</VL>
<NO>Suppl 2</NO>
<PG>10-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Galmiche-1997" MODIFIED="2013-03-24 09:03:03 -0400" MODIFIED_BY="Jan Lilleyman" NAME="Galmiche 1997" YEAR="1997">
<REFERENCE MODIFIED="2013-03-24 09:03:03 -0400" MODIFIED_BY="Jan Lilleyman" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Galmiche JP, Barthelemy P, Hamelin B</AU>
<TI>Treating the symptoms of gastro-oesophageal reflux disease: a double-blind comparison of omeprazole and cisapride</TI>
<SO>Alimentary Pharmacology and Therapeutics</SO>
<YR>1997</YR>
<VL>11</VL>
<PG>765-73</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1997450499"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hallerback-1998" MODIFIED="2013-03-24 09:03:40 -0400" MODIFIED_BY="Jan Lilleyman" NAME="Hallerback 1998" YEAR="1998">
<REFERENCE MODIFIED="2013-03-24 09:03:40 -0400" MODIFIED_BY="Jan Lilleyman" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hallerback B, Glise H, Johansson B, Rosseland AR, Hulten S, Carling L, et al</AU>
<TI>Gastro-oesophageal reflux symptoms - clinical findings and effect of ranitidine treatment</TI>
<SO>European Journal of Surgery</SO>
<YR>1998</YR>
<VL>Suppl 583</VL>
<PG>6-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hatlebakk-1999" MODIFIED="2013-03-24 09:04:28 -0400" MODIFIED_BY="Kate Cahill" NAME="Hatlebakk 1999" YEAR="1999">
<REFERENCE MODIFIED="2013-03-24 09:04:28 -0400" MODIFIED_BY="Kate Cahill" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hatlebakk JG, Hyggen A, Madsen PH, Walle PO, Schultz T, Mowinckel P, et al</AU>
<TI>Heartburn treatment in primary care: randomised, double blind study for 8 weeks</TI>
<SO>BMJ</SO>
<YR>1999</YR>
<VL>319</VL>
<PG>550-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Johansson-1986a" MODIFIED="2013-03-24 09:04:53 -0400" MODIFIED_BY="Jan Lilleyman" NAME="Johansson 1986a" YEAR="1986">
<REFERENCE MODIFIED="2013-03-24 09:04:53 -0400" MODIFIED_BY="Jan Lilleyman" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Johansson KE, Boeryd B, Johansson K, Tibbling L</AU>
<TI>Double-blind crossover study of ranitidine and placebo in gastro-oesophageal reflux disease</TI>
<SO>Scandinavian Journal of Gastroenterology</SO>
<YR>1986</YR>
<VL>21</VL>
<PG>769-78</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1987042500"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Johnsson-2003" MODIFIED="2013-03-24 09:05:52 -0400" MODIFIED_BY="Jan Lilleyman" NAME="Johnsson 2003" YEAR="2003">
<REFERENCE MODIFIED="2013-03-24 09:05:52 -0400" MODIFIED_BY="Jan Lilleyman" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Johnsson F, Hatlebakk JG, Klintenberg AC, Román J, Toth E, Stubberöd A, et al</AU>
<TI>One-week esomeprazole treatment: an effective confirmatory test in patients with suspected gastroesophageal reflux disease</TI>
<SO>Scandinavian Journal of Gastroenterology</SO>
<YR>2003</YR>
<VL>38</VL>
<PG>354-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2009-11-10 10:39:27 -0500" MODIFIED_BY="Jan Lilleyman" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Johnsson F, Hatlebakk JG, Klintenberg AC, Román J</AU>
<TI>Symptom-relieving effect of esomeprazole 40 mg daily in patients with heartburn</TI>
<SO>Scandinavian Journal of Gastroenterology</SO>
<YR>2003</YR>
<VL>38</VL>
<PG>347-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kahrilas-2005" MODIFIED="2009-11-10 10:40:43 -0500" MODIFIED_BY="Jan Lilleyman" NAME="Kahrilas 2005" YEAR="2005">
<REFERENCE MODIFIED="2009-11-10 10:39:43 -0500" MODIFIED_BY="Jan Lilleyman" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Damiano A, Siddique R, Johanson J, Sloan S</AU>
<TI>Reductions in symptom distress reported by patients with moderately severe, nonerosive gastroesophageal reflux disease treated with rabeprazole</TI>
<SO>Digestive Diseases and Sciences</SO>
<YR>2003</YR>
<VL>44</VL>
<PG>657-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2009-11-10 10:39:57 -0500" MODIFIED_BY="Jan Lilleyman" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Kahrilas PJ, Miner P, Johanson J, Mao L, Jokubaitis L, Sloan S</AU>
<TI>Efficacy of rabeprazole in the treatment of symptomatic gastroesophageal reflux disease</TI>
<SO>Digestive Diseases and Sciences</SO>
<YR>2005</YR>
<VL>50</VL>
<PG>2009-18</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2009-11-10 10:40:22 -0500" MODIFIED_BY="Jan Lilleyman" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Miner P Jr, Orr W, Filippone J, Jokubaitis L, Sloan S</AU>
<TI>Rabeprazole in nonerosive gastroesophageal reflux disease: a randomized placebo-controlled trial</TI>
<SO>American Journal of Gastroenterology</SO>
<YR>2002</YR>
<VL>97</VL>
<PG>1332-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2009-11-10 10:40:43 -0500" MODIFIED_BY="Jan Lilleyman" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sloan S</AU>
<TI>Rabeprazole-based therapy in the management of symptomatic gastroesophageal reflux disease</TI>
<SO>American Journal of Gastroenterology</SO>
<YR>2003</YR>
<VL>98</VL>
<PG>S49-S55</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Katz-2003" MODIFIED="2013-03-24 09:07:31 -0400" MODIFIED_BY="Jan Lilleyman" NAME="Katz 2003" YEAR="2003">
<REFERENCE MODIFIED="2013-03-24 09:07:31 -0400" MODIFIED_BY="Jan Lilleyman" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Katz PO, Castell DO, Levine D</AU>
<TI>Esomeprazole resolves chronic heartburn in patients without erosive oesophagitis</TI>
<SO>Alimentary Pharmacology and Therapeutics</SO>
<YR>2003</YR>
<VL>18</VL>
<PG>875-82</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lind-1997" MODIFIED="2009-11-10 10:41:49 -0500" MODIFIED_BY="Jan Lilleyman" NAME="Lind 1997" YEAR="1997">
<REFERENCE MODIFIED="2009-11-10 10:41:32 -0500" MODIFIED_BY="Jan Lilleyman" NOTES="&lt;p&gt;Havelund T, Lind T, Wiklund I, Glise H, Hernqvist H, Lauritsen K, Lundell L, Pedersen SA, Carlsson R, Junghard O, Stubberod A, Anker-Hansen O. Quality of life in patients with heartburn but without esophagitis: effects of treatment with omeprazole. Am J Gastroenterol 1999; 94: 1782-1789.&lt;/p&gt;" NOTES_MODIFIED="2009-11-10 10:41:32 -0500" NOTES_MODIFIED_BY="Jan Lilleyman" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Havelund T, Lind T, Wiklund I, Glise H, Hernqvist H, Lauritsen K, et al</AU>
<TI>Quality of life in patients with heartburn but without esophagitis: effects of treatment with omeprazole</TI>
<SO>American Journal of Gastroenterology</SO>
<YR>1999</YR>
<VL>94</VL>
<PG>1782-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2009-11-10 10:41:49 -0500" MODIFIED_BY="Jan Lilleyman" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Lind T, Havelund T, Carlsson R, Anker-Hansen O, Glise H, Hernqvist H, et al</AU>
<TI>Heartburn without oesophagitis: efficacy of omeprazole therapy and features determining therapeutic response</TI>
<SO>Scandinavian Journal of Gastroenterology</SO>
<YR>1997</YR>
<VL>32</VL>
<PG>974-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1998027031"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lind T, Havelund T, Carlsson R, Glise H, Hernqvist H, Junghard O, et al</AU>
<TI>The effect of omeprazole (ome) 20 mg and 10 mg daily on heartburn in patients with endoscopy negative reflux disease (enrd)</TI>
<SO>Gastroenterology</SO>
<YR>1995</YR>
<VL>108</VL>
<PG>A151</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lind T, Havelund T, Glise H, Hernqvist H, Lauritsen K, Lundell L, et al</AU>
<TI>Omeprazole (ome) improves quality of life (qol) in patients with endoscopy negative reflux disease (enrd)</TI>
<SO>Gastroenterology</SO>
<YR>1995</YR>
<VL>108</VL>
<PG>A151</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-McCallum-1977" MODIFIED="2013-03-24 09:09:15 -0400" MODIFIED_BY="Jan Lilleyman" NAME="McCallum 1977" YEAR="1977">
<REFERENCE MODIFIED="2013-03-24 09:09:15 -0400" MODIFIED_BY="Jan Lilleyman" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>McCallum RW, Ippoliti AF, Cooney C, Sturdevant RAL</AU>
<TI>A controlled trial of metoclopramide in symptomatic gastroesophageal reflux</TI>
<SO>New England Journal of Medicine</SO>
<YR>1977</YR>
<VL>296</VL>
<PG>354-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1977100168"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Richter-2000a" MODIFIED="2009-11-10 10:42:56 -0500" MODIFIED_BY="Jan Lilleyman" NAME="Richter 2000a" YEAR="2000">
<REFERENCE MODIFIED="2009-11-10 10:42:56 -0500" MODIFIED_BY="Jan Lilleyman" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Richter JE, Peura D, Benjamin SB, Joelsson B, Whipple J</AU>
<TI>Efficacy of omeprazole for the treatment of symptomatic acid reflux disease without esophagitis</TI>
<SO>Archives of Internal Medicine</SO>
<YR>2000</YR>
<VL>160</VL>
<PG>1810-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Richter-2000b" MODIFIED="2009-11-10 10:55:10 -0500" MODIFIED_BY="Jan Lilleyman" NAME="Richter 2000b" YEAR="2000">
<REFERENCE MODIFIED="2009-11-10 10:55:10 -0500" MODIFIED_BY="Jan Lilleyman" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Richter JE, Campell DR, Kahrilas PJ, Huang B, Fludas C</AU>
<TI>Lansoprazole compared with ranitidine for the treatment of nonerosive gastroesophageal reflux disease</TI>
<SO>Archives of Internal Medicine</SO>
<YR>2000</YR>
<VL>160</VL>
<PG>1803-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Riemann-1991" MODIFIED="2013-03-24 09:10:20 -0400" MODIFIED_BY="Jan Lilleyman" NAME="Riemann 1991" YEAR="1991">
<REFERENCE MODIFIED="2013-03-24 09:10:20 -0400" MODIFIED_BY="Jan Lilleyman" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Riemann JF, Hobel W</AU>
<TI>Cimetidine suspension in patients with stage 0 gastro-oesophageal reflux disease</TI>
<SO>Alimentary Pharmacology and Therapeutics</SO>
<YR>1991</YR>
<VL>5</VL>
<PG>191-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1991363582"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Robinson-1991" MODIFIED="2009-11-10 10:56:21 -0500" MODIFIED_BY="Jan Lilleyman" NAME="Robinson 1991" YEAR="1991">
<REFERENCE MODIFIED="2009-11-10 10:56:21 -0500" MODIFIED_BY="Jan Lilleyman" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Robinson M, Decktor DL, Stone RC, Pevelery M, Barden P, Moyer R, et al</AU>
<TI>Famotidine (20 mg) b.d. relieves gastro-oesophageal reflux symptoms in patients without erosive oesophagitis</TI>
<SO>Alimentary Pharmacology and Therapeutics</SO>
<YR>1991</YR>
<VL>5</VL>
<PG>631-43</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1992144831"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rush-1995" MODIFIED="2013-03-24 09:11:09 -0400" MODIFIED_BY="Jan Lilleyman" NAME="Rush 1995" YEAR="1995">
<REFERENCE MODIFIED="2013-03-24 09:11:09 -0400" MODIFIED_BY="Jan Lilleyman" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rush DR, Stelmach WJ, Young TL, Kirchdoerfer LJ, Scott-Lennox J, Holverson HE, et al</AU>
<TI>Clinical effectiveness and quality of life with ranitidine vs placebo in gastroesophageal reflux disease patients: a clinical experience network (CEN) study</TI>
<SO>Journal of Family Practice</SO>
<YR>1995</YR>
<VL>41</VL>
<PG>126-36</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1995363387"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sabesin-1991" MODIFIED="2013-03-24 09:11:42 -0400" MODIFIED_BY="Jan Lilleyman" NAME="Sabesin 1991" YEAR="1991">
<REFERENCE MODIFIED="2013-03-24 09:11:42 -0400" MODIFIED_BY="Jan Lilleyman" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sabesin SM, Berlin RG, Humphries TJ, Bradstreet DC, Walton-Bowen KL, Zaidi S</AU>
<TI>Famotidine relieves symptoms of gastroesophageal reflux disease and heals erosions and ulcerations. Results of a multicenter, placebo-controlled, dose-ranging study</TI>
<SO>Archives of Internal Medicine</SO>
<YR>1991</YR>
<VL>151</VL>
<PG>2394-400</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1992082301"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schenk-1997" MODIFIED="2013-03-24 09:12:13 -0400" MODIFIED_BY="Jan Lilleyman" NAME="Schenk 1997" YEAR="1997">
<REFERENCE MODIFIED="2013-03-24 09:12:13 -0400" MODIFIED_BY="Jan Lilleyman" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schenk BE, Kuipers EJ, Klinkenberg-Knol EC, Festen HPM, Jansen EH, Tuynman HARE, et al</AU>
<TI>Omeprazole as a diagnostic tool in gastroesophageal reflux disease</TI>
<SO>American Journal of Gastroenterology</SO>
<YR>1997</YR>
<VL>92</VL>
<PG>1997-2000</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1998026502"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sontag-1987" MODIFIED="2009-11-10 10:57:40 -0500" MODIFIED_BY="Jan Lilleyman" NAME="Sontag 1987" YEAR="1987">
<REFERENCE MODIFIED="2009-11-10 10:57:40 -0500" MODIFIED_BY="Jan Lilleyman" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Sontag S, Robinson M, McCallum RW, Barwick KW, Nardi R</AU>
<TI>Ranitidine therapy for gastroesophageal reflux disease. Results of a large double-blind trial</TI>
<SO>Archives of Internal Medicine</SO>
<YR>1987</YR>
<VL>147</VL>
<PG>1485-91</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1987325285"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Talley-2002" MODIFIED="2013-03-24 09:12:45 -0400" MODIFIED_BY="Jan Lilleyman" NAME="Talley 2002" YEAR="2002">
<REFERENCE MODIFIED="2013-03-24 09:12:45 -0400" MODIFIED_BY="Jan Lilleyman" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Talley NJ, Moore MG, Sprogis A, Katelaris P</AU>
<TI>Randomised controlled trial of pantoprazole versus ranitidine for the treatment of uninvestigated heartburn in primary care</TI>
<SO>Medical Journal of Australia</SO>
<YR>2002</YR>
<VL>177</VL>
<PG>423-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tan-2011" MODIFIED="2012-11-08 10:10:24 -0500" MODIFIED_BY="[Empty name]" NAME="Tan 2011" YEAR="2011">
<REFERENCE MODIFIED="2012-11-08 10:10:24 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tan VPY, Wong WM, Cheung TK, Lai KC, Hung IFN, Chan P, et al</AU>
<TI>Treatment of non-erosive reflux disease with a proton pump inhibitor in Chinese patients: a randomized controlled trial</TI>
<SO>Journal of Gastroenterology</SO>
<YR>2011</YR>
<VL>46</VL>
<PG>906-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Uemura-2008" MODIFIED="2009-11-10 10:58:26 -0500" MODIFIED_BY="Jan Lilleyman" NAME="Uemura 2008" YEAR="2008">
<REFERENCE MODIFIED="2009-11-10 10:58:26 -0500" MODIFIED_BY="Jan Lilleyman" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Uemura N, Inokuchi H, Serizawa H, Chikama T, Yamauchi M, Tsuru T, et al</AU>
<TI>Efficacy and safety of omeprazole in Japanese patients with nonerosive reflux disease</TI>
<SO>Journal of Gastroenterology</SO>
<YR>2008</YR>
<VL>43</VL>
<PG>670-8</PG>
<IDENTIFIERS MODIFIED="2009-10-03 09:28:48 -0400" MODIFIED_BY="Kirsten E. Sigterman"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2009-10-03 09:18:51 -0400" MODIFIED_BY="Kirsten E. Sigterman"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Van-Zyl-2004" MODIFIED="2013-03-24 09:13:40 -0400" MODIFIED_BY="Kate Cahill" NAME="Van Zyl 2004" YEAR="2004">
<REFERENCE MODIFIED="2013-03-24 09:13:40 -0400" MODIFIED_BY="Kate Cahill" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Van Zyl J, Van Rensburg C, Vieweg W, Fischer R</AU>
<TI>Efficacy and safety of pantoprazole versus ranitidine in the treatment of patients with symptomatic gastroesophageal reflux disease</TI>
<SO>Digestion</SO>
<YR>2004</YR>
<VL>70</VL>
<PG>61-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Venables-1997" MODIFIED="2013-02-04 11:23:33 -0500" MODIFIED_BY="Jan Lilleyman" NAME="Venables 1997" YEAR="1997">
<REFERENCE MODIFIED="2013-02-04 11:23:33 -0500" MODIFIED_BY="Jan Lilleyman" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Venables T, Newland R, Patel AC, Hole J, Mulholland G, Turbitt M, et al</AU>
<TI>A comparison of omeprazole 10mg and 20mg om with ranitidine 150mg bd for the treatment of GORD in primary care</TI>
<SO>Gut</SO>
<YR>1995</YR>
<VL>37</VL>
<PG>A45</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2009-11-10 10:59:31 -0500" MODIFIED_BY="Jan Lilleyman" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Venables TL, Newland RD, Patel AC, Hole J, Wilcock C, Turbitt ML</AU>
<TI>Omeprazole 10 milligrams once daily, omeprazole 20 milligrams once daily, or ranitidine 150 milligrams twice daily, evaluated as initial therapy for the relief of symptoms of gastro-oesophageal reflux disease in general practice</TI>
<SO>Scandinavian Journal of Gastroenterology</SO>
<YR>1997</YR>
<VL>32</VL>
<PG>965-73</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1998027030"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Watson-1997" NAME="Watson 1997" YEAR="1997">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Watson RGP, Tham TCK, Johnston BT, McDougall NI</AU>
<TI>Double blind cross-over placebo controlled study of omeprazole in the treatment of patients with reflux symptoms and physiological levels of acid reflux - the 'sensitive oesophagus'</TI>
<SO>Gut</SO>
<YR>1997</YR>
<VL>40</VL>
<PG>587-90</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1997347867"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2013-03-24 09:26:36 -0400" MODIFIED_BY="Jan Lilleyman">
<STUDY DATA_SOURCE="PUB" ID="STD-Bennett-1983" NAME="Bennett 1983" YEAR="1983">
<REFERENCE NOTES="&lt;p&gt;Bennett JR, Buckton G, Martin HD. Cimetidine in gastro-oesophageal reflux. Digestion 1983; 26: 166-172.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bennett JR, Buckton G, Martin HD</AU>
<TI>Cimetidine in gastro-oesophageal reflux</TI>
<SO>Digestion</SO>
<YR>1983</YR>
<VL>26</VL>
<PG>166-72</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1983210627"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Croxtall-2010" MODIFIED="2012-10-08 06:04:14 -0400" MODIFIED_BY="[Empty name]" NAME="Croxtall 2010" YEAR="2010">
<REFERENCE MODIFIED="2012-10-08 06:04:14 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Croxtall JD, Scott LJ</AU>
<TI>Dexlansoprazole modified release in erosive oesophagitis and non-erosive reflux disease</TI>
<SO>Drugs</SO>
<YR>2010</YR>
<VL>70</VL>
<PG>1593-1601</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fass-2010" MODIFIED="2012-11-08 10:10:53 -0500" MODIFIED_BY="[Empty name]" NAME="Fass 2010" YEAR="2010">
<REFERENCE MODIFIED="2012-11-08 10:10:53 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fass R, Johnson DA, Orr WC, Han C, Mody R, Stern KN, et al</AU>
<TI>The effect of dexlansoprazole MR on nocturnal heartburn and GERD-related sleep disturbances in patients with symptomatic GERD</TI>
<SO>The American Journal of Gastroenterology</SO>
<YR>2010</YR>
<VL>106</VL>
<PG>421-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fiasse-1980" MODIFIED="2013-03-24 09:15:34 -0400" MODIFIED_BY="Jan Lilleyman" NAME="Fiasse 1980" YEAR="1980">
<REFERENCE MODIFIED="2013-03-24 09:15:34 -0400" MODIFIED_BY="Jan Lilleyman" NOTES="&lt;p&gt;Fiasse R, Hanin C, Lepot A, Descamps C, Lamy F, Dive C. Controlled trial of cimetidine in reflux esophagitis. Digestive Diseases and Sciences 1980; 25: 750-755.&lt;/p&gt;" NOTES_MODIFIED="2013-03-24 09:15:34 -0400" NOTES_MODIFIED_BY="Jan Lilleyman" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fiasse R, Hanin C, Lepot A, Descamps C, Lamy F, Dive C</AU>
<TI>Controlled trial of cimetidine in reflux esophagitis</TI>
<SO>Digestive Diseases and Sciences</SO>
<YR>1980</YR>
<VL>25</VL>
<PG>750-5</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1981043562"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Greaney-1981" MODIFIED="2009-11-10 11:00:14 -0500" MODIFIED_BY="Jan Lilleyman" NAME="Greaney 1981" YEAR="1981">
<REFERENCE MODIFIED="2009-11-10 11:00:14 -0500" MODIFIED_BY="Jan Lilleyman" NOTES="&lt;p&gt;Greaney MG, Irvin TT. Cimetidine for the treatment of symptomatic gastro-oesophageal reflux. British Journal of Clinical Practice 1981; 35: 21-24.&lt;/p&gt;" NOTES_MODIFIED="2009-11-10 11:00:14 -0500" NOTES_MODIFIED_BY="Jan Lilleyman" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Greaney MG, Irvin TT</AU>
<TI>Cimetidine for the treatment of symptomatic gastro-oesophageal reflux</TI>
<SO>British Journal of Clinical Practice</SO>
<YR>1981</YR>
<VL>35</VL>
<PG>21-4</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1981256206"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hansen-2006" MODIFIED="2009-11-10 11:01:43 -0500" MODIFIED_BY="Jan Lilleyman" NAME="Hansen 2006" YEAR="2006">
<REFERENCE MODIFIED="2009-11-10 11:01:43 -0500" MODIFIED_BY="Jan Lilleyman" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hansen AN, Bergheim R, Fagertun H, Lund H, Wiklund I, Moum B</AU>
<TI>Long-term management of patients with symptoms of gastro-oesophageal reflux disease - a Norwegian randomised prospective study comparing the effects of esomeprazole and ranitidine treatment strategies on health-related quality of life in a general practitioners setting</TI>
<SO>International Journal of Clinical Practice</SO>
<YR>2006</YR>
<VL>60</VL>
<NO>1</NO>
<PG>15-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Haruma-2009" MODIFIED="2012-11-08 10:11:10 -0500" MODIFIED_BY="[Empty name]" NAME="Haruma 2009" YEAR="2009">
<REFERENCE MODIFIED="2012-11-08 10:11:10 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Haruma K, Sakurai K, Nagahara A, Mabe K, Akiyama J, Fujimoto K, et al</AU>
<TI>A randomized omeprazole controlled trial comparing famotidine, mosapride or teprenone in patients with uninvestigated dyspepsia- the J-focus study</TI>
<SO>Gastroenterology</SO>
<YR>2009</YR>
<VL>136</VL>
<PG>A149</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Herwaarden-1999" MODIFIED="2013-03-24 09:16:47 -0400" MODIFIED_BY="Jan Lilleyman" NAME="Herwaarden 1999" YEAR="1999">
<REFERENCE MODIFIED="2013-03-24 09:16:47 -0400" MODIFIED_BY="Jan Lilleyman" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Van Herwaarden MA, Samsom M, Van Nispen CHM, Verlinden M, Smout AJPM</AU>
<TI>The effect of motilin agonist ABT-229 on gastro-oesophageal reflux, oesophageal motility and lower oesophageal sphincter characteristics in GERD patients</TI>
<SO>Alimentary Pharmacology and Therapeutics</SO>
<YR>2000</YR>
<VL>14</VL>
<PG>453-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hongo-2008a" MODIFIED="2009-11-10 11:02:18 -0500" MODIFIED_BY="Jan Lilleyman" NAME="Hongo 2008a" YEAR="2008">
<REFERENCE MODIFIED="2009-11-10 11:02:18 -0500" MODIFIED_BY="Jan Lilleyman" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hongo M, Kinoshita Y, Haruma K</AU>
<TI>A randomized, double-blind, placebo-controlled clinical study of the histamine H2-receptor antagonist famotidine in Japanese patients with nonerosive reflux disease</TI>
<SO>Journal of Gastroenterology</SO>
<YR>2008</YR>
<VL>43</VL>
<NO>6</NO>
<PG>448-56</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hongo-2008b" MODIFIED="2009-11-10 11:02:37 -0500" MODIFIED_BY="Jan Lilleyman" NAME="Hongo 2008b" YEAR="2008">
<REFERENCE MODIFIED="2009-11-10 11:02:37 -0500" MODIFIED_BY="Jan Lilleyman" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hongo M, Hoshihara Y</AU>
<TI>Efficacy and safety of lansoprazole (AG-1749) 15 mg and 30 mg in Japanese patients with non-erosive reflux disease (NERD): A phase III multicenter, double-blind, placebo-controlled trial</TI>
<SO>Japanese Pharmacology and Therapeutics</SO>
<YR>2008</YR>
<VL>36</VL>
<NO>7</NO>
<PG>655-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jebbink-1993" MODIFIED="2013-03-24 09:18:07 -0400" MODIFIED_BY="Jan Lilleyman" NAME="Jebbink 1993" YEAR="1993">
<REFERENCE MODIFIED="2013-03-24 09:18:07 -0400" MODIFIED_BY="Jan Lilleyman" NOTES="&lt;p&gt;Jebbink HJA, Smout AJPM, van Berge Henegouwen GP. Ranitidine vooral werkzaam bij functionele dyspepsie met klachten passend bij refluxziekten. Ned Tijdschr Geneeskd 1993; 137: 1772-1775.&lt;/p&gt;" NOTES_MODIFIED="2013-03-24 09:18:07 -0400" NOTES_MODIFIED_BY="Jan Lilleyman" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jebbink HJA, Smout AJPM, Van Berge Henegouwen GP</AU>
<TI>Ranitidine therapeutically effective in functional dyspepsia with reflux-like symptoms</TI>
<TO>Ranitidine vooral werkzaam bij functionele dyspepsie met klachten passend bij refluxziekten</TO>
<SO>Nederlands Tijdschrift Voor Geneeskunde</SO>
<YR>1993</YR>
<VL>137</VL>
<NO>35</NO>
<PG>1772-5</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1993382586"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Johnson-2010" MODIFIED="2012-10-08 05:55:19 -0400" MODIFIED_BY="[Empty name]" NAME="Johnson 2010" YEAR="2010">
<REFERENCE MODIFIED="2012-10-08 05:55:19 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Johnson D, Crawley JA, Hwang C, Brown K</AU>
<TI>Clinical trial: esomeprazole for moderate-to-severe nighttime heartburn and gastro-oesophageal reflux disease-related sleep disturbances</TI>
<SO>Alimentary Pharmacology and Therapeutics</SO>
<YR>2010</YR>
<VL>32</VL>
<PG>182-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Johnsson-1993" MODIFIED="2009-11-10 11:07:51 -0500" MODIFIED_BY="Jan Lilleyman" NAME="Johnsson 1993" YEAR="1993">
<REFERENCE MODIFIED="2009-11-10 11:07:51 -0500" MODIFIED_BY="Jan Lilleyman" NOTES="&lt;p&gt;Johnsson F, Roth Y, Damgaard Pedersen N-E, Joelsson B. Cimetidine improves gerd symptoms in patients selected by a validated gerd questionnaire. Aliment Pharmacol Ther 1993; 7: 81-86.&lt;/p&gt;" NOTES_MODIFIED="2009-11-10 11:07:51 -0500" NOTES_MODIFIED_BY="Jan Lilleyman" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Johnsson F, Roth Y, Damgaard Pedersen N-E, Joelsson B</AU>
<TI>Cimetidine improves gerd symptoms in patients selected by a validated gerd questionnaire</TI>
<SO>Alimentary Pharmacology and Therapeutics</SO>
<YR>1993</YR>
<VL>7</VL>
<PG>81-6</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1993176931"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Johnsson-1998" MODIFIED="2009-11-10 11:08:16 -0500" MODIFIED_BY="Jan Lilleyman" NAME="Johnsson 1998" YEAR="1998">
<REFERENCE MODIFIED="2009-11-10 11:08:16 -0500" MODIFIED_BY="Jan Lilleyman" NOTES="&lt;p&gt;Johnsson F, Weywadt L, Solhaug J-H, Hernqvist H, Bengtsson L. One-week omeprazole treatment in the diagnosis of gastro-oesophageal reflux disease. Scand J Gastroenterol 1998; 33: 15-20.&lt;/p&gt;" NOTES_MODIFIED="2009-11-10 11:08:16 -0500" NOTES_MODIFIED_BY="Jan Lilleyman" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Johnsson F, Weywadt L, Solhaug J-H, Hernqvist H, Bengtsson L</AU>
<TI>One-week omeprazole treatment in the diagnosis of gastro-oesophageal reflux disease</TI>
<SO>Scandinavian Journal of Gastroenterology</SO>
<YR>1998</YR>
<VL>33</VL>
<PG>15-20</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1998149546"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Juul_x002d_Hansen-2008" MODIFIED="2012-11-08 10:11:37 -0500" MODIFIED_BY="[Empty name]" NAME="Juul-Hansen 2008" YEAR="2008">
<REFERENCE MODIFIED="2012-11-08 10:11:37 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Juul-Hansen P, Rydning A</AU>
<TI>On-demand requirements of patients with endoscopy-negative gastro-oesophageal reflux disease: H2-blocker vs. proton pump inhibitor</TI>
<SO>Alimentary Pharmacology and Therapeutics</SO>
<YR>2008</YR>
<VL>29</VL>
<PG>207-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kinoshita-2010" MODIFIED="2012-11-08 10:11:47 -0500" MODIFIED_BY="[Empty name]" NAME="Kinoshita 2010" YEAR="2010">
<REFERENCE MODIFIED="2012-11-08 10:11:47 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kinoshita Y, Ashida K, Hongo M</AU>
<TI>Randomised clinical trial: A multicentre, double-blind, placebo-controlled study on the efficacy and safety of rabeprazole 5 mg or 10 mg once daily in patients with non-erosive reflux disease</TI>
<SO>Alimentary Pharmacology and Therapeutics</SO>
<YR>2011</YR>
<VL>33</VL>
<PG>213-24</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kushner-2009" MODIFIED="2012-10-08 05:56:56 -0400" MODIFIED_BY="[Empty name]" NAME="Kushner 2009" YEAR="2009">
<REFERENCE MODIFIED="2012-10-08 05:56:56 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kushner PR, Snoddy AM, Gilderman L, Peura DA</AU>
<TI>Lansoprazole 15 mg once daily for 14 days is effective for treatment of frequent heartburn: Results of 2 randomized, placebo-controlled, double-blind studies</TI>
<SO>Postgraduate Medicine</SO>
<YR>2009</YR>
<VL>121</VL>
<PG>67-75</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Maddern-1986" MODIFIED="2009-11-10 11:08:29 -0500" MODIFIED_BY="Jan Lilleyman" NAME="Maddern 1986" YEAR="1986">
<REFERENCE MODIFIED="2009-11-10 11:08:29 -0500" MODIFIED_BY="Jan Lilleyman" NOTES="&lt;p&gt;Maddern GJ, Kiroff GK, Leppard PI, Jamieson GG. Domperidone, metoclopramide, and placebo all give symptomatic improvement in gastroesophageal reflux. J Clin Gastroenterol 1986; 8: 135-140.&lt;/p&gt;" NOTES_MODIFIED="2009-11-10 11:08:29 -0500" NOTES_MODIFIED_BY="Jan Lilleyman" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Maddern GJ, Kiroff GK, Leppard PI, Jamieson GG</AU>
<TI>Domperidone, metoclopramide, and placebo all give symptomatic improvement in gastroesophageal reflux</TI>
<SO>Journal of Clinical Gastroenterology</SO>
<YR>1986</YR>
<VL>8</VL>
<PG>135-40</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1986305653"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Marrero-1994" NAME="Marrero 1994" YEAR="1994">
<REFERENCE NOTES="&lt;p&gt;Marrero JM, de Caestecker JS, Maxwell JD. Effect of famotidine on oesophageal sensitivity in gastro-oesophageal reflux disease. Gut 1994; 35: 447-450.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Marrero JM, de Caestecker JS, Maxwell JD</AU>
<TI>Effect of famotidine on oesophageal sensitivity in gastro-oesophageal reflux disease</TI>
<SO>Gut</SO>
<YR>1994</YR>
<VL>35</VL>
<PG>447-50</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1994229569"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Masharova-2011" MODIFIED="2012-10-08 05:57:19 -0400" MODIFIED_BY="[Empty name]" NAME="Masharova 2011" YEAR="2011">
<REFERENCE MODIFIED="2012-10-08 05:57:19 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Masharova AA, Ianova OB, Valitova ÉR, Kim VA, Zelenkin SA</AU>
<TI>Panum (pantoprazole) effectiveness in the treatment of patients with GERD</TI>
<SO>Èksperimental&#697;naâ i klini&#269;eskaâ gastroènterologiâ</SO>
<YR>2011</YR>
<VL>4</VL>
<PG>81-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Meineche-2004" MODIFIED="2013-03-24 09:21:21 -0400" MODIFIED_BY="Jan Lilleyman" NAME="Meineche 2004" YEAR="2004">
<REFERENCE MODIFIED="2009-11-10 11:08:44 -0500" MODIFIED_BY="Jan Lilleyman" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Meineche-Schmidt V</AU>
<TI>Classification of dyspepsia and response to treatment with proton-pump inhibitors</TI>
<SO>Alimentary Pharmacology and Therapeutics</SO>
<YR>2004</YR>
<VL>20</VL>
<PG>1171-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-03-24 09:21:21 -0400" MODIFIED_BY="Jan Lilleyman" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Meineche-Schmidt V</AU>
<TI>Empiric treatment with high and standard dose of omeprazole in general practice: 2-week randomized placebo-controlled trial and 12-month follow-up of health-care consumption</TI>
<SO>American Journal of Gastroenterology</SO>
<YR>2004</YR>
<VL>99</VL>
<PG>1050-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nakamura-2010" MODIFIED="2012-11-08 10:12:20 -0500" MODIFIED_BY="[Empty name]" NAME="Nakamura 2010" YEAR="2010">
<REFERENCE MODIFIED="2012-11-08 10:12:20 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nakamura K, Akiho H, Ochiai T, Motomura Y, Higuchi N, Okamoto R, et al</AU>
<TI>Randomized controlled trial: roxatidine vs omeprazole for non-erosive reflux disease</TI>
<SO>Hepatogastroenterology</SO>
<YR>2010</YR>
<VL>57</VL>
<PG>497-500</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Powell_x002d_Jackson-1978" MODIFIED="2013-03-24 09:22:20 -0400" MODIFIED_BY="Kate Cahill" NAME="Powell-Jackson 1978" YEAR="1978">
<REFERENCE NOTES="&lt;p&gt;Powell-Jackson P, Barkley H, Northfield TC. Effect of cimetidine in symptomatic gastro-oesophageal reflux. Lancet 1978&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Powell-Jackson P, Barkley H, Northfield TC</AU>
<TI>Effect of cimetidine in symptomatic gastro-oesophageal reflux</TI>
<SO>Lancet</SO>
<YR>1978</YR>
<VL>2(8099)</VL>
<PG>1068-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1979052061"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Richter-1996" MODIFIED="2013-03-24 09:22:44 -0400" MODIFIED_BY="Jan Lilleyman" NAME="Richter 1996" YEAR="1996">
<REFERENCE MODIFIED="2013-03-24 09:22:44 -0400" MODIFIED_BY="Jan Lilleyman" NOTES="&lt;p&gt;Richter JE, Sabesin SM, Kogut DG. Omeprazole versus ranitidine or ranitidine/metoclopramide in poorly responsive symptomatic gastroesophageal reflux disease. Am J Gastroenterol 1996; 91; 1766-1772.&lt;/p&gt;" NOTES_MODIFIED="2013-03-24 09:22:44 -0400" NOTES_MODIFIED_BY="Jan Lilleyman" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Richter JE, Sabesin SM, Kogut DG</AU>
<TI>Omeprazole versus ranitidine or ranitidine/metoclopramide in poorly responsive symptomatic gastroesophageal reflux disease</TI>
<SO>American Journal of Gastroenterology</SO>
<YR>1996</YR>
<VL>91</VL>
<PG>1766-72</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1996384835"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Richter-1999" MODIFIED="2013-03-24 09:23:07 -0400" MODIFIED_BY="Jan Lilleyman" NAME="Richter 1999" YEAR="1999">
<REFERENCE MODIFIED="2013-03-24 09:23:07 -0400" MODIFIED_BY="Jan Lilleyman" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Richter JE, Kovacs TOG, Greski-Rose PA, Huang B, Fisher R</AU>
<TI>Lansoprazole in the treatment of heartburn in patients without erosive oesophagitis</TI>
<SO>Alimentary Pharmacology and Therapeutics</SO>
<YR>1999</YR>
<VL>13</VL>
<PG>795-804</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Robinson-1987" MODIFIED="2013-03-24 09:23:39 -0400" MODIFIED_BY="Jan Lilleyman" NAME="Robinson 1987" YEAR="1987">
<REFERENCE NOTES="&lt;p&gt;McCallum RW, Robinson M, Behar J, Nardi R. Ranitidine in the long-term treatment of gastroesophageal reflux disease (gerd): a randomized double-blind trial. Gastroenterology 1986; 90: 1541.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>McCallum RW, Robinson M, Behar J, Nardi R</AU>
<TI>Ranitidine in the long-term treatment of gastroesophageal reflux disease (gerd): a randomized double-blind trial</TI>
<SO>Gastroenterology</SO>
<YR>1986</YR>
<VL>90</VL>
<PG>1541</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-03-24 09:23:39 -0400" MODIFIED_BY="Jan Lilleyman" NOTES="&lt;p&gt;Robinson MG, Orr WC, McMallum R. Do endoscopic findings influence response to H2 antagonist therapy for gastroesophageal reflux disease? Am J Gastroenterol 1987; 82: 519-522.&lt;/p&gt;" NOTES_MODIFIED="2013-03-24 09:23:39 -0400" NOTES_MODIFIED_BY="Jan Lilleyman" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Robinson MG, Orr WC, McMallum R</AU>
<TI>Do endoscopic findings influence response to H2 antagonist therapy for gastroesophageal reflux disease?</TI>
<SO>The American Journal of Gastroenterology</SO>
<YR>1987</YR>
<VL>82</VL>
<PG>519-22</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1987210043"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Scheiman-2009" MODIFIED="2012-11-08 09:29:41 -0500" MODIFIED_BY="[Empty name]" NAME="Scheiman 2009" YEAR="2009">
<REFERENCE MODIFIED="2012-11-08 09:29:41 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Scheiman JM, Johnson DA, Atillasoy E, Fennerty MB </AU>
<TI>Lansoprazole 15 mg rapidly treats frequent heartburn over 14 days in a self-treating population: Pooled analysis of 3 randomized, double-blind, placebo-controlled studies</TI>
<SO>Gastroenterology</SO>
<YR>2009</YR>
<VL>136</VL>
<PG>A447</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schindlbeck-1995" MODIFIED="2009-11-10 11:10:50 -0500" MODIFIED_BY="Jan Lilleyman" NAME="Schindlbeck 1995" YEAR="1995">
<REFERENCE MODIFIED="2009-11-10 11:10:50 -0500" MODIFIED_BY="Jan Lilleyman" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schindlbeck NE, Klauser AG, Voderholzer WA, Muller-Lissner SA</AU>
<TI>Empiric therapy for gastroesophageal reflux disease</TI>
<SO>Archives of Internal Medicine</SO>
<YR>1995</YR>
<VL>155</VL>
<PG>1808-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Talley-2007" MODIFIED="2013-03-24 09:25:17 -0400" MODIFIED_BY="Jan Lilleyman" NAME="Talley 2007" YEAR="2007">
<REFERENCE MODIFIED="2013-03-24 09:25:17 -0400" MODIFIED_BY="Jan Lilleyman" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Talley NJ, Vakil N, Lauritsen K, Van Zanten SV, Flook N, Bolling-Sternevald E, et al</AU>
<TI>Randomized-controlled trial of esomeprazole in functional dyspepsia patients with epigastric pain or burning: does a 1-week trial of acid suppression predict symptom response?</TI>
<SO>Alimentary Pharmacology and Therapeutics</SO>
<YR>2007</YR>
<VL>26</VL>
<NO>5</NO>
<PG>673-82</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Van-Zanten-2005" MODIFIED="2013-03-24 09:26:36 -0400" MODIFIED_BY="Jan Lilleyman" NAME="Van Zanten 2005" YEAR="2005">
<REFERENCE MODIFIED="2009-11-10 11:11:36 -0500" MODIFIED_BY="Jan Lilleyman" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Veldhuyzen van Zanten SJO, Chiba N, Armstrong D, Barkun A, Thomson A, Smyth S, et al</AU>
<TI>A randomized trial comparing omeprazole, ranitidine, cisapride, or placebo in Helicobacter pylori negative, primary care patients with dyspepsia:The CADET-HN Study</TI>
<SO>The American Journal of Gastroenterology</SO>
<YR>2005</YR>
<VL>100</VL>
<PG>1477&#8211;88</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Van-Zanten-2007" MODIFIED="2009-11-10 11:14:03 -0500" MODIFIED_BY="Jan Lilleyman" NAME="Van Zanten 2007" YEAR="2007">
<REFERENCE MODIFIED="2009-11-10 11:14:03 -0500" MODIFIED_BY="Jan Lilleyman" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>van Zanten SV, Flook N, Talley NJ, Vakil N, Lauritsen K, Bolling-Sternevald E, et al</AU>
<TI>One-week acid suppression trial in uninvestigated dyspepsia patients with epigastric pain or burning to predict response to 8 weeks' treatment with esomeprazole: a randomized, placebo-controlled study</TI>
<SO>Alimentary Pharmacology and Therapeutics</SO>
<YR>2007</YR>
<VL>26</VL>
<NO>5</NO>
<PG>665-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2009-10-20 07:44:22 -0400" MODIFIED_BY="Kirsten E. Sigterman"/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2013-03-25 14:28:24 -0400" MODIFIED_BY="Karin L Dearness">
<ADDITIONAL_REFERENCES MODIFIED="2013-03-24 09:37:29 -0400" MODIFIED_BY="Karin L Dearness">
<REFERENCE ID="REF-Chiba-1997" MODIFIED="2010-11-15 09:54:08 -0500" MODIFIED_BY="Karin L Dearness" NAME="Chiba 1997" TYPE="JOURNAL_ARTICLE">
<AU>Chiba N, De Gara CJ, Wilkinson JM, Hunt RH</AU>
<TI>Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis</TI>
<SO>Gastroenterology</SO>
<YR>1997</YR>
<VL>112</VL>
<PG>1798-810</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1997322015"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Cochrane-Handbook" MODIFIED="2013-03-24 09:28:33 -0400" MODIFIED_BY="Cathy Bennett" NAME="Cochrane Handbook" TYPE="OTHER">
<AU>Higgins JPT, Green S (editors)</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011</TI>
<SO>Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Corder-1996" MODIFIED="2010-11-15 09:54:11 -0500" MODIFIED_BY="Karin L Dearness" NAME="Corder 1996" TYPE="JOURNAL_ARTICLE">
<AU>Corder AP, Jones RH, Sadler GH, Daniels P, Johnson CD</AU>
<TI>Heartburn, oesophagitis and Barrett's oesophagus in self-medicating patients in general practice</TI>
<SO>British Journal of Clinical Practice</SO>
<YR>1996</YR>
<VL>50</VL>
<PG>245-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1996386981"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Dent-1998" MODIFIED="2010-11-15 09:54:15 -0500" MODIFIED_BY="Karin L Dearness" NAME="Dent 1998" TYPE="JOURNAL_ARTICLE">
<AU>Dent J</AU>
<TI>Gastro-oesophageal reflux disease</TI>
<SO>Digestion</SO>
<YR>1998</YR>
<VL>59</VL>
<PG>433-45</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1998370931"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Devault-2005" MODIFIED="2009-11-10 11:16:39 -0500" MODIFIED_BY="Jan Lilleyman" NAME="Devault 2005" TYPE="JOURNAL_ARTICLE">
<AU>Devault KR, Castell DO; American College of Gastroenterology</AU>
<TI>Updated guidelines for the diagnosis and treatment of gastro-oesophageal reflux disease</TI>
<SO>American Journal of Gastroenterology</SO>
<YR>2005</YR>
<VL>100</VL>
<PG>190-200</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dimenas-1996" MODIFIED="2010-11-15 09:54:17 -0500" MODIFIED_BY="Karin L Dearness" NAME="Dimenas 1996" TYPE="JOURNAL_ARTICLE">
<AU>Dimenas E, Carlsson G, Glise H, Israelsson B, Wiklund I</AU>
<TI>Relevance of norm values as part of the documentation of quality of life instruments for use in upper gastrointestinal disease</TI>
<SO>Scandinavian Journal of Gastroenterology</SO>
<YR>1996</YR>
<VL>Supplement 221</VL>
<PG>8-13</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1997264584"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Galmiche-1990" MODIFIED="2009-11-10 11:18:08 -0500" MODIFIED_BY="Jan Lilleyman" NAME="Galmiche 1990" TYPE="JOURNAL_ARTICLE">
<AU>Galmiche JP, Fraitag B, Filoche B, Evreux M, Vitaux J, Zeitoun P, et al</AU>
<TI>Double-blind comparison of cisapride and cimetidine in treatment of reflux esophagitis</TI>
<SO>Digestive Diseases and Sciences</SO>
<YR>1990</YR>
<VL>35</VL>
<PG>649-55</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2003" MODIFIED="2013-03-24 05:23:44 -0400" MODIFIED_BY="Kate Cahill" NAME="Higgins 2003" TYPE="JOURNAL_ARTICLE">
<AU>Higgins JP, Thompson SG, Deeks JJ, Altman DG</AU>
<TI>Measuring inconsistency in meta-analyses</TI>
<SO>BMJ</SO>
<YR>2003</YR>
<VL>7414</VL>
<PG>557-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ip-2005" MODIFIED="2013-03-24 09:30:14 -0400" MODIFIED_BY="Jan Lilleyman" NAME="Ip 2005" TYPE="OTHER">
<AU>Ip S, Bonis P, Tatsioni A, Raman G, Chew P, Kupelnick B, et al</AU>
<TI>Comparative effectiveness of management strategies for gastroesophageal reflux disease</TI>
<SO>Evidence Report/Technology Assessment No. 1; Rockville, MD: Agency for Healthcare Research and Quality.</SO>
<YR>December 2005</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Isolauri-1995" MODIFIED="2010-11-15 09:54:22 -0500" MODIFIED_BY="Karin L Dearness" NAME="Isolauri 1995" TYPE="JOURNAL_ARTICLE">
<AU>Isolauri J, Laippala P</AU>
<TI>Prevalence of symptoms suggestive of gastro-oesophageal reflux disease in an adult population</TI>
<SO>Annals of Medicine</SO>
<YR>1995</YR>
<VL>27</VL>
<PG>67-70</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1995260492"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Janisch-1988" MODIFIED="2008-10-30 12:53:48 -0400" MODIFIED_BY="Karen Hovhannisyan" NAME="Janisch 1988" TYPE="JOURNAL_ARTICLE">
<AU>Janisch HD, Hutteman W, Bouzo MH</AU>
<TI>Cisapride versus ranitidine in the treatment of reflux esophagitis</TI>
<SO>Hepato-gastroenterology</SO>
<YR>1988</YR>
<VL>35</VL>
<PG>125-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Joelsson-1989" MODIFIED="2010-11-15 09:54:25 -0500" MODIFIED_BY="Karin L Dearness" NAME="Joelsson 1989" TYPE="JOURNAL_ARTICLE">
<AU>Joelsson B, Johnsson F</AU>
<TI>Heartburn - the acid test</TI>
<SO>Gut</SO>
<YR>1989</YR>
<VL>30</VL>
<PG>1523-5</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1990093085"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Johansson-1986b" MODIFIED="2010-11-15 09:54:26 -0500" MODIFIED_BY="Karin L Dearness" NAME="Johansson 1986b" TYPE="JOURNAL_ARTICLE">
<AU>Johansson KE, Ask P, Boeryd B, Fransson SG, Tibbling L</AU>
<TI>Oesophagitis, signs of reflux, and gastric acid secretion in patients with symptoms of gastro-oesophageal reflux disease</TI>
<SO>Scandinavian Journal of Gastroenterology</SO>
<YR>1986</YR>
<VL>21</VL>
<PG>837-47</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1987042512"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Johnsson-1987" MODIFIED="2010-11-15 09:54:30 -0500" MODIFIED_BY="Karin L Dearness" NAME="Johnsson 1987" TYPE="JOURNAL_ARTICLE">
<AU>Johnsson F, Joelsson B, Gudmundsson K, Greiff L</AU>
<TI>Symptoms and endoscopic findings in the diagnosis of gastroesophageal reflux disease</TI>
<SO>Scandinavian Journal of Gastroenterology</SO>
<YR>1987</YR>
<VL>22</VL>
<PG>714-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1988017822"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Klauser-1990" MODIFIED="2010-11-15 09:54:35 -0500" MODIFIED_BY="Karin L Dearness" NAME="Klauser 1990" TYPE="JOURNAL_ARTICLE">
<AU>Klauser AG, Schindlbeck NE, Muller-Lissner SA</AU>
<TI>Symptoms in gastro-oesophageal reflux disease</TI>
<SO>Lancet</SO>
<YR>1990</YR>
<VL>335</VL>
<PG>205-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1990135645"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Kroes-1999" MODIFIED="2013-03-24 09:32:16 -0400" MODIFIED_BY="Jan Lilleyman" NAME="Kroes 1999" TYPE="JOURNAL_ARTICLE">
<AU>Kroes RM, Numans ME, Jones RH, De Wit NJ, Verheij TJM</AU>
<TI>Gastro-oesophageal reflux disease in primary care. Comparison and evaluation of existing national guidelines and development of uniform European guidelines</TI>
<SO>European Journal of General Practice</SO>
<YR>1999</YR>
<VL>5</VL>
<PG>88-97</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lewin-2001" MODIFIED="2013-03-24 09:33:00 -0400" MODIFIED_BY="Jan Lilleyman" NAME="Lewin 2001" TYPE="JOURNAL_ARTICLE">
<AU>Lewin van den Broek NT, Numans ME, Buskens E, Verheij TJ, De Wit NJ, Smout AJ</AU>
<TI>A randomised controlled trial of four management strategies for dyspepsia: relationships between symptom subgroups and strategy outcome</TI>
<SO>British Journal of General Practice</SO>
<YR>2001</YR>
<VL>51</VL>
<PG>619-24</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Locke-1997" MODIFIED="2010-11-15 09:54:39 -0500" MODIFIED_BY="Karin L Dearness" NAME="Locke 1997" TYPE="JOURNAL_ARTICLE">
<AU>Locke GR 3rd, Talley NJ, Fett SL, Zinsmeister AR, Melton LJ 3rd</AU>
<TI>Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Olmsted County, Minnesota</TI>
<SO>Gastroenterology</SO>
<YR>1997</YR>
<VL>112</VL>
<PG>1448-56</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1997282512"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Maleev-1990" MODIFIED="2009-11-10 11:20:53 -0500" MODIFIED_BY="Jan Lilleyman" NAME="Maleev 1990" TYPE="JOURNAL_ARTICLE">
<AU>Maleev A, Mendizova A, Popov P, Vlahov v, Dimitrov B, Mihova A, et al</AU>
<TI>Cisapride and cimetidine in the treatment of erosive esophagitis</TI>
<SO>Hepato-gastroenterology</SO>
<YR>1990</YR>
<VL>37</VL>
<PG>403-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Nebel-1976" MODIFIED="2010-11-15 09:54:42 -0500" MODIFIED_BY="Karin L Dearness" NAME="Nebel 1976" TYPE="JOURNAL_ARTICLE">
<AU>Nebel OT, Fornes MF, Castell DO</AU>
<TI>Symptomatic gastroesophageal reflux: incidence and precipitating factors</TI>
<SO>American Journal of Digestive Diseases</SO>
<YR>1976</YR>
<VL>21</VL>
<PG>953-6</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1977042011"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Robinson--1998" MODIFIED="2010-11-15 09:54:44 -0500" MODIFIED_BY="Karin L Dearness" NAME="Robinson  1998" TYPE="JOURNAL_ARTICLE">
<AU>Robinson M, Earnest D, Rodriguez-Stanley S, Greenwood-Van Meerveld B, Jaffe P, Silver MT, et al</AU>
<TI>Heartburn requiring frequent antacid use may indicate significant illness</TI>
<SO>Archives of Internal Medicine</SO>
<YR>1998</YR>
<VL>158</VL>
<PG>2373-6</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1999043491"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Rodriguez-1999" MODIFIED="2013-03-24 09:34:54 -0400" MODIFIED_BY="Karin L Dearness" NAME="Rodriguez 1999" TYPE="JOURNAL_ARTICLE">
<AU>Rodriguez-Stanley S, Robinson M, Earnest DL, Greenwood-Van Meerveld B, Miner PB Jr</AU>
<TI>Esophageal hypersensitivity may be a major cause of heartburn</TI>
<SO>American Journal of Gastroenterology</SO>
<YR>1999</YR>
<VL>94</VL>
<PG>628-31</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1999184446"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Shi-1995" MODIFIED="2010-11-15 09:54:52 -0500" MODIFIED_BY="Karin L Dearness" NAME="Shi 1995" TYPE="JOURNAL_ARTICLE">
<AU>Shi G, Bruley des Varannes S, Scarpignato C, Le Rhun M, Galmiche JP</AU>
<TI>Reflux related symptoms in patients with normal oesophageal exposure to acid</TI>
<SO>Gut</SO>
<YR>1995</YR>
<VL>37</VL>
<PG>457-64</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1996097870"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Tefera-1997" MODIFIED="2010-11-15 09:54:54 -0500" MODIFIED_BY="Karin L Dearness" NAME="Tefera 1997" TYPE="JOURNAL_ARTICLE">
<AU>Tefera L, Fein M, Ritter MP, Bremner CG, Crookes PF, Peters JH, et al</AU>
<TI>Can the combination of symptoms and endoscopy confirm the presence of gastroesophageal reflux disease?</TI>
<SO>American Surgeon</SO>
<YR>1997</YR>
<VL>63</VL>
<PG>933-6</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1997463975"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Thompson-1982" MODIFIED="2010-11-15 09:54:56 -0500" MODIFIED_BY="Karin L Dearness" NAME="Thompson 1982" TYPE="JOURNAL_ARTICLE">
<AU>Thompson WG, Heaton KW</AU>
<TI>Heartburn and globus in apparently healthy people</TI>
<SO>Canadian Medical Association Journal</SO>
<YR>1982</YR>
<VL>126</VL>
<PG>46-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1982136505"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Vakil-2006" MODIFIED="2013-03-24 09:37:29 -0400" MODIFIED_BY="Cathy Bennett" NAME="Vakil 2006" TYPE="JOURNAL_ARTICLE">
<AU>Vakil N, Van Zanten SV, Kahrilas P, Dent J, Jones R; Global Consensus Group</AU>
<TI>The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus</TI>
<SO>American Journal of Gastroenterology</SO>
<YR>2006</YR>
<VL>101</VL>
<NO>8</NO>
<PG>1900-20</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2013-03-25 14:28:24 -0400" MODIFIED_BY="Kate Cahill">
<REFERENCE ID="REF-Van-Pinxteren-2004" MODIFIED="2013-03-25 14:26:30 -0400" MODIFIED_BY="Karin Dearness" NAME="Van Pinxteren 2004" TYPE="COCHRANE_REVIEW">
<AU>Van Pinxteren B, Numans ME, Bonis P, Lau J</AU>
<TI>Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2004</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2013-03-25 14:26:30 -0400" MODIFIED_BY="Karin Dearness">
<IDENTIFIER MODIFIED="2013-03-25 14:26:30 -0400" MODIFIED_BY="Karin Dearness" TYPE="DOI" VALUE="10.1002/14651858.CD002095"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Van-Pinxteren-2006" MODIFIED="2013-03-25 14:28:24 -0400" MODIFIED_BY="Karin Dearness" NAME="Van Pinxteren 2006" TYPE="COCHRANE_REVIEW">
<AU>Van Pinxteren B, Numans ME, Bonis P, Lau J</AU>
<TI>Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2006</YR>
<NO>3</NO>
<IDENTIFIERS MODIFIED="2013-03-25 14:25:20 -0400" MODIFIED_BY="Karin Dearness">
<IDENTIFIER MODIFIED="2013-03-25 14:25:20 -0400" MODIFIED_BY="Karin Dearness" TYPE="DOI" VALUE="10.1002/14651858.CD002095.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Van-Pinxteren-2010a" MODIFIED="2013-03-25 14:24:11 -0400" MODIFIED_BY="Karin Dearness" NAME="Van Pinxteren 2010a" TYPE="COCHRANE_REVIEW">
<AU>Van Pinxteren B, Sigterman KE, Bonis P, Lau J, Numans ME</AU>
<TI>Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2010</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2013-03-25 14:23:30 -0400" MODIFIED_BY="Karin Dearness">
<IDENTIFIER MODIFIED="2013-03-25 14:23:30 -0400" MODIFIED_BY="Karin Dearness" TYPE="DOI" VALUE="10.1002/14651858.CD002095.pub3"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Van-Pixteren-2010b" MODIFIED="2013-03-25 14:22:55 -0400" MODIFIED_BY="Kate Cahill" NAME="Van Pixteren 2010b" TYPE="COCHRANE_REVIEW">
<AU>Van Pinxteren B, Sigterman KE, Bonis P, Lau J, Numans ME</AU>
<TI>Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2010</YR>
<NO>11</NO>
<IDENTIFIERS MODIFIED="2013-03-24 09:41:06 -0400" MODIFIED_BY="Kate Cahill">
<IDENTIFIER MODIFIED="2013-03-24 09:41:06 -0400" MODIFIED_BY="Kate Cahill" TYPE="DOI" VALUE="10.1002/14651858.CD002095.pub4"/>
</IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2013-03-24 09:54:24 -0400" MODIFIED_BY="Karin L Dearness">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2013-03-24 09:54:24 -0400" MODIFIED_BY="Karin L Dearness" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2013-03-24 08:04:11 -0400" MODIFIED_BY="Kate Cahill" STUDY_ID="STD-Armstrong-2001">
<CHAR_METHODS>
<P>Randomised<BR/>Double-blinded<BR/>ITT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>n = 220<BR/>Heartburn<BR/>No grade 4 oesophagitis</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-03-24 08:04:11 -0400" MODIFIED_BY="Kate Cahill">
<P>Four weeks<BR/>PAN 40 mg<BR/>NIZ 150 mg bid</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-03-24 07:51:09 -0400" MODIFIED_BY="Kate Cahill">
<P>Complete heartburn relief<BR/>Adequate heartburn control<BR/>Quality of life</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>GORD/ENRD</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-03-24 08:04:29 -0400" MODIFIED_BY="Kate Cahill" STUDY_ID="STD-Armstrong-2005">
<CHAR_METHODS>
<P>Randomised<BR/>Double-blinded<BR/>ITT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>n = 390<BR/>Heartburn</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-03-24 08:04:29 -0400" MODIFIED_BY="Kate Cahill">
<P>Four weeks<BR/>OME 20 mg<BR/>RAN 150 mg bid</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Max 1 day per week mild heartburn<BR/>No heartburn<BR/>GSRS</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>GORD</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-03-24 08:25:03 -0400" MODIFIED_BY="Kate Cahill" STUDY_ID="STD-Bardhan-1999">
<CHAR_METHODS MODIFIED="2013-03-24 08:25:03 -0400" MODIFIED_BY="Kate Cahill">
<P>Randomised<BR/>Double-blinded<BR/>Per Protocol</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>n = 677<BR/>Heartburn<BR/>No circumferential oesophagitis</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-03-24 07:53:56 -0400" MODIFIED_BY="Kate Cahill">
<P>2 weeks<BR/>OME 20 mg<BR/>OME 10 mg<BR/>RAN 300 mg</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Asymptomatic</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>GORD</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-03-24 08:04:39 -0400" MODIFIED_BY="Kate Cahill" STUDY_ID="STD-Bate-1996">
<CHAR_METHODS>
<P>Randomised<BR/>Double-blinded<BR/>ITT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>n = 209<BR/>Heartburn<BR/>No oesophagitis</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-03-24 08:04:39 -0400" MODIFIED_BY="Kate Cahill">
<P>Four weeks<BR/>OME 20 mg<BR/>Placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Heartburn free<BR/>Asymptomatic</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>ENRD</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-03-24 08:04:49 -0400" MODIFIED_BY="Kate Cahill" STUDY_ID="STD-Bate-1997">
<CHAR_METHODS>
<P>Randomised<BR/>Double-blinded<BR/>ITT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>n = 221<BR/>Heartburn<BR/>No oesophageal ulcer</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-03-24 08:04:49 -0400" MODIFIED_BY="Kate Cahill">
<P>Four weeks<BR/>OME 20 mg<BR/>CIM 400 mg qid</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-03-24 07:56:13 -0400" MODIFIED_BY="Kate Cahill">
<P>Heartburn-free<BR/>Max 1day per week mild heartburn</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>GORD/ENRD</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-03-24 08:01:41 -0400" MODIFIED_BY="Kate Cahill" STUDY_ID="STD-Behar-1978">
<CHAR_METHODS MODIFIED="2013-03-24 08:01:41 -0400" MODIFIED_BY="Kate Cahill">
<P>Randomised<BR/>Double-blinded<BR/>ITT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>n = 94<BR/>Heartburn<BR/>Bernstein positive</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-03-24 07:59:08 -0400" MODIFIED_BY="Kate Cahill">
<P>8 weeks<BR/>CIM 300 mg qid<BR/>Placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-03-24 07:59:19 -0400" MODIFIED_BY="Kate Cahill">
<P>Pain-free at day<BR/>Pain-free at night</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>GORD</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-03-24 08:01:32 -0400" MODIFIED_BY="Kate Cahill" STUDY_ID="STD-Bright_x002d_Asare-1980">
<CHAR_METHODS MODIFIED="2013-03-24 08:01:32 -0400" MODIFIED_BY="Kate Cahill">
<P>Randomised<BR/>Double-blinded<BR/>ITT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>n = 50<BR/>Heartburn<BR/>Bernstein positive</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-03-24 08:00:41 -0400" MODIFIED_BY="Kate Cahill">
<P>8 weeks<BR/>CIM 300 mg qid<BR/>MET 10 mg qid<BR/>Placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Painfree at day<BR/>Painfree at night</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>GORD</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-03-24 08:05:00 -0400" MODIFIED_BY="Kate Cahill" STUDY_ID="STD-Carlsson-1998">
<CHAR_METHODS>
<P>Randomised<BR/>Double-blinded<BR/>ITT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>n = 261<BR/>Heartburn<BR/>No oesophagitis</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-03-24 08:05:00 -0400" MODIFIED_BY="Kate Cahill">
<P>Four weeks<BR/>OME 20 mg<BR/>OME 10 mg<BR/>Placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Symptom relief<BR/>Symptom control<BR/>Quality of life</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>ENRD</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-03-24 08:05:07 -0400" MODIFIED_BY="Kate Cahill" STUDY_ID="STD-Castell-1998">
<CHAR_METHODS>
<P>Randomised<BR/>Double-blinded<BR/>ITT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>n = 398<BR/>Heartburn</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-03-24 08:05:07 -0400" MODIFIED_BY="Kate Cahill">
<P>Four weeks<BR/>CIS 10 mg qid<BR/>Placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-03-24 08:02:44 -0400" MODIFIED_BY="Kate Cahill">
<P>VAS &gt; 25% reduced at day<BR/>VAS &gt; 25% reduced at night<BR/>Improvement</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>GORD</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-03-24 08:03:54 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Fass-2009">
<CHAR_METHODS MODIFIED="2012-09-25 04:25:17 -0400" MODIFIED_BY="[Empty name]">
<P>Randomised</P>
<P>Double-blind</P>
<P>ITT unclear</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-03-24 08:03:36 -0400" MODIFIED_BY="[Empty name]">
<P>n = 947</P>
<P>Heartburn for at least four of seven days, for at least six months</P>
<P>Endoscopy: Normal mucosa, no oesophagitis</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-03-24 08:03:51 -0400" MODIFIED_BY="[Empty name]">
<P>Four weeks</P>
<P>Dexlansoprazole MR 30 mg</P>
<P>Dexlansoprazole MR 60 mg</P>
<P>Placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-03-24 08:03:54 -0400" MODIFIED_BY="[Empty name]">
<P>24-hour heartburn-free days</P>
<P>Mean severity of heartburn</P>
<P>Sustained resolution</P>
<P>Days without rescue medication</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-09-25 04:25:45 -0400" MODIFIED_BY="[Empty name]">
<P>ENRD</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-03-24 08:05:53 -0400" MODIFIED_BY="Kate Cahill" STUDY_ID="STD-Fujiwara-2005">
<CHAR_METHODS>
<P>Randomised<BR/>ITT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>n = 106</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-03-24 08:05:53 -0400" MODIFIED_BY="Kate Cahill">
<P>Four weeks<BR/>FAM 20 mg bid<BR/>OME 20 mg</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Complete relief<BR/>Partial relief<BR/>GSRS<BR/>SF-36</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>ENRD</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-03-24 08:06:35 -0400" MODIFIED_BY="Kate Cahill" STUDY_ID="STD-Galmiche-1997">
<CHAR_METHODS>
<P>Randomised<BR/>Double-blinded<BR/>ITT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>n = 423<BR/>Heartburn<BR/>No circumferential oesophagitis</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-03-24 08:06:24 -0400" MODIFIED_BY="Kate Cahill">
<P>Four weeks<BR/>OME 20 mg<BR/>OME 10 mg<BR/>CIS 10 mg qid</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-03-24 08:06:35 -0400" MODIFIED_BY="Kate Cahill">
<P>Heartburn-free<BR/>Max one day per week mild heartburn<BR/>Quality of life</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>GORD/ENRD</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-03-24 08:07:22 -0400" MODIFIED_BY="Kate Cahill" STUDY_ID="STD-Hallerback-1998">
<CHAR_METHODS>
<P>Randomised<BR/>Double-blinded<BR/>ITT(m)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-03-24 08:07:13 -0400" MODIFIED_BY="Kate Cahill">
<P>n = 423<BR/>Two of the following: heartburn, epigastric pain, regurgitation<BR/>No oesophageal ulcer</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-03-24 08:07:22 -0400" MODIFIED_BY="Kate Cahill">
<P>Two weeks<BR/>RAN 150 mg bid<BR/>Placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Complete symptom relief<BR/>Improvement</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>GORD</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-03-24 08:08:07 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hatlebakk-1999">
<CHAR_METHODS>
<P>Randomised<BR/>Double-blinded<BR/>ITT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>n = 483<BR/>Heartburn<BR/>No grade C or D oesophagitis (LA)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-03-24 08:08:02 -0400" MODIFIED_BY="Kate Cahill">
<P>Eight weeks<BR/>OME 20 mg<BR/>CIS 20 mg bid<BR/>Placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-03-24 08:08:07 -0400" MODIFIED_BY="[Empty name]">
<P>Max one day per week mild heartburn</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>GORD</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-03-24 08:09:09 -0400" MODIFIED_BY="Kate Cahill" STUDY_ID="STD-Johansson-1986a">
<CHAR_METHODS>
<P>Randomised<BR/>Double-blinded<BR/>Cross-over<BR/>ITT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>n = 42<BR/>GORD symptoms</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-03-24 08:09:09 -0400" MODIFIED_BY="Kate Cahill">
<P>Eight weeks<BR/>RAN 150 mg bid<BR/>Placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Improvement</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>GORD</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-03-24 08:10:01 -0400" MODIFIED_BY="Kate Cahill" STUDY_ID="STD-Johnsson-2003">
<CHAR_METHODS>
<P>Randomised<BR/>Double-blinded<BR/>ITT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>n = 439<BR/>Heartburn<BR/>No grade C or D (LA) oesophagitis</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-03-24 08:09:55 -0400" MODIFIED_BY="Kate Cahill">
<P>Two weeks<BR/>ESO 20 mg bid<BR/>ESO 40 mg<BR/>Placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-03-24 08:10:01 -0400" MODIFIED_BY="Kate Cahill">
<P>Three days no heartburn</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>GORD</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-03-24 08:11:02 -0400" MODIFIED_BY="Cathy Bennett" STUDY_ID="STD-Kahrilas-2005">
<CHAR_METHODS>
<P>Randomised<BR/>Double-blinded<BR/>ITT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>n = 261<BR/>Heartburn<BR/>No oesophageal erosions</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-03-24 08:10:56 -0400" MODIFIED_BY="Kate Cahill">
<P>Four weeks<BR/>RAB 20 mg<BR/>Placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-03-24 08:11:02 -0400" MODIFIED_BY="Cathy Bennett">
<P>Complete heartburn relief<BR/>Marked improvement<BR/>Satisfactory daytime/night time relief</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>ENRD</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-03-24 08:11:51 -0400" MODIFIED_BY="Kate Cahill" STUDY_ID="STD-Katz-2003">
<CHAR_METHODS>
<P>Randomised<BR/>Double-blinded<BR/>ITT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>n = 717<BR/>Heartburn<BR/>No oesophagitis</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-03-24 08:11:51 -0400" MODIFIED_BY="Kate Cahill">
<P>Four weeks<BR/>ESO 40 mg<BR/>ESO 20 mg<BR/>Placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Complete resolution of heartburn (1w)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>ENRD</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-03-24 08:13:16 -0400" MODIFIED_BY="Kate Cahill" STUDY_ID="STD-Lind-1997">
<CHAR_METHODS>
<P>Randomised<BR/>Double-blinded<BR/>APT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>n = 509<BR/>Heartburn<BR/>No oesophagitis</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-03-24 08:13:06 -0400" MODIFIED_BY="Kate Cahill">
<P>Four weeks<BR/>OME 20 mg<BR/>OME 10 mg<BR/>Placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-03-24 08:13:16 -0400" MODIFIED_BY="Kate Cahill">
<P>Heartburn-free<BR/>Max one day per week mild heartburn<BR/>Heartburn control<BR/>Quality of life</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>ENRD</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-03-24 08:25:34 -0400" MODIFIED_BY="Kate Cahill" STUDY_ID="STD-McCallum-1977">
<CHAR_METHODS MODIFIED="2013-03-24 08:25:34 -0400" MODIFIED_BY="Kate Cahill">
<P>Randomised<BR/>Double-blinded<BR/>Cross-over<BR/>Per Protocol</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-03-24 08:14:20 -0400" MODIFIED_BY="Kate Cahill">
<P>n = 34<BR/>Heartburn<BR/>Regurgitation<BR/>Reflux on x-ray or oesophagoscopy</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-03-24 08:14:31 -0400" MODIFIED_BY="Kate Cahill">
<P>Eight weeks<BR/>MET 10 mg qid<BR/>Placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Improvement of heartburn frequency and antacid use</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>GORD</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-03-24 08:15:24 -0400" MODIFIED_BY="Kate Cahill" STUDY_ID="STD-Richter-2000a">
<CHAR_METHODS>
<P>Randomised<BR/>Double-blinded<BR/>ITT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>n = 359<BR/>Heartburn<BR/>No oesophageal erosions</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-03-24 08:15:14 -0400" MODIFIED_BY="Kate Cahill">
<P>Four weeks<BR/>OME 20 mg<BR/>OME 10 mg<BR/>Placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-03-24 08:15:24 -0400" MODIFIED_BY="Kate Cahill">
<P>Heartburn-free<BR/>Other GORD symptoms</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>ENRD</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-03-24 08:16:26 -0400" MODIFIED_BY="Kate Cahill" STUDY_ID="STD-Richter-2000b">
<CHAR_METHODS>
<P>Randomised<BR/>Double-blinded<BR/>ITT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>n = 831<BR/>Heartburn<BR/>No oesophageal erosions</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-03-24 08:16:19 -0400" MODIFIED_BY="Kate Cahill">
<P>Eight weeks<BR/>LAN 30 mg<BR/>LAN 15 mg<BR/>RAN 150 bid</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-03-24 08:16:26 -0400" MODIFIED_BY="Kate Cahill">
<P>&gt; 80% of days symptom-free</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>ENRD</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-03-24 08:25:49 -0400" MODIFIED_BY="Cathy Bennett" STUDY_ID="STD-Riemann-1991">
<CHAR_METHODS MODIFIED="2013-03-24 08:25:49 -0400" MODIFIED_BY="Kate Cahill">
<P>Randomised<BR/>Double-blinded<BR/>Per Protocol</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>n = 125<BR/>Heartburn<BR/>Regurgitation<BR/>No oesophagitis</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-03-24 08:17:10 -0400" MODIFIED_BY="Kate Cahill">
<P>Two weeks<BR/>CIM 200 mg qid<BR/>Placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-11-19 07:17:47 -0500" MODIFIED_BY="Cathy Bennett">
<P>Symptom disappearance<BR/>Symptom amelioration</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>ENRD</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-03-24 08:18:13 -0400" MODIFIED_BY="Kate Cahill" STUDY_ID="STD-Robinson-1991">
<CHAR_METHODS>
<P>Randomised<BR/>Double-blinded<BR/>APT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>n = 389<BR/>Heartburn<BR/>Bernstein positive<BR/>No oesophagitis</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-03-24 08:18:00 -0400" MODIFIED_BY="Kate Cahill">
<P>Six weeks<BR/>FAM 20 mg bid<BR/>FAM 40 mg<BR/>Placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-03-24 08:18:13 -0400" MODIFIED_BY="Kate Cahill">
<P>Symptom-free<BR/>Symptom improvement<BR/>Heartburn-free at day<BR/>Heartburn-free at night</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>ENRD</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-03-24 08:19:00 -0400" MODIFIED_BY="Kate Cahill" STUDY_ID="STD-Rush-1995">
<CHAR_METHODS>
<P>Randomised<BR/>Double-blinded<BR/>ITT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>n = 590<BR/>Heartburn</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-03-24 08:18:53 -0400" MODIFIED_BY="Kate Cahill">
<P>Six weeks<BR/>RAN 150 mg<BR/>Placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-03-24 08:19:00 -0400" MODIFIED_BY="Kate Cahill">
<P>Heartburn-free<BR/>Improvement<BR/>Quality of life</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>GORD</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-03-24 08:20:06 -0400" MODIFIED_BY="Kate Cahill" STUDY_ID="STD-Sabesin-1991">
<CHAR_METHODS>
<P>Randomised<BR/>Double-blinded<BR/>APT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>n = 338<BR/>Heartburn<BR/>Bernstein positive (in absence of oesophagitis)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-03-24 08:20:06 -0400" MODIFIED_BY="Kate Cahill">
<P>12 weeks<BR/>FAM 20 mg bid<BR/>FAM 40 mg<BR/>Placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Symptom relief<BR/>Heartburn free at day<BR/>Heartburn free at night</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>GORD</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-03-24 08:26:06 -0400" MODIFIED_BY="Kate Cahill" STUDY_ID="STD-Schenk-1997">
<CHAR_METHODS MODIFIED="2013-03-24 08:26:06 -0400" MODIFIED_BY="Kate Cahill">
<P>Randomised<BR/>Double-blinded<BR/>Per Protocol</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>n = 54<BR/>Heartburn, regurgitation or dysphagia<BR/>No oesophagitis</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-03-24 08:20:49 -0400" MODIFIED_BY="Kate Cahill">
<P>Two weeks<BR/>OME 40 mg<BR/>Placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Symptom improvement</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>ENRD</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-03-24 08:21:30 -0400" MODIFIED_BY="Kate Cahill" STUDY_ID="STD-Sontag-1987">
<CHAR_METHODS>
<P>Randomised<BR/>Double-blinded<BR/>ITT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>n = 284<BR/>Heartburn<BR/>Bernstein positive (in absence of oesophagitis)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-03-24 08:21:30 -0400" MODIFIED_BY="Kate Cahill">
<P>Six weeks<BR/>RAN 150 mg<BR/>Placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Improved heartburn frequency (day, night, total)<BR/>Improved heartburn severity (day, night)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>GORD</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-03-24 08:22:15 -0400" MODIFIED_BY="Kate Cahill" STUDY_ID="STD-Talley-2002">
<CHAR_METHODS>
<P>Randomised<BR/>Double-blinded<BR/>ITT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>n = 307<BR/>Heartburn</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-03-24 08:22:15 -0400" MODIFIED_BY="Kate Cahill">
<P>52 weeks<BR/>PAN 20 mg<BR/>RAN 150 mg bid</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Complete control of GORD symptoms<BR/>Quality of life</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>GORD</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-03-24 08:23:19 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tan-2011">
<CHAR_METHODS MODIFIED="2012-09-25 04:23:57 -0400" MODIFIED_BY="[Empty name]">
<P>Randomised</P>
<P>Double-blinded</P>
<P>Per protocol</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-09-25 04:24:05 -0400" MODIFIED_BY="[Empty name]">
<P>n= 175</P>
<P>Heartburn or regurgitation</P>
<P>Endoscopy: no erosive oesophagitis</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-03-24 08:23:19 -0400" MODIFIED_BY="[Empty name]">
<P>Eight weeks</P>
<P>ESO 20 mg</P>
<P>Placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-09-25 04:24:31 -0400" MODIFIED_BY="[Empty name]">
<P>Complete resolution of symptoms</P>
<P>Mild symptoms (acceptable)</P>
<P>GerdQ-Score</P>
<P>SF-36 </P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-09-25 04:24:28 -0400" MODIFIED_BY="[Empty name]">
<P>ENRD</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-03-24 08:26:37 -0400" MODIFIED_BY="Kirsten E. Sigterman" STUDY_ID="STD-Uemura-2008">
<CHAR_METHODS MODIFIED="2009-10-15 10:31:52 -0400" MODIFIED_BY="[Empty name]">
<P>Randomised</P>
<P>Double-blinded</P>
<P>ITT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-10-27 14:30:22 -0400" MODIFIED_BY="Kirsten E. Sigterman">
<P>n = 284</P>
<P>Heartburn</P>
<P>Grade M or N oesophagus according to Hoshihara's modified version of the LA classification (= no erosive changes)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-03-24 08:26:37 -0400" MODIFIED_BY="[Empty name]">
<P>Four weeks</P>
<P>OME 10 mg</P>
<P>OME 20 mg</P>
<P>Placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-10-15 10:32:58 -0400" MODIFIED_BY="[Empty name]">
<P>Complete resolution of heartburn</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-10-15 10:32:59 -0400" MODIFIED_BY="[Empty name]">
<P>ENRD</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-03-24 08:27:15 -0400" MODIFIED_BY="Kate Cahill" STUDY_ID="STD-Van-Zyl-2004">
<CHAR_METHODS>
<P>Randomised<BR/>Double-blinded<BR/>ITT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>n = 338<BR/>Heartburn, acid eructation or pain on swallowing/dysphagia</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-03-24 08:27:12 -0400" MODIFIED_BY="Kate Cahill">
<P>Four weeks<BR/>PAN 20 mg<BR/>RAN 300 mg</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-03-24 08:27:15 -0400" MODIFIED_BY="Kate Cahill">
<P>Free from key GORD symptoms</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>GORD</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-03-24 08:28:23 -0400" MODIFIED_BY="Kate Cahill" STUDY_ID="STD-Venables-1997">
<CHAR_METHODS>
<P>Randomised<BR/>Double-blinded<BR/>APT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>n = 994<BR/>Heartburn<BR/>No oesophageal ulcer</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-03-24 08:28:18 -0400" MODIFIED_BY="Kate Cahill">
<P>Four weeks<BR/>OME 20 mg<BR/>OME 10 mg<BR/>RAN 150 mg bid</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-03-24 08:28:23 -0400" MODIFIED_BY="Kate Cahill">
<P>Max one day per week mild heartburn</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>GORD/ENRD</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-03-24 08:29:21 -0400" MODIFIED_BY="Kate Cahill" STUDY_ID="STD-Watson-1997">
<CHAR_METHODS>
<P>Randomised<BR/>Double-blinded<BR/>Cross-over<BR/>ITT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-03-24 08:29:05 -0400" MODIFIED_BY="Kate Cahill">
<P>n = 19<BR/>Heartburn or regurgitation<BR/>24-hour pH normal<BR/>No oesophagitis</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-03-24 08:29:15 -0400" MODIFIED_BY="Kate Cahill">
<P>Four weeks<BR/>OME 40 mg<BR/>Placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-03-24 08:29:21 -0400" MODIFIED_BY="Kate Cahill">
<P>Max one day per week symptoms<BR/>Max mild heartburn</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>ENRD</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>APT: all patients treated<BR/>bid: twice daily<BR/>CIM: cimetidine<BR/>CIS: cisapride<BR/>ENRD: endoscopy negative reflux disease group<BR/>ESO: esomeprazole<BR/>FAM: famotidine<BR/>GORD: empirical treatment group<BR/>ITT: intention to treat<BR/>LAN: lansoprazole<BR/>MET: metoclopramide<BR/>NIZ: nizatidine<BR/>OME: omeprazole<BR/>PAN: pantoprazole<BR/>PP: per protocol<BR/>qid: four times daily<BR/>RAB: rabeprazole<BR/>RAN: ranitidine</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2013-03-24 08:32:02 -0400" MODIFIED_BY="Cathy Bennett" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2009-11-03 05:44:49 -0500" MODIFIED_BY="Cathy Bennett" STUDY_ID="STD-Bennett-1983">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-11-03 05:44:49 -0500" MODIFIED_BY="Cathy Bennett">
<P>No dichotomous outcome variable extractable.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-10-08 05:59:35 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Croxtall-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-10-08 05:59:35 -0400" MODIFIED_BY="[Empty name]">
<P>Design not RCT, one RCT written about is included.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-10-08 05:59:35 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Fass-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-10-08 05:59:35 -0400" MODIFIED_BY="[Empty name]">
<P>Patients with sleep disturbances.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-11-03 05:44:50 -0500" MODIFIED_BY="Cathy Bennett" STUDY_ID="STD-Fiasse-1980">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-11-03 05:44:50 -0500" MODIFIED_BY="Cathy Bennett">
<P>No dichotomous outcome variable extractable.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-11-03 05:44:51 -0500" MODIFIED_BY="Cathy Bennett" STUDY_ID="STD-Greaney-1981">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-11-03 05:44:51 -0500" MODIFIED_BY="Cathy Bennett">
<P>No dichotomous outcome variable extractable.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-11-03 05:44:52 -0500" MODIFIED_BY="Cathy Bennett" STUDY_ID="STD-Hansen-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-11-03 05:44:52 -0500" MODIFIED_BY="Cathy Bennett">
<P>Open design and only long-term outcome.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-10-08 05:59:35 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Haruma-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-10-08 05:59:35 -0400" MODIFIED_BY="[Empty name]">
<P>Patients with dyspepsia.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-11-03 05:44:53 -0500" MODIFIED_BY="Cathy Bennett" STUDY_ID="STD-Herwaarden-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-11-03 05:44:53 -0500" MODIFIED_BY="Cathy Bennett">
<P>No dichotomous outcome variable extractable.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-11-03 05:44:54 -0500" MODIFIED_BY="Cathy Bennett" STUDY_ID="STD-Hongo-2008a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-11-03 05:44:54 -0500" MODIFIED_BY="Cathy Bennett">
<P>Only selected group of patients with non-erosive reflux disease grade M included.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-11-03 05:44:55 -0500" MODIFIED_BY="Cathy Bennett" STUDY_ID="STD-Hongo-2008b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-11-03 05:44:55 -0500" MODIFIED_BY="Cathy Bennett">
<P>Only selected group of patients with non-erosive reflux disease grade M included.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-11-03 05:44:55 -0500" MODIFIED_BY="Cathy Bennett" STUDY_ID="STD-Jebbink-1993">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-11-03 05:44:55 -0500" MODIFIED_BY="Cathy Bennett">
<P>No dichotomous outcome variable extractable.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-03-24 08:31:08 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Johnson-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-03-24 08:31:08 -0400" MODIFIED_BY="[Empty name]">
<P>Only selected group of patients (with a history of GORD-related sleep disturbances).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-11-03 05:44:57 -0500" MODIFIED_BY="Cathy Bennett" STUDY_ID="STD-Johnsson-1993">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-11-03 05:44:57 -0500" MODIFIED_BY="Cathy Bennett">
<P>No dichotomous outcome variable extractable.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-11-03 05:44:58 -0500" MODIFIED_BY="Cathy Bennett" STUDY_ID="STD-Johnsson-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-11-03 05:44:58 -0500" MODIFIED_BY="Cathy Bennett">
<P>No dichotomous outcome variable extractable.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-03-24 08:31:20 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Juul_x002d_Hansen-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-03-24 08:31:20 -0400" MODIFIED_BY="[Empty name]">
<P>Patients were excluded if nonresponsive on lansoprazole.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-03-24 08:31:27 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kinoshita-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-03-24 08:31:27 -0400" MODIFIED_BY="[Empty name]">
<P>Only selected group of ENRD patients (only grade M) with minimal changes and only patients not responding to antacids during the observation period were included.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-03-24 08:32:02 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kushner-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-03-24 08:32:02 -0400" MODIFIED_BY="[Empty name]">
<P>Only selected group of patients: Only included if responsive to antacids, H2RAs or PPI, excluded if a history of GORD confirmed by endoscopy or if a history of pathologic pH monitoring.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-11-03 05:44:59 -0500" MODIFIED_BY="Cathy Bennett" STUDY_ID="STD-Maddern-1986">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-11-03 05:44:59 -0500" MODIFIED_BY="Cathy Bennett">
<P>No dichotomous outcome variable extractable.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-11-03 05:44:59 -0500" MODIFIED_BY="Cathy Bennett" STUDY_ID="STD-Marrero-1994">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-11-03 05:44:59 -0500" MODIFIED_BY="Cathy Bennett">
<P>No dichotomous outcome variable extractable.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-09-25 04:55:48 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Masharova-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-09-25 04:55:48 -0400" MODIFIED_BY="[Empty name]">
<P>No control group treated with placebo or H2RAs. In treatment group PPI dose was increased if needed.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-11-03 05:45:02 -0500" MODIFIED_BY="Cathy Bennett" STUDY_ID="STD-Meineche-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-11-03 05:45:02 -0500" MODIFIED_BY="Cathy Bennett">
<P>Outcome not stratified, no outcome for patients with heartburn available.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-09-25 04:55:51 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Nakamura-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-09-25 04:55:51 -0400" MODIFIED_BY="[Empty name]">
<P>Design not blinded.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-11-03 05:45:02 -0500" MODIFIED_BY="Cathy Bennett" STUDY_ID="STD-Powell_x002d_Jackson-1978">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-11-03 05:45:02 -0500" MODIFIED_BY="Cathy Bennett">
<P>No dichotomous outcome variable extractable.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-11-03 05:45:03 -0500" MODIFIED_BY="Cathy Bennett" STUDY_ID="STD-Richter-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-11-03 05:45:03 -0500" MODIFIED_BY="Cathy Bennett">
<P>Only patients refractory to ranitidine treatment included.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-11-03 05:45:04 -0500" MODIFIED_BY="Cathy Bennett" STUDY_ID="STD-Richter-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-11-03 05:45:04 -0500" MODIFIED_BY="Cathy Bennett">
<P>No dichotomous outcome variable extractable.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-11-03 05:45:05 -0500" MODIFIED_BY="Cathy Bennett" STUDY_ID="STD-Robinson-1987">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-11-03 05:45:05 -0500" MODIFIED_BY="Cathy Bennett">
<P>No dichotomous outcome variable extractable.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-09-25 04:56:04 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Scheiman-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-09-25 04:56:04 -0400" MODIFIED_BY="[Empty name]">
<P>Lack of information: only abstract available.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-11-03 05:45:06 -0500" MODIFIED_BY="Cathy Bennett" STUDY_ID="STD-Schindlbeck-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-11-03 05:45:06 -0500" MODIFIED_BY="Cathy Bennett">
<P>No dichotomous outcome variable extractable.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-11-03 05:45:07 -0500" MODIFIED_BY="Cathy Bennett" STUDY_ID="STD-Talley-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-11-03 05:45:07 -0500" MODIFIED_BY="Cathy Bennett">
<P>Patients with heartburn were excluded.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-11-03 05:45:09 -0500" MODIFIED_BY="Cathy Bennett" STUDY_ID="STD-Van-Zanten-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-11-03 05:45:09 -0500" MODIFIED_BY="Cathy Bennett">
<P>Patients with heartburn as exclusive symptom were excluded.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-11-03 05:45:10 -0500" MODIFIED_BY="Cathy Bennett" STUDY_ID="STD-Van-Zanten-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-11-03 05:45:10 -0500" MODIFIED_BY="Cathy Bennett">
<P>Patients with predominant symptoms of heartburn were excluded.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2009-10-20 07:44:22 -0400" MODIFIED_BY="Kirsten E. Sigterman" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2013-03-24 09:54:24 -0400" MODIFIED_BY="Karin L Dearness">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2013-03-24 09:54:07 -0400" MODIFIED_BY="Karin L Dearness" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-03-24 07:51:25 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Armstrong-2001">
<DESCRIPTION>
<P>"Patients were allocated to one of two treatment groups on the basis of a block design randomization list."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-03-24 07:52:53 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Armstrong-2005">
<DESCRIPTION>
<P>"Randomization, using a computer-generated table of random numbers, was concealed from patients, investigators and study personnel."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-03-24 07:54:31 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bardhan-1999">
<DESCRIPTION>
<P>"The patients were allocated to treatment according to a computer generated randomisation list. At each centre patients were allocated to the next available treatment number."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-01-16 08:14:33 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bate-1996">
<DESCRIPTION>
<P>Insufficient information about the sequence generation process to permit judgement.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-03 11:13:20 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bate-1997">
<DESCRIPTION>
<P>Sequence generation process not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-03 09:57:01 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Behar-1978">
<DESCRIPTION>
<P>Sequence generation process not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-03 11:14:01 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bright_x002d_Asare-1980">
<DESCRIPTION>
<P>Sequence generation process not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-01-16 08:34:30 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Carlsson-1998">
<DESCRIPTION>
<P>Insufficient information about the sequence generation process to permit judgement.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-01-16 09:06:47 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Castell-1998">
<DESCRIPTION>
<P>Insufficient information about the sequence generation process to permit judgement.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-03-24 08:05:25 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Fass-2009">
<DESCRIPTION>
<P>Patients were randomised using Interactive Voice Responce System in a 1:1:1 ratio.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-01-17 07:04:14 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Fujiwara-2005">
<DESCRIPTION>
<P>'Randomized' is stated, but Insufficient information about the sequence generation process to permit judgement.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-01-16 10:18:13 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Galmiche-1997">
<DESCRIPTION>
<P>Insufficient information about the sequence generation process to permit judgement.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-03 11:15:08 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hallerback-1998">
<DESCRIPTION>
<P>Sequence generation process not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-03-24 08:08:22 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hatlebakk-1999">
<DESCRIPTION>
<P>"Randomisation was done in blocks of eight for each network. The randomisation list was computer generated."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-03 11:16:23 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Johansson-1986a">
<DESCRIPTION>
<P>Sequence generation process not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-01-17 07:24:42 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Johnsson-2003">
<DESCRIPTION>
<P>Insufficient information about the sequence generation process to permit judgement.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-01-17 08:33:06 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kahrilas-2005">
<DESCRIPTION>
<P>Insufficient information about the sequence generation process to permit judgement.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-03-24 08:12:08 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Katz-2003">
<DESCRIPTION>
<P>"Blind blocks of six allocation numbers in a 1 : 1 : 1 ratio were used for randomization."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-03-24 08:13:30 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lind-1997">
<DESCRIPTION>
<P>"The randomization was performed by computer."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-03 11:18:23 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-McCallum-1977">
<DESCRIPTION>
<P>Sequence generation process not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-01-17 09:45:38 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Richter-2000a">
<DESCRIPTION>
<P>Insufficient information about the sequence generation process to permit judgement.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-01-17 09:03:39 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Richter-2000b">
<DESCRIPTION>
<P>Insufficient information about the sequence generation process to permit judgement.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-01-21 10:47:37 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Riemann-1991">
<DESCRIPTION>
<P>Sequence generation process not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-01-21 10:47:26 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Robinson-1991">
<DESCRIPTION>
<P>Sequence generation process not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-03-24 08:19:14 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rush-1995">
<DESCRIPTION>
<P>Randomisation was determined by a computerised random table</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-01-21 10:47:11 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sabesin-1991">
<DESCRIPTION>
<P>Sequence generation process not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-01-21 10:46:51 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Schenk-1997">
<DESCRIPTION>
<P>Sequence generation process not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-03-24 09:54:07 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sontag-1987">
<DESCRIPTION>
<P>Sequence generation process not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-03-24 08:22:29 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Talley-2002">
<DESCRIPTION>
<P>"Patients were allocated to treatment groups on the basis of a computer-generated randomisation list"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-03-24 08:23:30 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Tan-2011">
<DESCRIPTION>
<P>Adequate randomisation described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-01-17 09:59:09 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Uemura-2008">
<DESCRIPTION>
<P>Insufficient information about the sequence generation process to permit judgement.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-03-24 08:27:28 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Van-Zyl-2004">
<DESCRIPTION>
<P>"The patients were randomly assigned to one of two treatment groups using a computer-generated randomization list."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-01-17 05:58:09 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Venables-1997">
<DESCRIPTION>
<P>Insufficient information about the sequence generation process to permit judgement.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-01-16 12:26:06 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Watson-1997">
<DESCRIPTION>
<P>Insufficient information about the sequence generation process to permit judgement.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2013-03-24 09:54:12 -0400" MODIFIED_BY="Kirsten E. Sigterman" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-01-17 06:19:27 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Armstrong-2001">
<DESCRIPTION>
<P>Insufficient information to permit judgement.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-01-14 11:06:54 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Armstrong-2005">
<DESCRIPTION>
<P>'Randomization, using a computer-generated table of random numbers, was concealed from patients, investigators and study personnel.'</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-01-17 06:20:34 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bardhan-1999">
<DESCRIPTION>
<P>Insufficient information to permit judgement</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-01-16 08:15:23 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bate-1996">
<DESCRIPTION>
<P>Method of concealment is not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-03-24 07:56:32 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bate-1997">
<DESCRIPTION>
<P>Method of allocation concealment not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-03 09:57:04 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Behar-1978">
<DESCRIPTION>
<P>Method of concealment allocation not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-03 11:14:04 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bright_x002d_Asare-1980">
<DESCRIPTION>
<P>Method of concealment allocation not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-03-24 08:02:06 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Carlsson-1998">
<DESCRIPTION>
<P>Method of concealment not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-03-24 08:02:54 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Castell-1998">
<DESCRIPTION>
<P>Method of concealment not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-03-24 08:05:28 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Fass-2009">
<DESCRIPTION>
<P>Patients were randomised using Interactive Voice Responce System in a 1:1:1 ratio.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-01-17 07:04:01 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Fujiwara-2005">
<DESCRIPTION>
<P>Method of concealment is not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-03-24 08:06:47 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Galmiche-1997">
<DESCRIPTION>
<P>Method of concealment not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-03-24 08:07:31 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hallerback-1998">
<DESCRIPTION>
<P>Method of concealment not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-01-17 06:25:27 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hatlebakk-1999">
<DESCRIPTION>
<P>Insufficient information to permit judgement.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-03 11:16:29 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Johansson-1986a">
<DESCRIPTION>
<P>Method of concealment allocation not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-03-24 08:10:10 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Johnsson-2003">
<DESCRIPTION>
<P>The method of concealment not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-03-24 08:11:12 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kahrilas-2005">
<DESCRIPTION>
<P>The method of concealment not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-03-24 08:12:19 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Katz-2003">
<DESCRIPTION>
<P>"Investigators were provided with individually sealed and blind randomization envelopes indicating the treatment allocation for each patient."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-03-24 08:13:43 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lind-1997">
<DESCRIPTION>
<P>"The randomization was performed by computer and was carried out separately for each centre and within blocks of five consecutive patient numbers. The block size was not disclosed to the investigators until the study was completed."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-03 11:18:29 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-McCallum-1977">
<DESCRIPTION>
<P>Method of concealment allocation not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-01-17 09:45:59 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Richter-2000a">
<DESCRIPTION>
<P>Method of concealment is not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-03-24 08:16:34 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Richter-2000b">
<DESCRIPTION>
<P>The method of concealment not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-03-24 08:17:19 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Riemann-1991">
<DESCRIPTION>
<P>The method of concealment not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-01-21 10:47:30 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Robinson-1991">
<DESCRIPTION>
<P>Method of concealment allocation not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-03 11:20:42 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rush-1995">
<DESCRIPTION>
<P>Method of concealment allocation not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-01-21 10:47:13 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sabesin-1991">
<DESCRIPTION>
<P>Method of concealment allocation not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-01-21 10:46:53 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Schenk-1997">
<DESCRIPTION>
<P>Method of concealment allocation not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-03-24 09:54:12 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sontag-1987">
<DESCRIPTION>
<P>Method of concealment allocation not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-03-24 08:22:37 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Talley-2002">
<DESCRIPTION>
<P>"The allocation sequence was blinded"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-03-24 08:23:52 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Tan-2011">
<DESCRIPTION>
<P>"Randomization was performed by drawing a sealed envelope that contained a pre-assigned randomized code generated by computer on entry to the study. Both the investigators and patients were blinded to the assigned treatment throughout the study."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-03-24 08:26:47 -0400" MODIFIED_BY="Kirsten E. Sigterman" RESULT="UNKNOWN" STUDY_ID="STD-Uemura-2008">
<DESCRIPTION>
<P>Method of concealment not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-01-17 06:18:56 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Van-Zyl-2004">
<DESCRIPTION>
<P>Insufficient information to permit judgement.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-01-17 05:58:53 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Venables-1997">
<DESCRIPTION>
<P>Method of concealment is not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-03-24 08:29:35 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Watson-1997">
<DESCRIPTION>
<P>Method of concealment not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2013-03-24 09:54:24 -0400" MODIFIED_BY="Karin L Dearness" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-01-14 10:17:52 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Armstrong-2001">
<DESCRIPTION>
<P>Stated: double-blinded. Patients received blinded plastic bottles with placebo and identical study medication. Blinding of outcome assessment ensured, and unlikely that the blinding could have been broken.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-03-24 07:53:24 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Armstrong-2005">
<DESCRIPTION>
<P>"This was a prospective, randomized, controlled, double-blind, double-dummy active treatment trial." Blinding of outcome assessment ensured, and unlikely that the blinding could have been broken: "Double-blind dosing was maintained with an appropriate combination of active and identical-looking placebo tablets."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-03-24 07:54:45 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bardhan-1999">
<DESCRIPTION>
<P>Double-blind, double-dummy treatment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-03-24 07:55:44 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bate-1996">
<DESCRIPTION>
<P>"Patients were randomized to receive double-blind either omeprazole 20 mg or matched placebo capsules once daily (o.m.)."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-03-24 07:56:40 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bate-1997">
<DESCRIPTION>
<P>No information other than "double-blind"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-03-24 08:00:06 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Behar-1978">
<DESCRIPTION>
<P>No information other than "a double blind format was used"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-03-24 08:00:57 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bright_x002d_Asare-1980">
<DESCRIPTION>
<P>No information other than "a double blind format was used"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-03-24 08:02:18 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Carlsson-1998">
<DESCRIPTION>
<P>"Double blind treatment" stated, unclear how it was performed, insufficient information to permit judgement.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-01-16 09:09:13 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Castell-1998">
<DESCRIPTION>
<P>Cisapride 10 mg tablets and placebo tablets were of identical appearance.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-11-08 09:27:51 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Fass-2009">
<DESCRIPTION>
<P>Adequate blinding described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-01-17 07:04:40 -0500" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Fujiwara-2005">
<DESCRIPTION>
<P>No blinding described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-01-16 10:22:48 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Galmiche-1997">
<DESCRIPTION>
<P>Blinding of outcome assessment ensured, and unlikely that the blinding could have been broken.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-02-03 11:15:41 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hallerback-1998">
<DESCRIPTION>
<P>Double-blinded was stated, but method was not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-03-24 08:08:35 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hatlebakk-1999">
<DESCRIPTION>
<P>"Study drugs were double blinded using a double dummy technique. Drugs were dispensed and collected by the network pharmacy. Randomisation lists for emergency use were kept at the pharmacies, at the research coordination office, and at the research laboratory of the sponsor, but the code was not broken until the database had been formally closed."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-02-03 11:16:47 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Johansson-1986a">
<DESCRIPTION>
<P>Double-blinded was stated, but the method was not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-03-24 08:10:22 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Johnsson-2003">
<DESCRIPTION>
<P>Double-blind is stated. "One capsule was administered each morning and evening before food (for patients receiving esomeprazole 40 mg o.d., one dose was active drug and the other was placebo)."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-03-24 08:11:29 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kahrilas-2005">
<DESCRIPTION>
<P>"Trial participants and administering physicians were blinded as to whether patients were taking active drug or placebo. Any patients for whom the blinding code was broken because of an emergency were removed from the trial."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-03-24 08:12:38 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Katz-2003">
<DESCRIPTION>
<P>"To ensure the integrity of blinding, the three study drugs were identical in appearance."</P>
<P>"All envelopes were collected and checked at the end of the study."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-03-24 08:13:53 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lind-1997">
<DESCRIPTION>
<P>"Double-blind treatment" stated, unclear how it was performed, insufficient information to permit judgement.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-02-03 11:18:44 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-McCallum-1977">
<DESCRIPTION>
<P>Double-blinded was stated, but method was not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-03-24 08:15:41 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Richter-2000a">
<DESCRIPTION>
<P>"Double-blinded" is stated, but insufficient information to permit judgement.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-03-24 08:16:45 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Richter-2000b">
<DESCRIPTION>
<P>"Lansoprazole, ranitidine, and placebo were supplied to patients as identical gray, opaque capsules. Patients were instructed to self-administer one capsule prior to breakfast and dinner."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-02-03 11:19:36 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Riemann-1991">
<DESCRIPTION>
<P>Double-blinded was stated, but the method was not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-02-03 11:20:24 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Robinson-1991">
<DESCRIPTION>
<P>Double-blinded was stated, but the method was not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-03-24 08:19:36 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rush-1995">
<DESCRIPTION>
<P>"Investigators were blinded to the study medications, which were formulated and packaged"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-02-03 11:21:07 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sabesin-1991">
<DESCRIPTION>
<P>Double-blinded was stated, but the method was not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-02-03 11:21:32 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Schenk-1997">
<DESCRIPTION>
<P>Double-blinded was stated, but the method was not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-02-03 11:21:49 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sontag-1987">
<DESCRIPTION>
<P>Double-blinded was stated, but the method was not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-01-20 13:53:46 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Talley-2002">
<DESCRIPTION>
<P>'A "double-dummy" design was used to ensure double-blind status of doctor and patients'</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-03-24 08:24:13 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Tan-2011">
<DESCRIPTION>
<P>"Both the investigators and patients were blinded to the assigned treatment throughout the study.The esomeprazole and placebo tablets were identical in appearance to maintain blinding, and only the study investigators had access to the code key, stored on a word file in a locked computer, which decoded the patient&#8217;s treatment. The patient&#8217;s randomized treatment was not recorded in the patient&#8217;s file."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-01-17 10:00:42 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Uemura-2008">
<DESCRIPTION>
<P>Insufficient information to permit judgement.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-03-24 08:27:55 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Van-Zyl-2004">
<DESCRIPTION>
<P>"Double-blind, double-dummy": "The patients in group 1 were administered 20 mg pantoprazole once daily in the morning plus ranitidine placebo to be taken once daily in the evening. The patients in group 2 were administered pantoprazole placebo<BR/>once daily in the morning plus 300 mg ranitidine once daily to be taken in the evening."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-03-24 09:54:24 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Venables-1997">
<DESCRIPTION>
<P>Double blind, double dummy. Patients received either active capsules and placebo tablets or placebo capsules and active tablets. Matched placebos.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-03-24 08:29:44 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Watson-1997">
<DESCRIPTION>
<P>"Double blind treatment" stated, unclear how it was performed, insufficient information to permit judgement.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2013-03-24 09:53:43 -0400" MODIFIED_BY="Karin L Dearness" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-03-24 07:52:12 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Armstrong-2001">
<DESCRIPTION>
<P>"Data analysis for the primary efficacy endpoint was conducted according to the intent-to-treat (ITT) principle." Missing outcome data balanced in numbers across intervention groups, with similar reasons for missing data across groups: "Seven patients randomized to nizatidine and five randomized to pantoprazole did not have symptom relief data at 28 days."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-01-14 11:06:37 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Armstrong-2005">
<DESCRIPTION>
<P>Missing outcome data balanced in numbers across intervention groups, with similar reasons for missing data across groups. ITT analysis. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-03-24 07:55:14 -0400" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Bardhan-1999">
<DESCRIPTION>
<P>No ITT data extractable. Missing outcome data balanced in numbers across intervention groups, with similar reasons for missing data across groups: 161 (24%) continued in the study on maintenance treatment, and 197 (29%) discontinued the study at some stage mainly because of unwillingness to continue (21), adverse events (51), and loss to follow-up (58). There were no differences with respect to these outcomes between the three initially randomised groups.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-03-24 07:55:56 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bate-1996">
<DESCRIPTION>
<P>Missing outcome data balanced in numbers across intervention groups, with similar reasons for missing data across groups. "Analyses are presented on an all-patients-treated basis."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-03-24 09:53:43 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bate-1997">
<DESCRIPTION>
<P>"Analyses were performed on an intention-to-treat basis, or using all data available from the intention-to-treat population"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-01-20 10:38:20 -0500" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Behar-1978">
<DESCRIPTION>
<P>An as-treated analysis has been performed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-01-20 10:38:28 -0500" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Bright_x002d_Asare-1980">
<DESCRIPTION>
<P>An as-treated analysis has been performed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-01-16 08:47:47 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Carlsson-1998">
<DESCRIPTION>
<P>Missing outcome data balanced in numbers across intervention groups, with similar reasons for missing data across groups.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-03-24 08:03:08 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Castell-1998">
<DESCRIPTION>
<P>Missing outcome data balanced in numbers across intervention groups, with similar reasons for missing data across groups. Intention-to-treat analysis.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-10-24 04:19:11 -0400" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Fass-2009">
<DESCRIPTION>
<P>ITT analysis described, but unclear whether it was performed. Results are described in percentages.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-01-17 07:07:41 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Fujiwara-2005">
<DESCRIPTION>
<P>Missing outcome data balanced in numbers across intervention groups, with similar reasons for missing data across groups.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-01-16 10:28:24 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Galmiche-1997">
<DESCRIPTION>
<P>Patients who were lost to follow-up and those who left the study due to unwillingness to continue, adverse events or worsening of symptoms were included in the analysis and regarded as treatment failures.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-01-20 11:10:31 -0500" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Hallerback-1998">
<DESCRIPTION>
<P>After randomisation 4 of 427 withdrew and were not analysed or accounted for</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-03-24 08:08:56 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hatlebakk-1999">
<DESCRIPTION>
<P>Reasons for missing outcome data unlikely to be related to true outcome.</P>
<P>"We performed an `all patients treated` analysis."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-03-24 08:09:42 -0400" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Johansson-1986a">
<DESCRIPTION>
<P>No drop-outs and no missing data reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-03-24 08:10:34 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Johnsson-2003">
<DESCRIPTION>
<P>"All efficacy variables were analyzed using the intention-to-treat (ITT) population, which included all randomized patients who took at least 1 dose of the study drug."</P>
<P>Missing outcome data balanced in numbers across intervention groups, with similar reasons for missing data across groups</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-03-24 08:11:40 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kahrilas-2005">
<DESCRIPTION>
<P>"The integrated analysis included all intent-to-treat (ITT) patients who received rabeprazole 20 mg once daily or placebo from the 2 studies."</P>
<P>Missing outcome data balanced in numbers across intervention groups, with similar reasons for missing data across groups.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-03-24 08:12:52 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Katz-2003">
<DESCRIPTION>
<P>The proportion of missing outcomes compared with observed event risk not enough to have a clinically relevant impact on the intervention effect estimate. Intention-to-treat analysis.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-03-24 08:14:10 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lind-1997">
<DESCRIPTION>
<P>Missing outcome data balanced in numbers across intervention groups, with similar reasons for missing data across groups.</P>
<P>"The effect of treatment on heartburn after 4 weeks was analysed with the All Patients Treated (APT) method, in which all patients randomized to treatment were included."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-03-24 08:14:51 -0400" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-McCallum-1977">
<DESCRIPTION>
<P>"An as-treated analysis has been performed."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-03-24 08:16:01 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Richter-2000a">
<DESCRIPTION>
<P>The proportion of missing outcomes compared with observed event risk not enough to have a clinically relevant impact on the intervention effect estimate.</P>
<P>"The analyses of the data are based on an intent-to-treat population, ie, all patients who were randomized, took at least 1 dose of study medication, and had at least 1 observation."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-03-24 08:16:56 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Richter-2000b">
<DESCRIPTION>
<P>Missing outcome data balanced in numbers across intervention groups, with similar reasons for missing data across groups.</P>
<P>Intention-to-treat analyses.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-03-24 08:17:33 -0400" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Riemann-1991">
<DESCRIPTION>
<P>"In all, 37 patients were excluded from the evaluation, including those with protocol violations"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-03-24 08:18:33 -0400" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Robinson-1991">
<DESCRIPTION>
<P>"Seventeen and 13 of the 389 initially randomized patients had no global evaluation ... and were thus excluded from the intent-to-treat analysis"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-03-24 08:19:46 -0400" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Rush-1995">
<DESCRIPTION>
<P>"Of these, 590 patients comprise the per-protocol database"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-03-24 08:20:26 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sabesin-1991">
<DESCRIPTION>
<P>"All-patients treated approach"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-03-24 08:21:05 -0400" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Schenk-1997">
<DESCRIPTION>
<P>"Thirteen subjects ... had to be withdrawn from further analysis"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-03-24 08:21:58 -0400" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Sontag-1987">
<DESCRIPTION>
<P>"Patients who failed to complete the trial, who were missing any efficacy period ... symptom data, or who had other protocol violations were considered not evaluable and excluded from the efficacy analysis"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-03-24 08:22:55 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Talley-2002">
<DESCRIPTION>
<P>"All outcomes were analysed both on an intention-to-treat and per-protocol basis, whereby patients lost to follow-up were assigned treatment-failure status."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-03-24 08:24:18 -0400" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Tan-2011">
<DESCRIPTION>
<P>Per Protocol analysis, drop-out &gt; 10%.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-01-17 09:57:56 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Uemura-2008">
<DESCRIPTION>
<P>Missing outcome data balanced in numbers across intervention groups, with similar reasons for missing data across groups. The proportion of missing outcomes compared with observed event risk not enough to have a clinically relevant impact on the intervention effect estimate.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-01-17 06:37:33 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Van-Zyl-2004">
<DESCRIPTION>
<P>Intention-to-treat analysis. Missing outcome data balanced in numbers across intervention groups, with similar reasons for missing data across groups.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-03-24 08:28:52 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Venables-1997">
<DESCRIPTION>
<P>Reasons for missing outcome data unlikely to be related to true outcome. "Analyses were performed using an all patients treated (APT) approach."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-03-24 08:30:14 -0400" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Watson-1997">
<DESCRIPTION>
<P>Insufficient reporting of attrition/exclusions to permit judgement. "Two patients dropped out because of recurrence of severe symptoms", unclear which treatment they received. "One patient dropped out because of unacceptable side effects", unclear which treatment this patient received. This patient was not included in the final analysis, so no intention-to-treat analysis.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2013-03-24 08:22:01 -0400" MODIFIED_BY="Karin L Dearness" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-01-14 10:46:54 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Armstrong-2001">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-01-14 11:10:45 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Armstrong-2005">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-01-14 12:10:13 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bardhan-1999">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-01-16 08:30:54 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bate-1996">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-03-24 07:56:59 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bate-1997">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-03-24 08:00:12 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Behar-1978">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-03-24 08:01:03 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bright_x002d_Asare-1980">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-01-16 08:48:06 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Carlsson-1998">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-01-16 09:26:01 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Castell-1998">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-01-16 11:35:40 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Fass-2009">
<DESCRIPTION>
<P>Unclear. Quality of life was measured, but not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-01-17 07:07:57 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Fujiwara-2005">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-01-16 10:29:12 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Galmiche-1997">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-03 10:11:08 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hallerback-1998">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-01-16 11:33:57 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hatlebakk-1999">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-03-24 08:09:29 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Johansson-1986a">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-01-17 07:31:04 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Johnsson-2003">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-01-17 08:37:56 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kahrilas-2005">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-01-17 08:54:54 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Katz-2003">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-01-16 12:16:12 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lind-1997">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-03-24 08:14:55 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-McCallum-1977">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-01-17 09:51:35 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Richter-2000a">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-01-17 09:10:43 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Richter-2000b">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-03-24 08:17:38 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Riemann-1991">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-03-24 08:18:37 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Robinson-1991">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-03-24 08:19:52 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rush-1995">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-03-24 08:20:30 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sabesin-1991">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-03-24 08:21:11 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Schenk-1997">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-03-24 08:22:01 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sontag-1987">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-03 10:12:01 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Talley-2002">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-01-16 11:35:20 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Tan-2011">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-01-17 10:00:52 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Uemura-2008">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-01-17 06:37:40 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Van-Zyl-2004">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-01-17 06:02:40 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Venables-1997">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-01-16 12:33:05 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Watson-1997">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2013-03-24 08:23:00 -0400" MODIFIED_BY="Karin L Dearness" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-03 11:11:53 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Armstrong-2001">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-03 11:12:30 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Armstrong-2005">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-03 11:12:35 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bardhan-1999">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-03 11:12:40 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bate-1996">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-03-24 07:57:02 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bate-1997">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-03-24 08:00:15 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Behar-1978">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-03-24 08:01:07 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bright_x002d_Asare-1980">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-03 11:12:50 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Carlsson-1998">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-01-16 11:47:39 -0500" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Castell-1998">
<DESCRIPTION>
<P>Patient selection by a placebo run-in period.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-03 11:23:26 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Fass-2009">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-03 11:14:36 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Fujiwara-2005">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-03-24 08:07:00 -0400" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Galmiche-1997">
<DESCRIPTION>
<P>Inadequate dose of omeprazole (10 mg) in one treatment arm.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-03-24 08:07:43 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hallerback-1998">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-03 11:16:03 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hatlebakk-1999">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-03-24 08:09:33 -0400" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Johansson-1986a">
<DESCRIPTION>
<P>Cross-over study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-03 11:17:36 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Johnsson-2003">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-03 11:17:46 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kahrilas-2005">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-03 11:17:57 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Katz-2003">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-03 11:18:11 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lind-1997">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-03-24 08:14:59 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-McCallum-1977">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-03 11:18:58 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Richter-2000a">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-03 11:19:05 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Richter-2000b">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-03-24 08:17:44 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Riemann-1991">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-03-24 08:18:41 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Robinson-1991">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-03-24 08:19:56 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rush-1995">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-03-24 08:20:35 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sabesin-1991">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-03-24 08:21:14 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Schenk-1997">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-03-24 08:22:05 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sontag-1987">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-03-24 08:23:00 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Talley-2002">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-03 11:22:23 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Tan-2011">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-03 11:22:31 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Uemura-2008">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-03 11:22:40 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Van-Zyl-2004">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-03 11:22:47 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Venables-1997">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-03 11:22:55 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Watson-1997">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2013-03-24 09:55:20 -0400" MODIFIED_BY="[Empty name]">
<SOF_TABLE ID="SOF-01" MODIFIED="2013-03-24 08:54:10 -0400" MODIFIED_BY="Grade Profiler" NO="1" READONLY="YES">
<TITLE MODIFIED="2013-02-04 11:12:12 -0500" MODIFIED_BY="Grade Profiler">PPIs, H2RAs or prokinetics for heartburn remission in gastro-oesophageal reflux disease-like symptoms</TITLE>
<TABLE COLS="7" ROWS="7">
<TR>
<TD COLSPAN="7">
<P>
<B>PPIs, H2RAs or prokinetics for heartburn remission in gastro-oesophageal reflux disease-like symptoms</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> patients with heartburn remission in gastro-oesophageal reflux disease-like symptoms<BR/>
<B>Settings:</B>
<BR/>
<B>Intervention:</B> PPIs, H2RAs or prokinetics<BR/>
</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of Participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Control</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>PPIs, H2RAs or prokinetics</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>PPI versus placebo</B>
<BR/>Symptomatic outcome measures</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>75 per 100</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>28 per 100</B>
<BR/>(24 to 33)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>RR 0.37 </B>
<BR/>(0.32 to 0.44)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>760<BR/>(2 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8853;<BR/>
<B>high</B>
<SUP>1</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>H2RA versus placebo</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>59 per 100</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>46 per 100</B>
<BR/>(36 to 59)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>RR 0.77 </B>
<BR/>(0.6 to 0.99)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>1013<BR/>(2 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Prokinetic versus placebo</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>322<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8853;<BR/>
<B>high</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>PPI versus H2RA</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>68 per 100</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>45 per 100</B>
<BR/>(41 to 49)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>RR 0.66 </B>
<BR/>(0.60 to 0.73)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>3147<BR/>(7 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>3</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>PPI versus prokinetic</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>59 per 100</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>32 per 100</B>
<BR/>(19 to 52)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>RR 0.53 </B>
<BR/>(0.32 to 0.87)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>747<BR/>(2 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>4,5</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> Confidence interval; <B>RR:</B> Risk ratio;</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> Allocation of concealment unclear in both studies. No high risk of bias in either study.<BR/>
<SUP>2</SUP> Allocation of concealment unclear in both studies. High risk of attrition bias in both studies.<BR/>
<SUP>3</SUP> Heterogenity was caused by one study which could not be explained.<BR/>
<SUP>4</SUP> Allocation of concealment unclear in both studies. High risk of other bias in one study.<BR/>
<SUP>5</SUP> Risk Ratio 0.53 (95% CI 0.32 to 0.87)</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-02" MODIFIED="2013-03-24 09:55:20 -0400" MODIFIED_BY="Grade Profiler" NO="2" READONLY="YES">
<TITLE MODIFIED="2013-03-24 09:55:20 -0400" MODIFIED_BY="Grade Profiler">PPIs, H2RAs or prokinetics for heartburn remission in endoscopy negative reflux disease</TITLE>
<TABLE COLS="7" ROWS="6">
<TR>
<TD COLSPAN="7">
<P>
<B>PPIs, H2RAs or prokinetics for for heartburn remission in endoscopy negative reflux disease</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> patients with heartburn remission in endoscopy negative reflux disease<BR/>
<B>Settings:</B>
<BR/>
<B>Intervention:</B> PPIs, H2RAs or prokinetics for<BR/>
</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of Participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Control</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>PPIs, H2RAs or prokinetics for</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>PPI versus placebo</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>87 per 100</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>62 per 100</B>
<BR/>(57 to 68)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>RR 0.71 </B>
<BR/>(0.65 to 0.78)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>3710<BR/>(10 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>1</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>H2RA versus placebo</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>78 per 100</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>66 per 100</B>
<BR/>(58 to 74)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>RR 0.84 </B>
<BR/>(0.74 to 0.95)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>514<BR/>(2 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>PPI versus H2RA</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>57 per 100</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>45 per 100</B>
<BR/>(36 to 56)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>RR 0.78 </B>
<BR/>(0.62 to 0.97)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>960<BR/>(4 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>3,4</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>PPI versus prokinetic</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>54 per 100</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>39 per 100</B>
<BR/>(30 to 50)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>RR 0.72 </B>
<BR/>(0.56 to 0.92)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>302<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>5</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> Confidence interval; <B>RR:</B> Risk ratio;</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> Heterogenity was caused by two trials and could not be explained.<BR/>
<SUP>2</SUP> Allocation concealment unclear in both studies. High risk of attrition bias in both studies.<BR/>
<SUP>3</SUP> Allocation concealment unclear in all four studies.<BR/>
<SUP>4</SUP> Heterogenity was caused by one trial and could not be explained.<BR/>
<SUP>5</SUP> Allocation unclear in the study.<BR/>
</P>
</FOOTNOTES>
</SOF_TABLE>
</SOF_TABLES>
<ADDITIONAL_TABLES/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2013-01-20 15:16:25 -0500" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2013-01-20 15:09:50 -0500" MODIFIED_BY="[Empty name]" NO="1">
<NAME>PPI versus placebo</NAME>
<DICH_OUTCOME CHI2="113.81972761144618" CI_END="0.657825546778487" CI_START="0.5673547799215709" CI_STUDY="95" CI_TOTAL="95" DF="11" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6109177263096035" ESTIMABLE="YES" EVENTS_1="1607" EVENTS_2="1319" I2="90.33559451349996" I2_Q="98.11175492948028" ID="CMP-001.01" LOG_CI_END="-0.18188926461820187" LOG_CI_START="-0.24614528188728058" LOG_EFFECT_SIZE="-0.2140172732527412" METHOD="MH" MODIFIED="2013-01-20 15:09:50 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="-6.661338147750939E-16" P_Q="3.4061642395499803E-13" P_Z="5.866491855701694E-39" Q="52.95922735944259" RANDOM="YES" SCALE="5.250562606549214" SORT_BY="STUDY" STUDIES="12" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.040394342318469105" TOTALS="SUB" TOTAL_1="2925" TOTAL_2="1545" WEIGHT="200.00000000000003" Z="13.056089234048915">
<NAME>Heartburn remission</NAME>
<GROUP_LABEL_1>PPI</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PPI</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.4161347945393469" CI_END="0.4351877014780782" CI_START="0.32147067206954943" DF="1" EFFECT_SIZE="0.3740321949653001" ESTIMABLE="YES" EVENTS_1="151" EVENTS_2="188" I2="0.0" ID="CMP-001.01.01" LOG_CI_END="-0.3613233864157521" LOG_CI_START="-0.49285864183569134" LOG_EFFECT_SIZE="-0.4270910141257217" MODIFIED="2013-01-20 15:08:35 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.5188720514265797" P_Z="4.138831536700508E-37" STUDIES="2" TAU2="0.0" TOTAL_1="509" TOTAL_2="251" WEIGHT="100.0" Z="12.727888095623229">
<NAME>Empirical treatment</NAME>
<DICH_DATA CI_END="0.4645097668690809" CI_START="0.2591975565151477" EFFECT_SIZE="0.3469867382910861" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="111" LOG_CI_END="-0.33300515001747905" LOG_CI_START="-0.5863690969256339" LOG_EFFECT_SIZE="-0.45968712347155644" ORDER="3455" O_E="0.0" SE="0.14882723658561434" STUDY_ID="STD-Hatlebakk-1999" TOTAL_1="161" TOTAL_2="159" VAR="0.02214954634971042" WEIGHT="26.95223056509025"/>
<DICH_DATA CI_END="0.4590773794092814" CI_START="0.3220963978521397" EFFECT_SIZE="0.3845350052246604" ESTIMABLE="YES" EVENTS_1="112" EVENTS_2="77" LOG_CI_END="-0.33811410614436144" LOG_CI_START="-0.4920141320622904" LOG_EFFECT_SIZE="-0.4150641191033259" MODIFIED="2013-01-20 15:08:35 -0500" MODIFIED_BY="[Empty name]" ORDER="3456" O_E="0.0" SE="0.09040163704160621" STUDY_ID="STD-Johnsson-2003" TOTAL_1="348" TOTAL_2="92" VAR="0.008172455979802307" WEIGHT="73.04776943490975"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="40.56738375163519" CI_END="0.7755124930593964" CI_START="0.6545577221263184" DF="9" EFFECT_SIZE="0.7124729404949081" ESTIMABLE="YES" EVENTS_1="1456" EVENTS_2="1131" I2="77.81468961592272" ID="CMP-001.01.02" LOG_CI_END="-0.11041120156016924" LOG_CI_START="-0.18405204919636717" LOG_EFFECT_SIZE="-0.1472316253782682" MODIFIED="2013-01-20 15:09:50 -0500" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="5.99516881416573E-6" P_Z="4.6073805785633725E-15" STUDIES="10" TAU2="0.013356719230897979" TOTAL_1="2416" TOTAL_2="1294" WEIGHT="100.00000000000003" Z="7.837190700256255">
<NAME>Endoscopy negative reflux disease</NAME>
<DICH_DATA CI_END="0.72700511978658" CI_START="0.47008123439193483" EFFECT_SIZE="0.5845951283739302" ESTIMABLE="YES" EVENTS_1="48" EVENTS_2="93" LOG_CI_END="-0.13846253069910391" LOG_CI_START="-0.3278270854692667" LOG_EFFECT_SIZE="-0.2331448080841853" MODIFIED="2013-01-20 15:09:27 -0500" MODIFIED_BY="[Empty name]" ORDER="3457" O_E="0.0" SE="0.11123367684165743" STUDY_ID="STD-Bate-1996" TOTAL_1="98" TOTAL_2="111" VAR="0.012372930863714276" WEIGHT="7.272418809645177"/>
<DICH_DATA CI_END="0.9985596917650756" CI_START="0.7525808272853683" EFFECT_SIZE="0.8668891964503785" ESTIMABLE="YES" EVENTS_1="121" EVENTS_2="71" LOG_CI_END="-6.259688209830213E-4" LOG_CI_START="-0.12344684994152097" LOG_EFFECT_SIZE="-0.06203640938125201" MODIFIED="2013-01-20 15:09:26 -0500" MODIFIED_BY="[Empty name]" ORDER="3458" O_E="0.0" SE="0.0721455935433708" STUDY_ID="STD-Carlsson-1998" TOTAL_1="173" TOTAL_2="88" VAR="0.005204986667725266" WEIGHT="10.080797117226483"/>
<DICH_DATA CI_END="0.6440830136725813" CI_START="0.5294235228073495" EFFECT_SIZE="0.5839458006347098" ESTIMABLE="YES" EVENTS_1="295" EVENTS_2="253" LOG_CI_END="-0.19105815429160045" LOG_CI_START="-0.27619676647540004" LOG_EFFECT_SIZE="-0.23362746038350024" MODIFIED="2013-01-20 15:09:47 -0500" MODIFIED_BY="[Empty name]" ORDER="58" O_E="0.0" SE="0.05001084223969117" STUDY_ID="STD-Fass-2009" TOTAL_1="619" TOTAL_2="310" VAR="0.0025010843415232786" WEIGHT="11.799666357266965"/>
<DICH_DATA CI_END="0.8424198111860512" CI_START="0.6750367571995283" EFFECT_SIZE="0.7540983606557377" ESTIMABLE="YES" EVENTS_1="92" EVENTS_2="122" LOG_CI_END="-0.07447142839947825" LOG_CI_START="-0.17067257825890778" LOG_EFFECT_SIZE="-0.12257200332919299" MODIFIED="2013-01-20 15:09:47 -0500" MODIFIED_BY="[Empty name]" ORDER="3460" O_E="0.0" SE="0.05650903163080079" STUDY_ID="STD-Kahrilas-2005" TOTAL_1="126" TOTAL_2="126" VAR="0.003193270655850844" WEIGHT="11.306157441429429"/>
<DICH_DATA CI_END="0.79509154290887" CI_START="0.6732040578060141" EFFECT_SIZE="0.7316138687952107" ESTIMABLE="YES" EVENTS_1="303" EVENTS_2="211" LOG_CI_END="-0.0995828659455376" LOG_CI_START="-0.17185327493410832" LOG_EFFECT_SIZE="-0.13571807043982298" MODIFIED="2013-01-20 15:09:48 -0500" MODIFIED_BY="[Empty name]" ORDER="3463" O_E="0.0" SE="0.04245199598418055" STUDY_ID="STD-Katz-2003" TOTAL_1="475" TOTAL_2="242" VAR="0.0018021719630408814" WEIGHT="12.34369908192651"/>
<DICH_DATA CI_END="0.7859306290754662" CI_START="0.6332027254328406" EFFECT_SIZE="0.7054455445544554" ESTIMABLE="YES" EVENTS_1="247" EVENTS_2="91" LOG_CI_END="-0.10461578568998509" LOG_CI_START="-0.1984572245142045" LOG_EFFECT_SIZE="-0.1515365051020948" MODIFIED="2013-01-20 15:09:48 -0500" MODIFIED_BY="[Empty name]" ORDER="3459" O_E="0.0" SE="0.05512292568796042" STUDY_ID="STD-Lind-1997" TOTAL_1="404" TOTAL_2="105" VAR="0.0030385369364004065" WEIGHT="11.412861708551157"/>
<DICH_DATA CI_END="0.728801973877693" CI_START="0.5883552359697739" EFFECT_SIZE="0.6548239895697523" ESTIMABLE="YES" EVENTS_1="147" EVENTS_2="117" LOG_CI_END="-0.13739045979599515" LOG_CI_START="-0.23036037726139325" LOG_EFFECT_SIZE="-0.18387541852869418" MODIFIED="2013-01-20 15:09:49 -0500" MODIFIED_BY="[Empty name]" ORDER="3461" O_E="0.0" SE="0.05461098972768846" STUDY_ID="STD-Richter-2000a" TOTAL_1="236" TOTAL_2="123" VAR="0.002982360199037694" WEIGHT="11.452101210232238"/>
<DICH_DATA CI_END="0.9232098915522902" CI_START="0.706558116818321" EFFECT_SIZE="0.8076518076518077" ESTIMABLE="YES" EVENTS_1="59" EVENTS_2="74" LOG_CI_END="-0.03469955099990847" LOG_CI_START="-0.15085211014175845" LOG_EFFECT_SIZE="-0.09277583057083347" MODIFIED="2013-01-20 15:09:49 -0500" MODIFIED_BY="[Empty name]" ORDER="59" O_E="0.0" SE="0.06822858820436334" STUDY_ID="STD-Tan-2011" TOTAL_1="77" TOTAL_2="78" VAR="0.004655140248360588" WEIGHT="10.388532706971205"/>
<DICH_DATA CI_END="0.9064749443693979" CI_START="0.7153783636477936" EFFECT_SIZE="0.8052779410804102" ESTIMABLE="YES" EVENTS_1="134" EVENTS_2="81" LOG_CI_END="-0.04264419561976468" LOG_CI_START="-0.1454641990632973" LOG_EFFECT_SIZE="-0.09405419734153102" MODIFIED="2013-01-20 15:09:50 -0500" MODIFIED_BY="[Empty name]" ORDER="57" O_E="0.0" SE="0.060396978989956634" STUDY_ID="STD-Uemura-2008" TOTAL_1="189" TOTAL_2="92" VAR="0.0036477950711132634" WEIGHT="11.003948009942006"/>
<DICH_DATA CI_END="0.8622191580624079" CI_START="0.35796232596156524" EFFECT_SIZE="0.5555555555555556" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="18" LOG_CI_END="-0.0643823315768288" LOG_CI_START="-0.4461626786297833" LOG_EFFECT_SIZE="-0.25527250510330607" MODIFIED="2013-01-20 15:09:50 -0500" MODIFIED_BY="[Empty name]" ORDER="3462" O_E="0.0" SE="0.2242596657021024" STUDY_ID="STD-Watson-1997" TOTAL_1="19" TOTAL_2="19" VAR="0.05029239766081872" WEIGHT="2.939817556808842"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.089050585552422" CI_END="0.6866385533671635" CI_START="0.5535135628227802" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6164931078655611" ESTIMABLE="YES" EVENTS_1="337" EVENTS_2="298" I2="2.1777814602504217" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="-0.16327181546815994" LOG_CI_START="-0.25687173307445993" LOG_EFFECT_SIZE="-0.21007177427130994" METHOD="MH" MODIFIED="2012-11-08 09:31:39 -0500" MODIFIED_BY="Cathy Bennett" NO="2" P_CHI2="0.39408855793460695" P_Q="1.0" P_Z="1.3961915444983129E-18" Q="0.0" RANDOM="YES" SCALE="5.6237368080084" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="3.5042505396325186E-4" TOTALS="SUB" TOTAL_1="806" TOTAL_2="425" WEIGHT="99.99999999999997" Z="8.79772380723726">
<NAME>Overall improvement</NAME>
<GROUP_LABEL_1>PPI</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PPI</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="4.089050585552422" CI_END="0.6866385533671635" CI_START="0.5535135628227802" DF="4" EFFECT_SIZE="0.6164931078655611" ESTIMABLE="YES" EVENTS_1="337" EVENTS_2="298" I2="2.1777814602504217" ID="CMP-001.02.01" LOG_CI_END="-0.16327181546815994" LOG_CI_START="-0.25687173307445993" LOG_EFFECT_SIZE="-0.21007177427130994" MODIFIED="2012-05-13 05:43:18 -0400" MODIFIED_BY="Cathy Bennett" NO="1" P_CHI2="0.39408855793460695" P_Z="1.3961915444983129E-18" STUDIES="5" TAU2="3.5042505396325186E-4" TOTAL_1="806" TOTAL_2="425" WEIGHT="99.99999999999997" Z="8.79772380723726">
<NAME>Endoscopy negative reflux disease</NAME>
<DICH_DATA CI_END="0.9570012996126597" CI_START="0.5847130476725679" EFFECT_SIZE="0.7480448826929615" ESTIMABLE="YES" EVENTS_1="75" EVENTS_2="51" LOG_CI_END="-0.019087472448628254" LOG_CI_START="-0.23305721492109804" LOG_EFFECT_SIZE="-0.12607234368486311" ORDER="3464" O_E="0.0" SE="0.125686885895636" STUDY_ID="STD-Carlsson-1998" TOTAL_1="173" TOTAL_2="88" VAR="0.015797193286142625" WEIGHT="18.720509349655977"/>
<DICH_DATA CI_END="0.719743257815179" CI_START="0.48075582159121594" EFFECT_SIZE="0.5882352941176471" ESTIMABLE="YES" EVENTS_1="60" EVENTS_2="102" LOG_CI_END="-0.14282239467826263" LOG_CI_START="-0.31807544807828525" LOG_EFFECT_SIZE="-0.2304489213782739" ORDER="3466" O_E="0.0" SE="0.10294451108377875" STUDY_ID="STD-Kahrilas-2005" TOTAL_1="126" TOTAL_2="126" VAR="0.010597572362278245" WEIGHT="27.61159220426695"/>
<DICH_DATA CI_END="0.6732069631890081" CI_START="0.47103314973504185" EFFECT_SIZE="0.5631188118811881" ESTIMABLE="YES" EVENTS_1="156" EVENTS_2="72" LOG_CI_END="-0.1718514006300772" LOG_CI_START="-0.3269485276048704" LOG_EFFECT_SIZE="-0.2493999641174738" ORDER="3465" O_E="0.0" SE="0.09110482012815402" STUDY_ID="STD-Lind-1997" TOTAL_1="404" TOTAL_2="105" VAR="0.008300088250583298" WEIGHT="34.94493673014173"/>
<DICH_DATA CI_END="0.8816662187703981" CI_START="0.3859485262487894" EFFECT_SIZE="0.5833333333333334" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="24" LOG_CI_END="-0.05469579897484047" LOG_CI_START="-0.4134706130918954" LOG_EFFECT_SIZE="-0.23408320603336796" ORDER="3467" O_E="0.0" SE="0.21074610177633038" STUDY_ID="STD-Schenk-1997" TOTAL_1="26" TOTAL_2="28" VAR="0.04441391941391941" WEIGHT="6.752955811237567"/>
<DICH_DATA CI_END="0.9294990867269665" CI_START="0.500719502841667" EFFECT_SIZE="0.6822157434402333" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="49" LOG_CI_END="-0.031751032604975346" LOG_CI_START="-0.30040549266027994" LOG_EFFECT_SIZE="-0.16607826263262762" MODIFIED="2012-05-13 05:43:18 -0400" MODIFIED_BY="[Empty name]" ORDER="60" O_E="0.0" SE="0.15780895969751088" STUDY_ID="STD-Tan-2011" TOTAL_1="77" TOTAL_2="78" VAR="0.02490366776081061" WEIGHT="11.97000590469776"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2013-01-20 11:55:15 -0500" MODIFIED_BY="[Empty name]" NO="2">
<NAME>H2RA versus placebo</NAME>
<DICH_OUTCOME CHI2="5.566856022415067" CI_END="0.9201947876543113" CI_START="0.7344550222674201" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8220959087947166" ESTIMABLE="YES" EVENTS_1="473" EVENTS_2="408" I2="46.10961756653244" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="-0.036120231079244364" LOG_CI_START="-0.13403479508021907" LOG_EFFECT_SIZE="-0.08507751307973176" METHOD="MH" MODIFIED="2013-01-20 11:55:15 -0500" MODIFIED_BY="Karin Dearness" NO="1" P_CHI2="0.13469423408786663" P_Q="0.5755344086969599" P_Z="6.592040840719058E-4" Q="0.31350993288641754" RANDOM="YES" SCALE="2.2871016263943904" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.006649785844355641" TOTALS="SUB" TOTAL_1="884" TOTAL_2="643" WEIGHT="200.0" Z="3.4060073336761154">
<NAME>Heartburn remission</NAME>
<GROUP_LABEL_1>H2RA</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours H2RA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="4.409663384662793" CI_END="0.9887706800293561" CI_START="0.6026352624991859" DF="1" EFFECT_SIZE="0.7719249175347234" ESTIMABLE="YES" EVENTS_1="232" EVENTS_2="298" I2="77.32253206723013" ID="CMP-002.01.01" LOG_CI_END="-0.0049044201782481684" LOG_CI_START="-0.2199454596843073" LOG_EFFECT_SIZE="-0.11242493993127775" NO="1" P_CHI2="0.03573592863465169" P_Z="0.040426397703255484" STUDIES="2" TAU2="0.02474915698134741" TOTAL_1="511" TOTAL_2="502" WEIGHT="100.0" Z="2.0493654023949666">
<NAME>Empirical treatment</NAME>
<DICH_DATA CI_END="1.0031493979926664" CI_START="0.7500019048356873" EFFECT_SIZE="0.8673891625615764" ESTIMABLE="YES" EVENTS_1="124" EVENTS_2="145" LOG_CI_END="0.0013656168610207413" LOG_CI_START="-0.12493763359686343" LOG_EFFECT_SIZE="-0.06178600836792135" ORDER="3468" O_E="0.0" SE="0.0741911545301342" STUDY_ID="STD-Hallerback-1998" TOTAL_1="210" TOTAL_2="213" VAR="0.005504327410514253" WEIGHT="52.74028891573557"/>
<DICH_DATA CI_END="0.8163433811458808" CI_START="0.5626709164990153" EFFECT_SIZE="0.6777408637873754" ESTIMABLE="YES" EVENTS_1="108" EVENTS_2="153" LOG_CI_END="-0.08812712412819926" LOG_CI_START="-0.24974553220768994" LOG_EFFECT_SIZE="-0.1689363281679446" ORDER="3469" O_E="0.0" SE="0.09493545292991543" STUDY_ID="STD-Rush-1995" TOTAL_1="301" TOTAL_2="289" VAR="0.009012740223008187" WEIGHT="47.25971108426444"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.6006244716763235" CI_END="0.9485570822786878" CI_START="0.7363546091737493" DF="1" EFFECT_SIZE="0.8357477966469999" ESTIMABLE="YES" EVENTS_1="241" EVENTS_2="110" I2="0.0" ID="CMP-002.01.02" LOG_CI_END="-0.02293652901073078" LOG_CI_START="-0.13291299039200072" LOG_EFFECT_SIZE="-0.07792475970136574" MODIFIED="2013-01-20 11:55:15 -0500" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.43834002670054173" P_Z="0.005477911052421752" STUDIES="2" TAU2="0.0" TOTAL_1="373" TOTAL_2="141" WEIGHT="100.00000000000001" Z="2.777498395572609">
<NAME>Endoscopy negative reflux disease</NAME>
<DICH_DATA CI_END="0.9723325538969029" CI_START="0.6204757894498671" EFFECT_SIZE="0.7767295597484277" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="53" LOG_CI_END="-0.01218517373479272" LOG_CI_START="-0.20727515971474114" LOG_EFFECT_SIZE="-0.10973016672476692" ORDER="3470" O_E="0.0" SE="0.11459682347562711" STUDY_ID="STD-Riemann-1991" TOTAL_1="60" TOTAL_2="65" VAR="0.01313243195070404" WEIGHT="31.778217141541926"/>
<DICH_DATA CI_END="1.008010330581243" CI_START="0.7418496411694683" EFFECT_SIZE="0.8647497337593184" ESTIMABLE="YES" EVENTS_1="203" EVENTS_2="57" LOG_CI_END="0.003464982993870148" LOG_CI_START="-0.12968410904374136" LOG_EFFECT_SIZE="-0.06310956302493562" MODIFIED="2013-01-20 11:55:15 -0500" MODIFIED_BY="[Empty name]" ORDER="3471" O_E="0.0" SE="0.07821243576152836" STUDY_ID="STD-Robinson-1991" TOTAL_1="313" TOTAL_2="76" VAR="0.006117185107751201" WEIGHT="68.22178285845808"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.8680685858194392" CI_END="0.8687141955919442" CI_START="0.7107581644730205" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7857771357774332" ESTIMABLE="YES" EVENTS_1="395" EVENTS_2="225" I2="0.0" I2_Q="0.0" ID="CMP-002.02" LOG_CI_END="-0.0611230816562582" LOG_CI_START="-0.14827814287182883" LOG_EFFECT_SIZE="-0.10470061226404352" METHOD="MH" MODIFIED="2012-11-08 09:32:02 -0500" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.5801409797229556" P_Q="0.632610823066897" P_Z="2.4885556784260857E-6" Q="0.22853692853060986" RANDOM="YES" SCALE="6.035573361936135" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="764" TOTAL_2="313" WEIGHT="200.0" Z="4.709065115317856">
<NAME>Painfree at day</NAME>
<GROUP_LABEL_1>H2RA</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PPI</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.669273176055267" CI_END="0.8923893095025535" CI_START="0.7104229807662442" DF="3" EFFECT_SIZE="0.7962247630290925" ESTIMABLE="YES" EVENTS_1="251" EVENTS_2="178" I2="0.0" ID="CMP-002.02.01" LOG_CI_END="-0.04944564104604321" LOG_CI_START="-0.14848299844208956" LOG_EFFECT_SIZE="-0.09896431974406637" NO="1" P_CHI2="0.4454743356589167" P_Z="8.96439507705927E-5" STUDIES="4" TAU2="0.0" TOTAL_1="458" TOTAL_2="238" WEIGHT="100.0" Z="3.9170371171599863">
<NAME>Empirical treatment</NAME>
<DICH_DATA CI_END="0.9908926630101793" CI_START="0.5974838823513504" EFFECT_SIZE="0.7694429123000551" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="37" LOG_CI_END="-0.003973387277680701" LOG_CI_START="-0.22367380569410397" LOG_EFFECT_SIZE="-0.11382359648589231" ORDER="3472" O_E="0.0" SE="0.1290531133124177" STUDY_ID="STD-Behar-1978" TOTAL_1="49" TOTAL_2="45" VAR="0.01665470605562772" WEIGHT="20.320590270112568"/>
<DICH_DATA CI_END="1.3322041307764492" CI_START="0.18765892870658823" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="5" LOG_CI_END="0.12457077594344682" LOG_CI_START="-0.7266307672714092" LOG_EFFECT_SIZE="-0.3010299956639812" ORDER="3473" O_E="0.0" SE="0.5" STUDY_ID="STD-Bright_x002d_Asare-1980" TOTAL_1="20" TOTAL_2="10" VAR="0.25" WEIGHT="1.353733831302294"/>
<DICH_DATA CI_END="1.1936556956207387" CI_START="0.7248099717633776" EFFECT_SIZE="0.9301470588235294" ESTIMABLE="YES" EVENTS_1="138" EVENTS_2="36" LOG_CI_END="0.0768790746530865" LOG_CI_START="-0.139775840369848" LOG_EFFECT_SIZE="-0.03144838285838078" ORDER="3474" O_E="0.0" SE="0.1272641695435975" STUDY_ID="STD-Sabesin-1991" TOTAL_1="272" TOTAL_2="66" VAR="0.01619616884962153" WEIGHT="20.895895873145456"/>
<DICH_DATA CI_END="0.8950224647322436" CI_START="0.6624414731057873" EFFECT_SIZE="0.77" ESTIMABLE="YES" EVENTS_1="77" EVENTS_2="100" LOG_CI_END="-0.048166063916702646" LOG_CI_START="-0.17885248573833365" LOG_EFFECT_SIZE="-0.11350927482751812" ORDER="3475" O_E="0.0" SE="0.07676585108624727" STUDY_ID="STD-Sontag-1987" TOTAL_1="117" TOTAL_2="117" VAR="0.005892995892995891" WEIGHT="57.42978002543968"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.927597622461416" CI_START="0.6079240367432206" DF="0" EFFECT_SIZE="0.7509386733416771" ESTIMABLE="YES" EVENTS_1="144" EVENTS_2="47" I2="0.0" ID="CMP-002.02.02" LOG_CI_END="-0.03264037317895198" LOG_CI_START="-0.21615068468174362" LOG_EFFECT_SIZE="-0.12439552893034778" NO="2" P_CHI2="1.0" P_Z="0.007879534114919717" STUDIES="1" TAU2="0.0" TOTAL_1="306" TOTAL_2="75" WEIGHT="100.0" Z="2.657188629289456">
<NAME>Treatment of ENRD</NAME>
<DICH_DATA CI_END="0.927597622461416" CI_START="0.6079240367432206" EFFECT_SIZE="0.7509386733416771" ESTIMABLE="YES" EVENTS_1="144" EVENTS_2="47" LOG_CI_END="-0.03264037317895198" LOG_CI_START="-0.21615068468174362" LOG_EFFECT_SIZE="-0.12439552893034778" ORDER="3476" O_E="0.0" SE="0.10779486536743209" STUDY_ID="STD-Robinson-1991" TOTAL_1="306" TOTAL_2="75" VAR="0.011619732999582811" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.5121360487487756" CI_END="0.9205832136486518" CI_START="0.6576937803655957" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="0.778114293613535" ESTIMABLE="YES" EVENTS_1="307" EVENTS_2="177" I2="14.581896647518192" I2_Q="0.0" ID="CMP-002.03" LOG_CI_END="-0.03593694850160145" LOG_CI_START="-0.18197626512823542" LOG_EFFECT_SIZE="-0.10895660681491846" METHOD="MH" MODIFIED="2012-11-08 09:32:13 -0500" MODIFIED_BY="Karin Dearness" NO="3" P_CHI2="0.3191916558292994" P_Q="0.8617708664645934" P_Z="0.0034493365790791712" Q="0.030317918650745877" RANDOM="YES" SCALE="2.813732966406973" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.003214202139934302" TOTALS="SUB" TOTAL_1="679" TOTAL_2="275" WEIGHT="200.0" Z="2.9245689471541256">
<NAME>Painfree at night</NAME>
<GROUP_LABEL_1>H2RA</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours H2RA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="3.5069107734394507" CI_END="0.9419052331150062" CI_START="0.6303927552280271" DF="2" EFFECT_SIZE="0.7705648805045984" ESTIMABLE="YES" EVENTS_1="212" EVENTS_2="148" I2="42.9697494687476" ID="CMP-002.03.01" LOG_CI_END="-0.025992790206676157" LOG_CI_START="-0.20038878660760354" LOG_EFFECT_SIZE="-0.11319078840713981" NO="1" P_CHI2="0.17317457051461582" P_Z="0.010952575636050078" STUDIES="3" TAU2="0.013782419306767433" TOTAL_1="428" TOTAL_2="214" WEIGHT="100.0" Z="2.544208275855904">
<NAME>Empirical treatment</NAME>
<DICH_DATA CI_END="0.8421516902691972" CI_START="0.37620655385568086" EFFECT_SIZE="0.5628703094140882" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="31" LOG_CI_END="-0.07460967534899061" LOG_CI_START="-0.4245736429202368" LOG_EFFECT_SIZE="-0.2495916591346137" ORDER="3477" O_E="0.0" SE="0.20557056690092845" STUDY_ID="STD-Behar-1978" TOTAL_1="49" TOTAL_2="45" VAR="0.042259257975969106" WEIGHT="18.725658565532818"/>
<DICH_DATA CI_END="1.1653165360992166" CI_START="0.6829176633887428" EFFECT_SIZE="0.8920847750865052" ESTIMABLE="YES" EVENTS_1="125" EVENTS_2="34" LOG_CI_END="0.06644390923240806" LOG_CI_START="-0.16563165428546553" LOG_EFFECT_SIZE="-0.04959387252652875" ORDER="3478" O_E="0.0" SE="0.13632233480296582" STUDY_ID="STD-Sabesin-1991" TOTAL_1="272" TOTAL_2="66" VAR="0.018583778966131906" WEIGHT="32.42324926109696"/>
<DICH_DATA CI_END="0.936644273873713" CI_START="0.6640394057876311" EFFECT_SIZE="0.7886499268100439" ESTIMABLE="YES" EVENTS_1="68" EVENTS_2="83" LOG_CI_END="-0.028425317571875205" LOG_CI_START="-0.17780614772787487" LOG_EFFECT_SIZE="-0.10311573264987504" ORDER="3479" O_E="0.0" SE="0.08774703908066915" STUDY_ID="STD-Sontag-1987" TOTAL_1="107" TOTAL_2="103" VAR="0.00769954286742448" WEIGHT="48.85109217337021"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.082861965304583" CI_START="0.5853159273766579" DF="0" EFFECT_SIZE="0.7961258414617393" ESTIMABLE="YES" EVENTS_1="95" EVENTS_2="29" I2="0.0" ID="CMP-002.03.02" LOG_CI_END="0.03457309972116647" LOG_CI_START="-0.2326096578819253" LOG_EFFECT_SIZE="-0.09901827908037943" NO="2" P_CHI2="1.0" P_Z="0.14629861538362315" STUDIES="1" TAU2="0.0" TOTAL_1="251" TOTAL_2="61" WEIGHT="99.99999999999999" Z="1.4527304272903712">
<NAME>Treatment of ENRD</NAME>
<DICH_DATA CI_END="1.082861965304583" CI_START="0.5853159273766579" EFFECT_SIZE="0.7961258414617393" ESTIMABLE="YES" EVENTS_1="95" EVENTS_2="29" LOG_CI_END="0.03457309972116647" LOG_CI_START="-0.2326096578819253" LOG_EFFECT_SIZE="-0.09901827908037943" ORDER="3480" O_E="0.0" SE="0.1569444743920365" STUDY_ID="STD-Robinson-1991" TOTAL_1="251" TOTAL_2="61" VAR="0.024631568042192593" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="11.93882275999812" CI_END="0.8057320877775799" CI_START="0.6312794127917014" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7131914744580604" ESTIMABLE="YES" EVENTS_1="509" EVENTS_2="560" I2="58.11982386778655" I2_Q="0.0" ID="CMP-002.04" LOG_CI_END="-0.09380934050482985" LOG_CI_START="-0.19977837360112746" LOG_EFFECT_SIZE="-0.14679385705297865" METHOD="MH" MODIFIED="2012-11-08 09:32:22 -0500" MODIFIED_BY="Karin Dearness" NO="4" P_CHI2="0.03563577981136146" P_Q="0.36002713395383457" P_Z="5.632576133801283E-8" Q="0.8377988457884009" RANDOM="YES" SCALE="25.676809723288272" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.013880488626944356" TOTALS="SUB" TOTAL_1="1290" TOTAL_2="859" WEIGHT="200.0" Z="5.430089613332732">
<NAME>Overall improvement</NAME>
<GROUP_LABEL_1>H2RA</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours H2RA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="6.671481406741352" CI_END="0.8111221804771087" CI_START="0.6346472719745192" DF="3" EFFECT_SIZE="0.7174792534128221" ESTIMABLE="YES" EVENTS_1="428" EVENTS_2="515" I2="55.032476040949746" ID="CMP-002.04.01" LOG_CI_END="-0.09091372247148403" LOG_CI_START="-0.19746758241986118" LOG_EFFECT_SIZE="-0.1441906524456726" NO="1" P_CHI2="0.08313960287352096" P_Z="1.1297049578808984E-7" STUDIES="4" TAU2="0.008080094049457276" TOTAL_1="917" TOTAL_2="718" WEIGHT="100.00000000000001" Z="5.304518969801147">
<NAME>Empirical treatment</NAME>
<DICH_DATA CI_END="0.9733981839811033" CI_START="0.6289578260361658" EFFECT_SIZE="0.7824489795918367" ESTIMABLE="YES" EVENTS_1="81" EVENTS_2="105" LOG_CI_END="-0.01170946833262083" LOG_CI_START="-0.20137847464031894" LOG_EFFECT_SIZE="-0.1065439714864699" ORDER="3481" O_E="0.0" SE="0.11141251318186511" STUDY_ID="STD-Hallerback-1998" TOTAL_1="210" TOTAL_2="213" VAR="0.012412748093499267" WEIGHT="19.116632131241133"/>
<DICH_DATA CI_END="0.7641196883504815" CI_START="0.6103842872350406" EFFECT_SIZE="0.6829397128122437" ESTIMABLE="YES" EVENTS_1="170" EVENTS_2="239" LOG_CI_END="-0.1168386101167302" LOG_CI_START="-0.21439665469758823" LOG_EFFECT_SIZE="-0.16561763240715924" ORDER="3482" O_E="0.0" SE="0.05730607830690511" STUDY_ID="STD-Rush-1995" TOTAL_1="301" TOTAL_2="289" VAR="0.0032839866109171407" WEIGHT="34.473015132364274"/>
<DICH_DATA CI_END="0.751451690361099" CI_START="0.41964586328649695" EFFECT_SIZE="0.5615546218487395" ESTIMABLE="YES" EVENTS_1="81" EVENTS_2="35" LOG_CI_END="-0.12409893428397663" LOG_CI_START="-0.3771170536439352" LOG_EFFECT_SIZE="-0.25060799396395594" ORDER="3483" O_E="0.0" SE="0.14862409577192992" STUDY_ID="STD-Sabesin-1991" TOTAL_1="272" TOTAL_2="66" VAR="0.0220891218440238" WEIGHT="12.985227257932987"/>
<DICH_DATA CI_END="0.8893559686499619" CI_START="0.7020401440658746" EFFECT_SIZE="0.7901668129938543" ESTIMABLE="YES" EVENTS_1="96" EVENTS_2="136" LOG_CI_END="-0.05092437595040396" LOG_CI_START="-0.15363805332914698" LOG_EFFECT_SIZE="-0.10228121463977548" ORDER="3484" O_E="0.0" SE="0.060334522533176706" STUDY_ID="STD-Sontag-1987" TOTAL_1="134" TOTAL_2="150" VAR="0.0036402546093064073" WEIGHT="33.42512547846162"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.7750353205200002" CI_END="1.3317344500325323" CI_START="0.12930016697291755" DF="1" EFFECT_SIZE="0.4149620304953129" ESTIMABLE="YES" EVENTS_1="81" EVENTS_2="45" I2="73.51018162494297" ID="CMP-002.04.02" LOG_CI_END="0.12441763445668555" LOG_CI_START="-0.8884009142892123" LOG_EFFECT_SIZE="-0.38199163991626334" NO="2" P_CHI2="0.052022842473011255" P_Z="0.13929314670568024" STUDIES="2" TAU2="0.5476983700621875" TOTAL_1="373" TOTAL_2="141" WEIGHT="100.0" Z="1.478428406664391">
<NAME>Treatment of ENRD</NAME>
<DICH_DATA CI_END="0.6624605714823645" CI_START="0.062282598242299134" EFFECT_SIZE="0.203125" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="16" LOG_CI_END="-0.1788399650850593" LOG_CI_START="-1.2056332782690415" LOG_EFFECT_SIZE="-0.6922366216770504" ORDER="3485" O_E="0.0" SE="0.6031434748731443" STUDY_ID="STD-Riemann-1991" TOTAL_1="60" TOTAL_2="65" VAR="0.36378205128205127" WEIGHT="38.832124593517776"/>
<DICH_DATA CI_END="0.9219675313972667" CI_START="0.4626111458027637" EFFECT_SIZE="0.6530792111931255" ESTIMABLE="YES" EVENTS_1="78" EVENTS_2="29" LOG_CI_END="-0.035284373071417366" LOG_CI_START="-0.3347839078768482" LOG_EFFECT_SIZE="-0.1850341404741328" ORDER="3486" O_E="0.0" SE="0.17592750929131756" STUDY_ID="STD-Robinson-1991" TOTAL_1="313" TOTAL_2="76" VAR="0.03095048852544663" WEIGHT="61.16787540648222"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" MODIFIED="2012-11-08 09:33:47 -0500" MODIFIED_BY="Karin Dearness" NO="3">
<NAME>Prokinetic versus placebo</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="98" EVENTS_2="111" I2="0.0" I2_Q="0.0" ID="CMP-003.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2012-11-08 09:33:00 -0500" MODIFIED_BY="Karin Dearness" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="2.38" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="163" TOTAL_2="159" WEIGHT="0.0" Z="0.0">
<NAME>Heartburn remission</NAME>
<GROUP_LABEL_1>prokinetic</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours prokinetic</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="98" EVENTS_2="111" I2="0.0" ID="CMP-003.01.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="163" TOTAL_2="159" WEIGHT="0.0" Z="0.0">
<NAME>Empirical treatment</NAME>
<DICH_DATA CI_END="1.0121543203638887" CI_START="0.7327882558365817" EFFECT_SIZE="0.861217045266125" ESTIMABLE="YES" EVENTS_1="98" EVENTS_2="111" LOG_CI_END="0.005246733228097405" LOG_CI_START="-0.13502149958343523" LOG_EFFECT_SIZE="-0.06488738317766893" ORDER="3487" O_E="0.0" SE="0.08239425429244485" STUDY_ID="STD-Hatlebakk-1999" TOTAL_1="163" TOTAL_2="159" VAR="0.0067888131404080666" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.010615974073077336" CI_END="0.7725912320671824" CI_START="0.5116025408677445" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.628696776974172" ESTIMABLE="YES" EVENTS_1="82" EVENTS_2="122" I2="0.0" I2_Q="0.0" ID="CMP-003.02" LOG_CI_END="-0.11205022485602831" LOG_CI_START="-0.2910673072698097" LOG_EFFECT_SIZE="-0.20155876606291898" METHOD="MH" MODIFIED="2012-11-08 09:33:10 -0500" MODIFIED_BY="Karin Dearness" NO="2" P_CHI2="0.9179361070937635" P_Q="1.0" P_Z="1.0170234389963934E-5" Q="0.0" RANDOM="YES" SCALE="6.1550909963666784" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="222" TOTAL_2="206" WEIGHT="100.00000000000001" Z="4.413522072028176">
<NAME>Painfree at day</NAME>
<GROUP_LABEL_1>prokinetic</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours prokinetic</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.010615974073077336" CI_END="0.7725912320671824" CI_START="0.5116025408677445" DF="1" EFFECT_SIZE="0.628696776974172" ESTIMABLE="YES" EVENTS_1="82" EVENTS_2="122" I2="0.0" ID="CMP-003.02.01" LOG_CI_END="-0.11205022485602831" LOG_CI_START="-0.2910673072698097" LOG_EFFECT_SIZE="-0.20155876606291898" NO="1" P_CHI2="0.9179361070937635" P_Z="1.0170234389963934E-5" STUDIES="2" TAU2="0.0" TOTAL_1="222" TOTAL_2="206" WEIGHT="100.00000000000001" Z="4.413522072028176">
<NAME>Empirical therapy</NAME>
<DICH_DATA CI_END="1.494046127611527" CI_START="0.24095641583403973" EFFECT_SIZE="0.6" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" LOG_CI_END="0.17436400621960393" LOG_CI_START="-0.6180615054523168" LOG_EFFECT_SIZE="-0.2218487496163564" ORDER="3488" O_E="0.0" SE="0.46547466812563143" STUDY_ID="STD-Bright_x002d_Asare-1980" TOTAL_1="20" TOTAL_2="10" VAR="0.2166666666666667" WEIGHT="5.103546213189213"/>
<DICH_DATA CI_END="0.7787827916937337" CI_START="0.5100920069701208" EFFECT_SIZE="0.6302784124566303" ESTIMABLE="YES" EVENTS_1="76" EVENTS_2="117" LOG_CI_END="-0.10858365339625636" LOG_CI_START="-0.2923514817147797" LOG_EFFECT_SIZE="-0.200467567555518" ORDER="3489" O_E="0.0" SE="0.10794613201972163" STUDY_ID="STD-Castell-1998" TOTAL_1="202" TOTAL_2="196" VAR="0.011652367418019172" WEIGHT="94.8964537868108"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="65" EVENTS_2="124" I2="0.0" I2_Q="0.0" ID="CMP-003.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2012-11-08 09:33:34 -0500" MODIFIED_BY="Karin Dearness" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="5.315696530104045" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="202" TOTAL_2="196" WEIGHT="0.0" Z="0.0">
<NAME>Painfree at night</NAME>
<GROUP_LABEL_1>prokinetic</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours prokinetic</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="65" EVENTS_2="124" I2="0.0" ID="CMP-003.03.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="202" TOTAL_2="196" WEIGHT="0.0" Z="0.0">
<NAME>Empirical treatment</NAME>
<DICH_DATA CI_END="0.638142336907793" CI_START="0.405392013342993" EFFECT_SIZE="0.5086234429894603" ESTIMABLE="YES" EVENTS_1="65" EVENTS_2="124" LOG_CI_END="-0.19508244159372073" LOG_CI_START="-0.3921248116253336" LOG_EFFECT_SIZE="-0.29360362660952716" ORDER="3490" O_E="0.0" SE="0.1157436635320317" STUDY_ID="STD-Castell-1998" TOTAL_1="202" TOTAL_2="196" VAR="0.013396595647816163" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.3806704328999661" CI_END="0.9072053044475239" CI_START="0.5607176668143189" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7132222946819522" ESTIMABLE="YES" EVENTS_1="61" EVENTS_2="84" I2="0.0" I2_Q="0.0" ID="CMP-003.04" LOG_CI_END="-0.042294419115240185" LOG_CI_START="-0.2512557601506619" LOG_EFFECT_SIZE="-0.14677508963295105" METHOD="MH" MODIFIED="2012-11-08 09:33:47 -0500" MODIFIED_BY="Karin Dearness" NO="4" P_CHI2="0.5372449726207269" P_Q="1.0" P_Z="0.005898528464485829" Q="0.0" RANDOM="YES" SCALE="5.315696530104045" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="216" TOTAL_2="213" WEIGHT="100.0" Z="2.7533694805247038">
<NAME>Overall improvement</NAME>
<GROUP_LABEL_1>prokinetic</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours prokinetic</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.3806704328999661" CI_END="0.9072053044475239" CI_START="0.5607176668143189" DF="1" EFFECT_SIZE="0.7132222946819522" ESTIMABLE="YES" EVENTS_1="61" EVENTS_2="84" I2="0.0" ID="CMP-003.04.01" LOG_CI_END="-0.042294419115240185" LOG_CI_START="-0.2512557601506619" LOG_EFFECT_SIZE="-0.14677508963295105" NO="1" P_CHI2="0.5372449726207269" P_Z="0.005898528464485829" STUDIES="2" TAU2="0.0" TOTAL_1="216" TOTAL_2="213" WEIGHT="100.0" Z="2.7533694805247038">
<NAME>Empirical treatment</NAME>
<DICH_DATA CI_END="1.0209045617738457" CI_START="0.5554965183449695" EFFECT_SIZE="0.7530663514112605" ESTIMABLE="YES" EVENTS_1="52" EVENTS_2="67" LOG_CI_END="0.008985144405914204" LOG_CI_START="-0.2553186587182642" LOG_EFFECT_SIZE="-0.12316675715617498" ORDER="3491" O_E="0.0" SE="0.15525336228006822" STUDY_ID="STD-Castell-1998" TOTAL_1="202" TOTAL_2="196" VAR="0.02410360649926611" WEIGHT="62.50648376473077"/>
<DICH_DATA CI_END="0.964934367903213" CI_START="0.4397803599799178" EFFECT_SIZE="0.6514285714285715" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="17" LOG_CI_END="-0.015502225129593249" LOG_CI_START="-0.35676416957005036" LOG_EFFECT_SIZE="-0.1861331973498218" ORDER="3492" O_E="0.0" SE="0.20045895543819375" STUDY_ID="STD-McCallum-1977" TOTAL_1="14" TOTAL_2="17" VAR="0.04018379281537175" WEIGHT="37.49351623526923"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-004" MODIFIED="2013-01-20 15:16:25 -0500" MODIFIED_BY="[Empty name]" NO="4">
<NAME>PPI versus H2RA</NAME>
<DICH_OUTCOME CHI2="25.795667510422458" CI_END="0.7441171028687426" CI_START="0.6187279196640804" CI_STUDY="95" CI_TOTAL="95" DF="10" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6785322593985046" ESTIMABLE="YES" EVENTS_1="1136" EVENTS_2="1078" I2="61.23380022649304" I2_Q="41.97067868752549" ID="CMP-004.01" LOG_CI_END="-0.12835871347593972" LOG_CI_START="-0.20850028630347017" LOG_EFFECT_SIZE="-0.16842949988970496" METHOD="MH" MODIFIED="2013-01-20 15:16:25 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.004024945344797137" P_Q="0.18927318352337463" P_Z="1.746531153020677E-16" Q="1.7232667509847834" RANDOM="YES" SCALE="3.3137731070990375" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.015248932747993058" TOTALS="SUB" TOTAL_1="2459" TOTAL_2="1648" WEIGHT="200.0" Z="8.238314823901543">
<NAME>Heartburn remission</NAME>
<GROUP_LABEL_1>PPI</GROUP_LABEL_1>
<GROUP_LABEL_2>H2RA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PPI</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours H2RA</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="13.58554891045872" CI_END="0.730169609464343" CI_START="0.5963596590764905" DF="6" EFFECT_SIZE="0.6598815798066876" ESTIMABLE="YES" EVENTS_1="851" EVENTS_2="873" I2="55.835424541580714" ID="CMP-004.01.01" LOG_CI_END="-0.13657624686780553" LOG_CI_START="-0.22449174220265988" LOG_EFFECT_SIZE="-0.18053399453523267" MODIFIED="2013-01-20 15:16:25 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.034624525727854794" P_Z="8.309839440440997E-16" STUDIES="7" TAU2="0.0096301315268696" TOTAL_1="1856" TOTAL_2="1291" WEIGHT="100.0" Z="8.049550899451651">
<NAME>Empirical treatment</NAME>
<DICH_DATA CI_END="0.7830496290976856" CI_START="0.4598943882460163" EFFECT_SIZE="0.6001001001001001" ESTIMABLE="YES" EVENTS_1="44" EVENTS_2="72" LOG_CI_END="-0.10621071181150053" LOG_CI_START="-0.3373418897707292" LOG_EFFECT_SIZE="-0.22177630079111485" MODIFIED="2013-01-20 15:16:16 -0500" MODIFIED_BY="[Empty name]" ORDER="3493" O_E="0.0" SE="0.1357675980510339" STUDY_ID="STD-Armstrong-2001" TOTAL_1="111" TOTAL_2="109" VAR="0.018432840680547104" WEIGHT="9.503255213900575"/>
<DICH_DATA CI_END="0.7377085625257316" CI_START="0.5172894388804372" EFFECT_SIZE="0.6177449703285569" ESTIMABLE="YES" EVENTS_1="88" EVENTS_2="141" LOG_CI_END="-0.1321151756901968" LOG_CI_START="-0.28626638817272587" LOG_EFFECT_SIZE="-0.20919078193146132" MODIFIED="2013-01-20 15:16:14 -0500" MODIFIED_BY="[Empty name]" ORDER="3499" O_E="0.0" SE="0.09054918527304587" STUDY_ID="STD-Armstrong-2005" TOTAL_1="196" TOTAL_2="194" VAR="0.008199154953612387" WEIGHT="14.9579506302526"/>
<DICH_DATA CI_END="0.7991394444009989" CI_START="0.6322002811449818" EFFECT_SIZE="0.7107856086221471" ESTIMABLE="YES" EVENTS_1="235" EVENTS_2="169" LOG_CI_END="-0.09737743263853628" LOG_CI_START="-0.19914531536185023" LOG_EFFECT_SIZE="-0.14826137400019326" MODIFIED="2013-01-20 15:16:12 -0500" MODIFIED_BY="[Empty name]" ORDER="3494" O_E="0.0" SE="0.05977895807081858" STUDY_ID="STD-Bardhan-1999" TOTAL_1="448" TOTAL_2="229" VAR="0.003573523828032686" WEIGHT="20.198163294883525"/>
<DICH_DATA CI_END="0.657469477966899" CI_START="0.36981627585827004" EFFECT_SIZE="0.4930952380952381" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="75" LOG_CI_END="-0.1821244038393178" LOG_CI_START="-0.43201397916957796" LOG_EFFECT_SIZE="-0.3070691915044479" MODIFIED="2013-01-20 15:16:25 -0500" MODIFIED_BY="[Empty name]" ORDER="3495" O_E="0.0" SE="0.14678637352234236" STUDY_ID="STD-Bate-1997" TOTAL_1="112" TOTAL_2="109" VAR="0.021546239451840612" WEIGHT="8.554221629252398"/>
<DICH_DATA CI_END="0.8569283610887753" CI_START="0.6340582938639251" EFFECT_SIZE="0.7371177209886888" ESTIMABLE="YES" EVENTS_1="92" EVENTS_2="124" LOG_CI_END="-0.06705548342603215" LOG_CI_START="-0.19787081224505593" LOG_EFFECT_SIZE="-0.13246314783554403" MODIFIED="2013-01-20 15:16:23 -0500" MODIFIED_BY="[Empty name]" ORDER="3496" O_E="0.0" SE="0.07684157169461571" STUDY_ID="STD-Talley-2002" TOTAL_1="154" TOTAL_2="153" VAR="0.005904627140498767" WEIGHT="17.167282264118857"/>
<DICH_DATA CI_END="0.7242277736502603" CI_START="0.43220757426909495" EFFECT_SIZE="0.559478980183962" ESTIMABLE="YES" EVENTS_1="53" EVENTS_2="97" LOG_CI_END="-0.14012482429701922" LOG_CI_START="-0.36430762654475124" LOG_EFFECT_SIZE="-0.25221622542088523" MODIFIED="2013-01-20 15:16:21 -0500" MODIFIED_BY="[Empty name]" ORDER="3498" O_E="0.0" SE="0.13168608776308632" STUDY_ID="STD-Van-Zyl-2004" TOTAL_1="167" TOTAL_2="171" VAR="0.017341225710347276" WEIGHT="9.887881599806319"/>
<DICH_DATA CI_END="0.8512063686211531" CI_START="0.6666704097628727" EFFECT_SIZE="0.7533087670812222" ESTIMABLE="YES" EVENTS_1="301" EVENTS_2="195" LOG_CI_END="-0.06996513569907734" LOG_CI_START="-0.17608882065348533" LOG_EFFECT_SIZE="-0.12302697817628132" MODIFIED="2013-01-20 15:16:19 -0500" MODIFIED_BY="[Empty name]" ORDER="3497" O_E="0.0" SE="0.062337577862932037" STUDY_ID="STD-Venables-1997" TOTAL_1="668" TOTAL_2="326" VAR="0.003885973613817114" WEIGHT="19.731245367785736"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="5.655391401570315" CI_END="0.9739603180061457" CI_START="0.6217460120296971" DF="3" EFFECT_SIZE="0.7781747513222828" ESTIMABLE="YES" EVENTS_1="285" EVENTS_2="205" I2="46.95327366436566" ID="CMP-004.01.02" LOG_CI_END="-0.011458737189179315" LOG_CI_START="-0.20638699167773047" LOG_EFFECT_SIZE="-0.10892286443345493" MODIFIED="2013-01-20 15:15:58 -0500" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.1296344574349525" P_Z="0.02849563624423202" STUDIES="4" TAU2="0.024364289550309035" TOTAL_1="603" TOTAL_2="357" WEIGHT="100.0" Z="2.1903945320050995">
<NAME>Endoscopy negative reflux disease</NAME>
<DICH_DATA CI_END="1.274732823475977" CI_START="0.5357346913032417" EFFECT_SIZE="0.8263888888888888" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="24" LOG_CI_END="0.10541916873140425" LOG_CI_START="-0.27105023013684215" LOG_EFFECT_SIZE="-0.08281553070271892" ORDER="3500" O_E="0.0" SE="0.22113998844878732" STUDY_ID="STD-Armstrong-2001" TOTAL_1="36" TOTAL_2="42" VAR="0.04890289449112979" WEIGHT="17.894323796606166"/>
<DICH_DATA CI_END="0.7748530781639048" CI_START="0.3158934140335503" EFFECT_SIZE="0.49474335188620905" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="33" LOG_CI_END="-0.11078063735387048" LOG_CI_START="-0.5004594284750445" LOG_EFFECT_SIZE="-0.30562003291445755" MODIFIED="2013-01-20 15:15:58 -0500" MODIFIED_BY="[Empty name]" ORDER="3501" O_E="0.0" SE="0.22889925084570326" STUDY_ID="STD-Bate-1997" TOTAL_1="49" TOTAL_2="50" VAR="0.05239486703772418" WEIGHT="17.08026472906085"/>
<DICH_DATA CI_END="1.2061948369120508" CI_START="0.5757315677310262" EFFECT_SIZE="0.8333333333333334" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="30" LOG_CI_END="0.08141746515184248" LOG_CI_START="-0.23977995724709214" LOG_EFFECT_SIZE="-0.0791812460476248" ORDER="3503" O_E="0.0" SE="0.1886729558700175" STUDY_ID="STD-Fujiwara-2005" TOTAL_1="53" TOTAL_2="53" VAR="0.03559748427672957" WEIGHT="21.86504219646421"/>
<DICH_DATA CI_END="1.0210060938193846" CI_START="0.7533992468105672" EFFECT_SIZE="0.8770548569345726" ESTIMABLE="YES" EVENTS_1="227" EVENTS_2="118" LOG_CI_END="0.009028334157659154" LOG_CI_START="-0.12297481830606943" LOG_EFFECT_SIZE="-0.05697324207420515" ORDER="3502" O_E="0.0" SE="0.0775393051833372" STUDY_ID="STD-Venables-1997" TOTAL_1="465" TOTAL_2="212" VAR="0.006012343848314702" WEIGHT="43.16036927786877"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="16.56457778764347" CI_END="0.8836674007235894" CI_START="0.6984487303199269" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7856184659620095" ESTIMABLE="YES" EVENTS_1="377" EVENTS_2="274" I2="87.92604299584428" I2_Q="92.16338278429575" ID="CMP-004.02" LOG_CI_END="-0.05371116622073891" LOG_CI_START="-0.15586546779797175" LOG_EFFECT_SIZE="-0.10478831700935536" METHOD="MH" MODIFIED="2012-11-08 09:35:53 -0500" MODIFIED_BY="Karin Dearness" NO="2" P_CHI2="2.5295874408848285E-4" P_Q="3.539980652912389E-4" P_Z="5.795110395210419E-5" Q="12.760607957168595" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.364742932551339" TOTALS="SUB" TOTAL_1="712" TOTAL_2="433" WEIGHT="200.0" Z="4.021002036485478">
<NAME>Overall improvement</NAME>
<GROUP_LABEL_1>PPI</GROUP_LABEL_1>
<GROUP_LABEL_2>H2RA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PPI</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours H2RA</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.5080859373144564" CI_START="0.16657170520956635" DF="0" EFFECT_SIZE="0.2909170688898639" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="43" I2="0.0" ID="CMP-004.02.01" LOG_CI_END="-0.2940628252259972" LOG_CI_START="-0.7783987683252078" LOG_EFFECT_SIZE="-0.5362307967756026" NO="1" P_CHI2="1.0" P_Z="1.4252542094969833E-5" STUDIES="1" TAU2="0.0" TOTAL_1="106" TOTAL_2="102" WEIGHT="100.0" Z="4.3399341471797985">
<NAME>Empirical treatment</NAME>
<DICH_DATA CI_END="0.5080859373144564" CI_START="0.16657170520956635" EFFECT_SIZE="0.29091706888986396" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="43" LOG_CI_END="-0.2940628252259972" LOG_CI_START="-0.7783987683252078" LOG_EFFECT_SIZE="-0.5362307967756025" ORDER="3504" O_E="0.0" SE="0.28450133047806103" STUDY_ID="STD-Armstrong-2001" TOTAL_1="106" TOTAL_2="102" VAR="0.0809410070437869" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.0291484361261258" CI_END="0.9280061685241603" CI_START="0.7295341506711677" DF="1" EFFECT_SIZE="0.8228075060254846" ESTIMABLE="YES" EVENTS_1="364" EVENTS_2="231" I2="2.8322868794170315" ID="CMP-004.02.02" LOG_CI_END="-0.03244913698469325" LOG_CI_START="-0.1369543732689614" LOG_EFFECT_SIZE="-0.0847017551268273" NO="2" P_CHI2="0.3103590700123058" P_Z="0.0014874987998173014" STUDIES="2" TAU2="0.0017952521189556166" TOTAL_1="606" TOTAL_2="331" WEIGHT="99.99999999999999" Z="3.1771114133331397">
<NAME>Endoscopy negative reflux disease</NAME>
<DICH_DATA CI_END="1.1634541048712301" CI_START="0.29740817432929334" EFFECT_SIZE="0.5882352941176471" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="17" LOG_CI_END="0.06574925621381218" LOG_CI_START="-0.52664709897036" LOG_EFFECT_SIZE="-0.2304489213782739" ORDER="3506" O_E="0.0" SE="0.3479765514444342" STUDY_ID="STD-Fujiwara-2005" TOTAL_1="53" TOTAL_2="53" VAR="0.12108768035516093" WEIGHT="3.066618422040761"/>
<DICH_DATA CI_END="0.9095878971754853" CI_START="0.7602801181095691" EFFECT_SIZE="0.8315897990569705" ESTIMABLE="YES" EVENTS_1="354" EVENTS_2="214" LOG_CI_END="-0.04115532693165742" LOG_CI_START="-0.11902636648839258" LOG_EFFECT_SIZE="-0.08009084671002498" ORDER="3505" O_E="0.0" SE="0.045741834103488775" STUDY_ID="STD-Richter-2000b" TOTAL_1="553" TOTAL_2="278" VAR="0.002092315387151089" WEIGHT="96.93338157795922"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-005" MODIFIED="2012-11-08 09:34:55 -0500" MODIFIED_BY="Karin Dearness" NO="5">
<NAME>PPI versus prokinetic</NAME>
<DICH_OUTCOME CHI2="10.07088648323376" CI_END="0.8451584559676335" CI_START="0.538445286415662" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.674589939807963" ESTIMABLE="YES" EVENTS_1="231" EVENTS_2="231" I2="80.14077506156339" I2_Q="12.870953350263484" ID="CMP-005.01" LOG_CI_END="-0.07306185897827144" LOG_CI_START="-0.26885842052753817" LOG_EFFECT_SIZE="-0.17096013975290478" METHOD="MH" MODIFIED="2012-11-08 09:34:55 -0500" MODIFIED_BY="Karin Dearness" NO="1" P_CHI2="0.006503335504326246" P_Q="0.28402638396496915" P_Z="6.200416439190924E-4" Q="1.1477228759543923" RANDOM="YES" SCALE="5.16" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.06452483578880656" TOTALS="SUB" TOTAL_1="652" TOTAL_2="397" WEIGHT="200.0" Z="3.4226925545198132">
<NAME>Heartburn remission</NAME>
<GROUP_LABEL_1>PPI</GROUP_LABEL_1>
<GROUP_LABEL_2>prokinetic</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PPI</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours prokinetic</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="7.939460084957622" CI_END="0.8744030994987444" CI_START="0.3161228573566197" DF="1" EFFECT_SIZE="0.5257554624490627" ESTIMABLE="YES" EVENTS_1="151" EVENTS_2="179" I2="87.40468508816318" ID="CMP-005.01.01" LOG_CI_END="-0.058288311610943284" LOG_CI_START="-0.5001441012342538" LOG_EFFECT_SIZE="-0.27921620642259853" NO="1" P_CHI2="0.004836846857781407" P_Z="0.013246617430834577" STUDIES="2" TAU2="0.11803348311656157" TOTAL_1="446" TOTAL_2="301" WEIGHT="100.00000000000001" Z="2.47706931238691">
<NAME>Empirical treatment</NAME>
<DICH_DATA CI_END="0.8185943351645188" CI_START="0.5476028824036202" EFFECT_SIZE="0.6695256660168941" ESTIMABLE="YES" EVENTS_1="112" EVENTS_2="81" LOG_CI_END="-0.08693126508447378" LOG_CI_START="-0.26153427454700984" LOG_EFFECT_SIZE="-0.17423276981574182" ORDER="3507" O_E="0.0" SE="0.10256267205712974" STUDY_ID="STD-Galmiche-1997" TOTAL_1="285" TOTAL_2="138" VAR="0.01051910169949834" WEIGHT="52.402920355992876"/>
<DICH_DATA CI_END="0.5441067228141309" CI_START="0.2983433949921078" EFFECT_SIZE="0.4029027760172392" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="98" LOG_CI_END="-0.26431590805284844" LOG_CI_START="-0.5252835725349267" LOG_EFFECT_SIZE="-0.3947997402938876" ORDER="3508" O_E="0.0" SE="0.15329369792754602" STUDY_ID="STD-Hatlebakk-1999" TOTAL_1="161" TOTAL_2="163" VAR="0.023498957824301725" WEIGHT="47.59707964400714"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.9219258194909266" CI_START="0.5575519435435635" DF="0" EFFECT_SIZE="0.7169529499626587" ESTIMABLE="YES" EVENTS_1="80" EVENTS_2="52" I2="0.0" ID="CMP-005.01.02" LOG_CI_END="-0.035304021985219855" LOG_CI_START="-0.25371466595966125" LOG_EFFECT_SIZE="-0.14450934397244058" NO="2" P_CHI2="1.0" P_Z="0.009498150134533053" STUDIES="1" TAU2="0.0" TOTAL_1="206" TOTAL_2="96" WEIGHT="100.0" Z="2.5935833937528985">
<NAME>Endoscopy negative reflux disease</NAME>
<DICH_DATA CI_END="0.9219258194909266" CI_START="0.5575519435435635" EFFECT_SIZE="0.7169529499626587" ESTIMABLE="YES" EVENTS_1="80" EVENTS_2="52" LOG_CI_END="-0.035304021985219855" LOG_CI_START="-0.25371466595966125" LOG_EFFECT_SIZE="-0.14450934397244058" ORDER="3509" O_E="0.0" SE="0.12829549342071112" STUDY_ID="STD-Galmiche-1997" TOTAL_1="206" TOTAL_2="96" VAR="0.016459733632063732" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-006" MODIFIED="2012-11-08 09:35:06 -0500" MODIFIED_BY="Karin Dearness" NO="6">
<NAME>H2RA versus prokinetic</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="5" EVENTS_2="6" I2="0.0" I2_Q="0.0" ID="CMP-006.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2012-11-08 09:35:06 -0500" MODIFIED_BY="Karin Dearness" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="20" TOTAL_2="20" WEIGHT="0.0" Z="0.0">
<NAME>Painfree at day</NAME>
<GROUP_LABEL_1>H2RA</GROUP_LABEL_1>
<GROUP_LABEL_2>prokinetic</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours H2RA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours prokinetic</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="5" EVENTS_2="6" I2="0.0" ID="CMP-006.01.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="0.0" Z="0.0">
<NAME>Empirical treatment</NAME>
<DICH_DATA CI_END="2.2928589592378805" CI_START="0.3028727264913275" EFFECT_SIZE="0.8333333333333334" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="6" LOG_CI_END="0.36037734077066724" LOG_CI_START="-0.5187398328659169" LOG_EFFECT_SIZE="-0.0791812460476248" ORDER="3510" O_E="0.0" SE="0.5163977794943223" STUDY_ID="STD-Bright_x002d_Asare-1980" TOTAL_1="20" TOTAL_2="20" VAR="0.2666666666666667" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2013-04-30 10:24:51 -0400" MODIFIED_BY="Cathy Bennett">
<FIGURE FILENAME="Flowchart.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2013-02-04 11:16:24 -0500" MODIFIED_BY="Karin Dearness" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Study flow diagram.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAUAAAAJHCAYAAADhfY+PAAAuCUlEQVR42u2dD4RVW8OHI0mSRHIl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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2013-03-24 09:54:25 -0400" MODIFIED_BY="Karin Dearness" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAiMAAADnCAMAAAD7EqYIAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2013-03-25 14:19:28 -0400" MODIFIED_BY="Cathy Bennett" NO="3" REF_ID="CMP-001.01" SETTINGS="SHOW_RAW_DATA_COLUMNS:YES;SHOW_MORE_DECIMALS:NO;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 PPI versus placebo, outcome: 1.1 Heartburn remission.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAArcAAAHQCAMAAACMWrI6AAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-04" MODIFIED="2013-03-25 14:19:28 -0400" MODIFIED_BY="Kirsten E. Sigterman" NO="4" REF_ID="CMP-002.01" SETTINGS="SHOW_RAW_DATA_COLUMNS:YES;SHOW_MORE_DECIMALS:NO;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 2 H2RA versus placebo, outcome: 2.1 Heartburn remission.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAArcAAAFQCAMAAACS6qbiAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-05" MODIFIED="2013-04-30 10:24:51 -0400" MODIFIED_BY="[Empty name]" NO="5" REF_ID="CMP-004.01" SETTINGS="SHOW_RAW_DATA_COLUMNS:YES;SHOW_MORE_DECIMALS:NO;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 4 PPI versus H2RA, outcome: 4.1 Heartburn remission.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAArcAAAHACAMAAACPjLChAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK MODIFIED="2009-11-10 11:15:54 -0500" MODIFIED_BY="Jan Lilleyman">
<FEEDBACK_ITEM ID="FBK-01" MODIFIED="2009-11-10 11:15:54 -0500" MODIFIED_BY="Jan Lilleyman" NO="1">
<TITLE MODIFIED="2009-07-05 09:06:29 -0400" MODIFIED_BY="[Empty name]">Problem reading analyses</TITLE>
<DATE_SUBMITTED>
<DATE DAY="5" MONTH="7" YEAR="2009"/>
</DATE_SUBMITTED>
<FEEDBACK_SUMMARY MODIFIED="2009-11-03 05:47:32 -0500" MODIFIED_BY="Cathy Bennett">
<P>Dr Wen-Yi Shau<BR/>
<BR/>03-Jun-2009<BR/>
<BR/>Feedback: I like to ask questions about analysis of "Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease."<BR/>
<BR/>I have problem reading the number (n/N) in analysis correctly. The result in favour of PPI but all the (n/N) for PPI looks no better then comparators (including placebo). For example:<BR/>analysis 1.1, the outcome 1 was heartburn remission, the first row showed study result of <LINK REF="STD-Hatlebakk-1999" TYPE="STUDY">Hatlebakk 1999</LINK>, the number for PPI (n/N) was 39/161, and placebo was 111/159, they turn out to be 24% vs. 70%, there were higher remission in placebo group. Same situation happened to all the analysis.<BR/>
<BR/>This could be a typo: the "<LINK REF="CMP-002.02" TYPE="ANALYSIS">Analysis 2.2</LINK>" should be for H2RA but there are "PPI" on top of table.<BR/>
</P>
</FEEDBACK_SUMMARY>
<FEEDBACK_REPLY MODIFIED="2009-11-10 11:15:54 -0500" MODIFIED_BY="Jan Lilleyman">
<P>Dear Dr Shau,<BR/>
<BR/>Thank you very much for your feedback.<BR/>
<BR/>Reading the number (n/N) indeed is confusing. Actually you should read 'n' as the number of participants NOT reaching a certain outcome or endpoint - so in your example (study <LINK REF="STD-Hatlebakk-1999" TYPE="STUDY">Hatlebakk 1999</LINK>): 161 - 39 = 122 patients on PPI reached heartburn remission, vs. 159 - 111 = 48 patients on placebo. One should focus on the note just below the graph indicating what the results indicate; clearly the results were in favour of PPI. Unfortunately at that time the software (Review Manager) forced me to register my data in this way.<BR/>
<BR/>Our review is being updated at the moment and I will see if it is possible to adjust the way the data are presented, because I agree with you it is confusing at this moment.<BR/>
<BR/>We will also correct the 'PPI on top of the H2RA-table', which is clearly a mistake.<BR/>
<BR/>Once again: thank you very much for your comments.<BR/>
<BR/>Kind regards,<BR/>
<BR/>Bart van Pinxteren</P>
<P>*Note on update, November 2009: All issues raised in this feedback have now been addressed.*</P>
</FEEDBACK_REPLY>
<FEEDBACK_CONTRIBUTORS MODIFIED="2009-07-05 09:07:42 -0400" MODIFIED_BY="[Empty name]">
<P>Bart van Pinxteren<BR/>Mattjis Numans<BR/>
</P>
</FEEDBACK_CONTRIBUTORS>
</FEEDBACK_ITEM>
</FEEDBACK>
<APPENDICES MODIFIED="2012-11-08 09:43:49 -0500" MODIFIED_BY="Cathy Bennett">
<APPENDIX ID="APP-01" MODIFIED="2012-11-08 09:43:49 -0500" MODIFIED_BY="Cathy Bennett" NO="1">
<TITLE MODIFIED="2012-11-08 09:43:49 -0500" MODIFIED_BY="Cathy Bennett">2008 search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2008-11-19 06:16:07 -0500" MODIFIED_BY="Cathy Bennett">
<P>exp gastroesophageal reflux/<BR/>gastro?esophageal reflux.tw.<BR/>gastro-esophageal reflux.tw.<BR/>gastro-oesophageal reflux.tw.<BR/>exp esophagitis/<BR/>esophagitis.tw.<BR/>oesophagitis.tw.<BR/>reflux esophagitis.tw.<BR/>reflux oesophagitis.tw.<BR/>belch.tw.<BR/>burp$.tw.<BR/>eructation.tw.<BR/>GORD.tw.<BR/>GERD.tw.<BR/>Bile Reflux/<BR/>(acid adj5 reflux).tw.<BR/>exp dyspepsia/<BR/>dyspep$.tw.<BR/>or/30-47<BR/>exp anti-ulcer agents/<BR/>exp omeprazole/<BR/>omeprazole.tw.<BR/>lansoprazole.tw.<BR/>pantoprazole.tw.<BR/>rabeprazole.tw.<BR/>esomeprazole.tw.<BR/>exp histamine H2 antagonists/<BR/>cimetidine/<BR/>cimetidine.tw.<BR/>exp ranitidine/<BR/>ranitidine.tw.<BR/>exp famotidine/<BR/>famotidine.tw.<BR/>exp nizatidine/<BR/>nizatidine.tw.<BR/>exp domperidone/<BR/>domperidone.tw.<BR/>exp metoclopramide/<BR/>metoclopramide.tw.<BR/>exp cisapride/<BR/>cisapride.tw.<BR/>prokinetic$.tw.</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2012-11-08 09:43:31 -0500" MODIFIED_BY="Cathy Bennett" NO="2">
<TITLE MODIFIED="2012-11-08 09:41:20 -0500" MODIFIED_BY="Cathy Bennett">MEDLINE search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2012-11-08 09:43:31 -0500" MODIFIED_BY="Cathy Bennett">
<SUBSECTION>
<HEADING LEVEL="3">Summary of 2011 revisions</HEADING>
<UL>
<LI>Step 1 to 11:  filter changed to new version of Cochrane RCT filter for Medline, sensitivity &#8211; maximising strategy as per Cochrane Handbook V5.  (Old RCT filter Step 1-12 deleted)</LI>
<LI>Step 22 (duodenogastric adj2 reflux).tw. added</LI>
<LI>Step 24 (bile adj2 reflux added).tw.</LI>
<LI>Step 30 eructation.tw. added</LI>
<LI>Step 38: new subject heading proton pump inhibitors added (2008) and exploded</LI>
<LI>Step 42:  &#8216;lansoprazole.tw&#8217; amended to &#8216;(lansoprazole or lanzoprazole).tw.</LI>
<LI>Step 47: (histamine adj3 h2 adj3 antagonist$)  added</LI>
<LI>Added date limit of 2006-2008</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">MEDLINE Search Strategy (19 November 2008)</HEADING>
<P>Database: Ovid MEDLINE(R) &lt;1996 to November Week 1 2008&gt;<BR/>
</P>
<P>1 randomized controlled trial.pt. (162955)<BR/>2 controlled clinical trial.pt. (32199)<BR/>3 randomized.ab. (126026)<BR/>4 placebo.ab. (64782)<BR/>5 drug therapy.fs. (619533)<BR/>6 randomly.ab. (86062)<BR/>7 trial.ab. (121278)<BR/>8 groups.ab. (517149)<BR/>9 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 (1246833)<BR/>10 humans.sh. (4721216)<BR/>11 9 and 10 (1027119)<BR/>12 exp esophagus/ (10673)<BR/>13 esophag$.tw. (32782)<BR/>14 oesophag$.tw. (9880)<BR/>15 exp gastroesophageal reflux/ (9931)<BR/>16 (gastroesophageal adj3 reflux).tw. (6381)<BR/>17 (gastro adj3 oesophageal adj3 reflux).tw. (1854)<BR/>18 (gastro adj3 esophageal adj3 reflux).tw. (429)<BR/>19 gord.tw. (406)<BR/>20 gerd.tw. (2890)<BR/>21 exp duodenogastric reflux/ (462)<BR/>22 (duodenogastric adj3 reflux).tw. (210)<BR/>23 exp bile reflux/ (193)<BR/>24 (bile adj3 reflux).tw. (327)<BR/>25 (acid adj3 reflux).tw. (1100)<BR/>26 exp dyspepsia/ (3259)<BR/>27 dyspep$.tw. (4938)<BR/>28 (belch$ or burp$).tw. (378)<BR/>29 exp eructation/ (88)<BR/>30 eructation.tw. (57)<BR/>31 exp heartburn/ (709)<BR/>32 (heartburn or indigestion).tw. (2166)<BR/>33 exp esophagitis/ (2923)<BR/>34 esophagitis.tw. (3463)<BR/>35 oesophagitis.tw. (1093)<BR/>36 exp proton pumps/ (18082)<BR/>37 (proton adj3 pump adj3 inhibitor$).tw. (4287)<BR/>38 exp proton pump inhibitors/ (330)<BR/>39 ppi.tw. (3069)<BR/>40 exp omeprazole/ (5073)<BR/>41 omeprazole.tw. (3417)<BR/>42 (lansoprazole or lanzoprazole).tw. (1196)<BR/>43 pantoprazole.tw. (647)<BR/>44 rabeprazole.tw. (504)<BR/>45 esomeprazole.tw. (436)<BR/>46 exp histamine h2 antagonists/ (4281)<BR/>47 (histamine adj3 h2 adj3 antagonist$).tw. (430)<BR/>48 cimetidine.tw. (1679)<BR/>49 exp cimetidine/ (1179)<BR/>50 famotidine.tw. (635)<BR/>51 exp famotidine/ (539)<BR/>52 nizatidine.tw. (133)<BR/>53 exp nizatidine/ (105)<BR/>54 ranitidine.tw. (1791)<BR/>55 exp ranitidine/ (1543)<BR/>56 (prokinetic adj3 agent$).tw. (369)<BR/>57 exp domperidone/ (332)<BR/>58 domperidone.tw. (426)<BR/>59 exp metoclopramide/ (916)<BR/>60 metoclopramide.tw. (1180)<BR/>61 exp cisapride/ (836)<BR/>62 cisapride.tw. (944)<BR/>63 or/12-35 (53964)<BR/>64 or/36-62 (32754)<BR/>65 63 and 64 (4758)<BR/>66 11 and 65 (3592)<BR/>67 pylori.ti. (15068)<BR/>68 66 not 67 (2921)<BR/>69 limit 68 to yr="2006-2008" (694)<BR/>70 from 69 keep 1-694 (694)</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">MEDLINE Search Strategy (November 2011)</HEADING>
<P>Database: Ovid MEDLINE(R) 1948 to November Week 3 2011</P>
<OL>
<LI>randomized controlled trial.pt.</LI>
<LI>controlled clinical trial.pt.</LI>
<LI>randomized.ab.</LI>
<LI>placebo.ab.</LI>
<LI>drug therapy.fs.</LI>
<LI>randomly.ab.</LI>
<LI>trial.ab.</LI>
<LI>groups.ab.</LI>
<LI>or/1-8</LI>
<LI>exp animals/ not humans.sh.</LI>
<LI>9 not 10</LI>
<LI>exp esophagus/</LI>
<LI>esophag$.tw.</LI>
<LI>oesophag$.tw.</LI>
<LI>exp gastroesophageal reflux/</LI>
<LI>(gastroesophageal adj3 reflux).tw.</LI>
<LI>(gastro adj3 oesophageal adj3 reflux).tw.</LI>
<LI>(gastro adj3 esophageal adj3 reflux).tw.</LI>
<LI>gord.tw.</LI>
<LI>gerd.tw.</LI>
<LI>exp duodenogastric reflux/</LI>
<LI>(duodenogastric adj2 reflux).tw.</LI>
<LI>exp bile reflux/</LI>
<LI>(bile adj2 reflux).tw.</LI>
<LI>(acid adj3 reflux).tw.</LI>
<LI>exp dyspepsia/</LI>
<LI>dyspep$.tw.</LI>
<LI>(belch$ or burp$).tw.</LI>
<LI>exp eructation/</LI>
<LI>eructation.tw.</LI>
<LI>exp heartburn/</LI>
<LI>(heartburn or indigestion).tw.</LI>
<LI>exp esophagitis/</LI>
<LI>esophagitis.tw.</LI>
<LI>oesophagitis.tw.</LI>
<LI>exp proton pumps/</LI>
<LI>(proton adj3 pump adj3 inhibitor$).tw.</LI>
<LI>exp proton pump inhibitors/</LI>
<LI>ppi.tw.</LI>
<LI>exp omeprazole/</LI>
<LI>omeprazole.tw.</LI>
<LI>(lansoprazole or lanzoprazole).tw.</LI>
<LI>pantoprazole.tw.</LI>
<LI>rabeprazole.tw.</LI>
<LI>esomeprazole.tw.</LI>
<LI>exp histamine h2 antagonists/</LI>
<LI>(histamine adj3 h2 adj3 antagonist$).tw.</LI>
<LI>cimetidine.tw.</LI>
<LI>exp cimetidine/</LI>
<LI>famotidine.tw.</LI>
<LI>exp famotidine/</LI>
<LI>nizatidine.tw.</LI>
<LI>exp nizatidine/</LI>
<LI>ranitidine.tw.</LI>
<LI>exp ranitidine/</LI>
<LI>(prokinetic adj3 agent$).tw.</LI>
<LI>exp domperidone/</LI>
<LI>domperidone.tw.</LI>
<LI>exp metoclopramide/</LI>
<LI>metoclopramide.tw.</LI>
<LI>exp cisapride/</LI>
<LI>cisapride.tw.</LI>
<LI>or/12-35</LI>
<LI>or/36-62</LI>
<LI>63 and 64</LI>
<LI>11 and 65</LI>
<LI>pylori.ti.</LI>
<LI>66 not 67</LI>
<LI>limit 68 to ed=20080101-20111119</LI>
</OL>
</SUBSECTION>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-03" MODIFIED="2012-11-08 09:43:10 -0500" MODIFIED_BY="Cathy Bennett" NO="3">
<TITLE MODIFIED="2012-11-08 09:41:27 -0500" MODIFIED_BY="Cathy Bennett">EMBASE search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2012-11-08 09:43:10 -0500" MODIFIED_BY="Cathy Bennett" NOTES="&lt;p&gt;Note for RGC - check with TSC (Deirdre Andre) to ensure the coorect EMBAse details are here.&lt;/p&gt;" NOTES_MODIFIED="2012-11-08 09:43:10 -0500" NOTES_MODIFIED_BY="Cathy Bennett">
<SUBSECTION>
<HEADING LEVEL="3">Summary of 2011 revisions</HEADING>
<P>Filter subject headings updated in 2011 as follows:</P>
<UL>
<LI>exp single blind method changed to exp single blind procedure</LI>
<LI>exp double blind method changed to exp double blind procedure</LI>
<LI>exp evaluation studies changed to exp evaluation</LI>
<LI>exp prospective studies changed to exp prospective study</LI>
</UL>
<UL>
<LI>Step 40: (duodenogastric adj3 reflux).tw. added</LI>
<LI>Step 42: (bile adj3 reflux added).tw.</LI>
<LI>Step 48: eructation.tw. added</LI>
<LI>Step 54: exp omeprazole deleted as covered in new subject heading proton pump inhibitors exploded</LI>
<LI>Step 55 new subject heading proton pump inhibitors added (2008) and exploded</LI>
<LI>Step 56:  &#8216;lansoprazole.tw&#8217; amended to &#8216;(lansoprazole or lanzoprazole).tw. (now step 58)</LI>
<LI>Step 60 subject heading exp histamine h2 antagonists changed to exp h2 receptor antagonist added  (now Step 63)</LI>
<LI>Step 64: (h2 adj3 receptor adj3 antagonist$).tw. added</LI>
<LI>Step 62: exp Cimetidine deleted as associate term to and contained within exp Histamine H2 Receptor Antagonist</LI>
<LI>Step 64:  exp Famotidine deleted as associate term to and contained within exp Histamine H2 Receptor Antagonist</LI>
<LI>Step 66: exp Nizatidine deleted as associate term to and contained within exp Histamine H2 Receptor Antagonist</LI>
<LI>Step 68: exp Ranitidine deleted as associate term to and contained within  exp Histamine H2 Receptor Antagonist</LI>
<LI>Added date limit of 2006 -2008 (as search last ran on 21/12/05)</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">EMBASE search strategy (19 November 2008)</HEADING>
<P>Database: EMBASE &lt;1996 to 2008 Week 46&gt;<BR/>
</P>
<P>1 exp randomized controlled trial/ (133000)<BR/>2 randomized controlled trial$.tw. (20954)<BR/>3 exp randomization/ (24312)<BR/>4 exp single blind procedure/ (6841)<BR/>5 exp double blind procedure/ (51296)<BR/>6 or/1-5 (170858)<BR/>7 animal.hw. (1047847)<BR/>8 human.hw. (3907249)<BR/>9 7 not (7 and 8) (901617)<BR/>10 6 not 9 (166132)<BR/>11 exp clinical trial/ (429570)<BR/>12 (clin$ adj3 (stud$ or trial$)).ti,ab,tw. (156240)<BR/>13 (clin$ adj3 trial$).ti,ab,tw. (92041)<BR/>14 ((singl$ or doubl$ or treb$ or tripl$) adj3 (blind$ or mask$)).ti,ab,tw. (52701)<BR/>15 exp placebo/ (81167)<BR/>16 placebo$.ti,ab,tw. (67305)<BR/>17 random.ti,ab,tw. (56879)<BR/>18 (crossover$ or cross-over$).ti,ab,tw. (22268)<BR/>19 or/11-18 (599557)<BR/>20 19 not 9 (582247)<BR/>21 20 not 10 (427515)<BR/>22 exp comparative study/ (211066)<BR/>23 exp evaluation/ (53469)<BR/>24 exp prospective study/ (70096)<BR/>25 exp controlled study/ (2208077)<BR/>26 (control$ or prospective$ or volunteer$).ti,ab,tw. (1117898)<BR/>27 or/22-26 (2740729)<BR/>28 27 not 9 (2022865)<BR/>29 10 or 21 or 28 (2256151)<BR/>30 exp esophagus/ (8629)<BR/>31 esophag$.tw. (31532)<BR/>32 oesophag$.tw. (9917)<BR/>33 exp gastroesophageal reflux/ (14014)<BR/>34 (gastroesophageal adj3 reflux).tw. (6296)<BR/>35 (gastro adj3 oesophageal adj3 reflux).tw. (1930)<BR/>36 (gastro adj3 esophageal adj3 reflux).tw. (433)<BR/>37 gord.tw. (421)<BR/>38 gerd.tw. (2956)<BR/>39 exp duodenogastric reflux/ (675)<BR/>40 (duodenogastric adj3 reflux).tw. (170)<BR/>41 exp bile reflux/ (363)<BR/>42 (bile adj3 reflux).tw. (324)<BR/>43 (acid adj3 reflux).tw. (1116)<BR/>44 exp dyspepsia/ (10754)<BR/>45 dyspep$.tw. (5038)<BR/>46 (belch$ or burp$).tw. (367)<BR/>47 exp eructation/ (191)<BR/>48 eructation.tw. (59)<BR/>49 exp heartburn/ (3729)<BR/>50 (heartburn or indigestion).tw. (2130)<BR/>51 exp esophagitis/ (7912)<BR/>52 esophagitis.tw. (3478)<BR/>53 oesophagitis.tw. (1149)<BR/>54 (proton adj3 pump adj3 inhibitor$).tw. (4749)<BR/>55 exp proton pump inhibitor/ (22842)<BR/>56 ppi.tw. (3215)<BR/>57 omeprazole.tw. (3756)<BR/>58 (lansoprazole or lanzoprozole).tw. (1333)<BR/>59 pantoprazole.tw. (800)<BR/>60 rabeprazole.tw. (537)<BR/>61 esomeprazole.tw. (536)<BR/>62 exp h2 receptor antagonist/ (21143)<BR/>63 (h2 adj receptor adj3 antagonist$).tw. (1479)<BR/>64 cimetidine.tw. (1787)<BR/>65 famotidine.tw. (747)<BR/>66 nizatidine.tw. (150)<BR/>67 ranitidine.tw. (2021)<BR/>68 exp prokinetic agent/ (1998)<BR/>69 (prokinetic adj3 agent$).tw. (415)<BR/>70 exp domperidone/ (2506)<BR/>71 domperidone.tw. (495)<BR/>72 exp metoclopramide/ (7531)<BR/>73 metoclopramide.tw. (1338)<BR/>74 exp cisapride/ (4418)<BR/>75 cisapride.tw. (1065)<BR/>76 or/30-53 (63171)<BR/>77 or/54-75 (48970)<BR/>78 76 and 77 (10430)<BR/>79 29 and 78 (5662)<BR/>80 pylori.ti. (14545)<BR/>81 79 not 80 (4762)<BR/>82 limit 81 to yr="2006-2008" (1500)<BR/>83 from 82 keep 1-1500 (1500)<BR/>84 from 83 keep 1-1500 (1500)</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">EMBASE search strategy (November 2011)</HEADING>
<P>Database: Embase &lt;1980 to 2011 Week 50&gt;</P>
<OL>
<LI>exp esophagus/</LI>
<LI>esophag$.tw.</LI>
<LI>oesophag$.tw.</LI>
<LI>exp gastroesophageal reflux/</LI>
<LI>(gastroesophageal adj3 reflux).tw.</LI>
<LI>(gastro adj3 oesophageal adj3 reflux).tw.</LI>
<LI>(gastro adj3 esophageal adj3 reflux).tw.</LI>
<LI>gord.tw.</LI>
<LI>gerd.tw.</LI>
<LI>exp duodenogastric reflux/</LI>
<LI>(duodenogastric adj3 reflux).tw.</LI>
<LI>exp bile reflux/</LI>
<LI>(bile adj3 reflux).tw.</LI>
<LI>(acid adj3 reflux).tw.</LI>
<LI>exp dyspepsia/</LI>
<LI>dyspep$.tw.</LI>
<LI>(belch$ or burp$).tw.</LI>
<LI>exp eructation/</LI>
<LI>eructation.tw.</LI>
<LI>exp heartburn/</LI>
<LI>(heartburn or indigestion).tw.</LI>
<LI>exp esophagitis/</LI>
<LI>esophagitis.tw.</LI>
<LI>oesophagitis.tw.</LI>
<LI>(proton adj3 pump adj3 inhibitor$).tw.</LI>
<LI>exp proton pump inhibitor/</LI>
<LI>ppi.tw.</LI>
<LI>omeprazole.tw.</LI>
<LI>(lansoprazole or lanzoprazole).tw.</LI>
<LI>pantoprazole.tw.</LI>
<LI>rabeprazole.tw.</LI>
<LI>esomeprazole.tw.</LI>
<LI>exp histamine H2 receptor antagonist/</LI>
<LI>(h2 adj receptor adj3 antagonist$).tw.</LI>
<LI>cimetidine.tw.</LI>
<LI>famotidine.tw.</LI>
<LI>nizatidine.tw.</LI>
<LI>ranitidine.tw.</LI>
<LI>exp prokinetic agent/</LI>
<LI>(prokinetic adj3 agent$).tw.</LI>
<LI>exp domperidone/</LI>
<LI>domperidone.tw.</LI>
<LI>exp metoclopramide/</LI>
<LI>metoclopramide.tw.</LI>
<LI>exp cisapride/</LI>
<LI>cisapride.tw.</LI>
<LI>or/1-24</LI>
<LI>or/25-46</LI>
<LI>47 and 48</LI>
<LI>random:.tw. or placebo:.mp. or double-blind:.tw.</LI>
<LI>50 and 49</LI>
<LI>pylori.ti.</LI>
<LI>51 not 52</LI>
<LI>animal.hw.</LI>
<LI>human.hw.</LI>
<LI>54 not (54 and 55)</LI>
<LI>53 not 56</LI>
<LI>limit 57 to em=200846-201150</LI>
</OL>
</SUBSECTION>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-04" MODIFIED="2012-11-08 09:43:03 -0500" MODIFIED_BY="Cathy Bennett" NO="4">
<TITLE MODIFIED="2012-11-08 09:41:32 -0500" MODIFIED_BY="Cathy Bennett">EMBR search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2012-11-08 09:43:03 -0500" MODIFIED_BY="Cathy Bennett">
<SUBSECTION>
<HEADING LEVEL="3">Summary of 2011 revisions</HEADING>
<UL>
<LI>RCT filter removed</LI>
<LI>Limited to 2006- 2008</LI>
<LI>Selected only Cochrane Central Trials from display menu</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">EBMR Search Strategy (19 November 2008)</HEADING>
<P>Database: All EBM Reviews - Cochrane DSR, ACP Journal Club, DARE, CCTR, CMR, HTA, and NHSEED<BR/>
<BR/>1 exp esophagus/ (881)<BR/>2 esophag$.tw. (3800)<BR/>3 oesophag$.tw. (2315)<BR/>4 exp gastroesophageal reflux/ (1106)<BR/>5 (gastroesophageal adj3 reflux).tw. (948)<BR/>6 (gastro adj3 oesophageal adj3 reflux).tw. (585)<BR/>7 (gastro adj3 esophageal adj3 reflux).tw. (73)<BR/>8 gord.tw. (124)<BR/>9 gerd.tw. (383)<BR/>10 exp duodenogastric reflux/ (46)<BR/>11 (duodenogastric adj3 reflux).tw. (39)<BR/>12 exp bile reflux/ (18)<BR/>13 (bile adj3 reflux).tw. (70)<BR/>14 (acid adj3 reflux).tw. (262)<BR/>15 exp dyspepsia/ (742)<BR/>16 dyspep$.tw. (1860)<BR/>17 (belch$ or burp$).tw. (114)<BR/>18 exp eructation/ (17)<BR/>19 eructation.tw. (35)<BR/>20 exp heartburn/ (216)<BR/>21 (heartburn or indigestion).tw. (823)<BR/>22 exp esophagitis/ (518)<BR/>23 esophagitis.tw. (684)<BR/>24 oesophagitis.tw. (542)<BR/>25 exp proton pumps/ (606)<BR/>26 exp proton pump inhibitors/ (0)<BR/>27 (proton adj3 pump adj3 inhibitor$).tw. (1079)<BR/>28 ppi.tw. (474)<BR/>29 exp omeprazole/ (1990)<BR/>30 omeprazole.tw. (2296)<BR/>31 (lansoprazole or lanzoprazole).tw. (773)<BR/>32 pantoprazole.tw. (416)<BR/>33 rabeprazole.tw. (271)<BR/>34 esomeprazole.tw. (234)<BR/>35 exp histamine h2 antagonists/ (3018)<BR/>36 (histamine adj3 h2 adj3 antagonist$).tw. (335)<BR/>37 cimetidine.tw. (2420)<BR/>38 exp cimetidine/ (1313)<BR/>39 famotidine.tw. (652)<BR/>40 exp famotidine/ (347)<BR/>41 nizatidine.tw. (221)<BR/>42 exp nizatidine/ (112)<BR/>43 ranitidine.tw. (2591)<BR/>44 exp ranitidine/ (1483)<BR/>45 (prokinetic adj3 agent$).tw. (140)<BR/>46 exp domperidone/ (148)<BR/>47 domperidone.tw. (344)<BR/>48 exp metoclopramide/ (879)<BR/>49 metoclopramide.tw. (1533)<BR/>50 exp cisapride/ (316)<BR/>51 cisapride.tw. (620)<BR/>52 or/1-24 (8543)<BR/>53 or/25-51 (10496)<BR/>54 52 and 53 (2293)<BR/>55 pylori.ti. (2362)<BR/>56 54 not 55 (1895)<BR/>57 limit 56 to yr="2006-2008" [Limit not valid in DARE; records were retained] (342)<BR/>58 from 57 keep 1-342 (342)<BR/>59 from 57 keep 72-212 (141)</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">EBMR Search Strategy (November 2011)</HEADING>
<P>EBM Reviews - Cochrane Central Register of Controlled Trials 4th Quarter 2011</P>
<OL>
<LI>exp esophagus/</LI>
<LI>esophag$.tw.</LI>
<LI>oesophag$.tw.</LI>
<LI>exp gastroesophageal reflux/</LI>
<LI>(gastroesophageal adj3 reflux).tw.</LI>
<LI>(gastro adj3 oesophageal adj3 reflux).tw.</LI>
<LI>(gastro adj3 esophageal adj3 reflux).tw.</LI>
<LI>gord.tw.</LI>
<LI>gerd.tw.</LI>
<LI>exp duodenogastric reflux/</LI>
<LI>(duodenogastric adj3 reflux).tw.</LI>
<LI>exp bile reflux/</LI>
<LI>(bile adj3 reflux).tw.</LI>
<LI>(acid adj3 reflux).tw.</LI>
<LI>exp dyspepsia/</LI>
<LI>dyspep$.tw.</LI>
<LI>(belch$ or burp$).tw.</LI>
<LI>exp eructation/</LI>
<LI>eructation.tw.</LI>
<LI>exp heartburn/</LI>
<LI>(heartburn or indigestion).tw.</LI>
<LI>exp esophagitis/</LI>
<LI>esophagitis.tw.</LI>
<LI>oesophagitis.tw.</LI>
<LI>exp proton pumps/</LI>
<LI>exp proton pump inhibitors/</LI>
<LI>(proton adj3 pump adj3 inhibitor$).tw.</LI>
<LI>ppi.tw.</LI>
<LI>exp omeprazole/</LI>
<LI>omeprazole.tw.</LI>
<LI>(lansoprazole or lanzoprazole).tw.</LI>
<LI>pantoprazole.tw.</LI>
<LI>rabeprazole.tw.</LI>
<LI>esomeprazole.tw.</LI>
<LI>exp histamine h2 antagonists/</LI>
<LI>(histamine adj3 h2 adj3 antagonist$).tw.</LI>
<LI>cimetidine.tw.</LI>
<LI>exp cimetidine/</LI>
<LI>famotidine.tw.</LI>
<LI>exp famotidine/</LI>
<LI>nizatidine.tw.</LI>
<LI>exp nizatidine/</LI>
<LI>ranitidine.tw.</LI>
<LI>exp ranitidine/</LI>
<LI>(prokinetic adj3 agent$).tw.</LI>
<LI>exp domperidone/</LI>
<LI>domperidone.tw.</LI>
<LI>exp metoclopramide/</LI>
<LI>metoclopramide.tw.</LI>
<LI>exp cisapride/</LI>
<LI>cisapride.tw.</LI>
<LI>or/1-24</LI>
<LI>or/25-51</LI>
<LI>52 and 53</LI>
<LI>pylori.ti.</LI>
<LI>54 not 55</LI>
<LI>limit 56 to yr="2008 -Current"</LI>
</OL>
</SUBSECTION>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS>
<EXTENSION ID="FLOW_1" NAME="FIGURE" REVMAN_VERSION="5.1.0" TYPE="FLOWCHART">
<ALIAS ALIAS_ID="1">
<FLOWCHARTBOX TEXT="&lt;p&gt;34 studies included in quantitative synthesis (meta-analysis)&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;138 full-text articles assessed for eligibility&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;&amp;gt;3000 records screened&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;&amp;gt;3000 records after duplicates removed&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;&amp;gt;3000 records identified through database searching&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;31 full-text articles excluded, with reasons&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</ALIAS>
</EXTENSION>
</EXTENSIONS>
</COCHRANE_REVIEW>